



*International Conference  
On Pharmacoepidemiology &  
Therapeutic Risk Management*

**August 16-19, 2009**



# *Final Program*

**Rhode Island  
Convention Center**

**Providence, RI**

**Jointly sponsored by**

- International Society for Pharmacoepidemiology
- Program in Pharmacoepidemiology and Pharmacoeconomics, College of Pharmacy, University of Rhode Island
- School of Medicine and College of Pharmacy, Virginia Commonwealth University
- The Brown University Program in Public Health

# ISPE Board of Directors & Committees

## Scientific Program Committee

Kate L. Lapane, FISPE, Chair

## Core Program Committee

Annlouise Assaf  
M. Miles Braun, FISPE  
Corinne de Vries  
Mark H. Epstein  
Andrew Gilbert  
Joanna F. Haas, FISPE  
Kate L. Lapane, FISPE  
James D. Lewis, FISPE  
Susana Perez-Gutthann, FISPE  
June Raine  
Elena Rivero, FISPE  
Patricia Saddier  
Glenn Schumock  
John Seeger  
Scott Smith  
Miriam CJM Sturkenboom  
Alexander M. Walker, FISPE

## Local Host Committee

Susan Andrade  
Annlouise Assaf  
Kristen Butterfield  
Jennifer Christian  
Erin Degulis  
David Dore  
Mark H. Epstein  
Joshua Gagne  
Crystal Holick

Jessica Jalbert  
Kate L. Lapane, FISPE  
Paul Larrat  
Tamar Lasky  
Rita Marcoux  
Brian J. Quilliam, Chair  
Margaret Richards  
Chuck Wentworth

## Development Committee

Annlouise Assaf, Chair  
Dimitri Bennett  
Rhonda L. Bohn, FISPE, Vice Chair  
Melissa Campanelli  
Andrzej Czarniecki, FISPE  
David Dore  
Mark H. Epstein  
Jessica Jalbert  
Barbara King

Hilal Maradit-Kremers  
Susan Oliveria  
Brian Quilliam  
Matthew Reynolds  
Cees Schep, FISPE  
Soko Setoguchi  
Marianne Ulcicklas Yood  
Natalie Volkova

## 25th Anniversary ICPE Committee

Allison Burke  
Wei Dong  
David Dore  
Mark H. Epstein  
Kate L. Lapane, FISPE, Co-Chair  
Susan Oliveria  
Michael Peng  
Brian J. Quilliam  
Susan Sacks, FISPE, Co-Chair  
Nancy Santanello  
Teresa Simon  
Walter Straus  
Marianne Ulcickas Yood

## ISPE Board of Directors

### Officers

Miriam CJM Sturkenboom  
*President*

Sebastian G. Schneeweiss, FISPE  
*President-Elect*

Yola Moride, FISPE  
*Immediate Past President*

Nancy A. Dryer, FISPE  
*Treasurer*

Mark H. Epstein  
*Executive Secretary*

### Directors

Alejandro Arana, FISPE  
Arial E. Arias  
Ulf Bergman, FISPE  
Stella Blackburn, FISPE  
Lolkje T. de Jong-van den Berg  
Daniel Fife, FISPE  
Sonia Hernandez-Diaz, FISPE  
Kate L. Lapane, FISPE  
James D. Lewis, FISPE  
Daniel Mines  
Nicholas D. Moore, FISPE  
Robert Reynolds  
Elena Rivero, FISPE  
Scott R. Smith  
Alexander M. Walker, FISPE  
Songlin Xue  
Stan A. Edlavitch, *Lifetime Emeritus*



You will notice that the "ICPE 25th Anniversary" logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.

# ICPE Abstract Reviewers

Ana Afonso  
Kadir Alam  
Anna Birna Almarsdóttir  
Keith Altman  
Daniel Ankrach  
Ariel E. Arias  
Ali Artaman  
Darren Ashcroft  
Annlouise Assaf  
Kathleen Beach  
Begler Begovic  
Paul Beninger  
Dimitri Bennett  
Bhajish Bharathar  
Pipasha Biswas  
William Blumentals  
Rhonda Bohn, FISPE  
Nancy Brandenburg  
M. Miles Braun, FISPE  
Kimberly Brodovicz  
M. Alan Brookhart  
Jeffrey Brown  
Bin Cai  
Herve Caspard  
Jordi Castellsague  
Yan Chen  
Jennifer Christian  
Barton Cobert  
Alexander Cole  
Lyn Colvin  
Michael Cook  
Deborah Covington  
Suellen Curkendall  
Wanju Dai, FISPE  
Johan De Haes  
Carl de Moor  
Frank de Vries  
Corinne de Vries  
Rachael DiSantostefano  
David Dore  
Sascha Dublin  
Tomasz Dyszynski  
Stanley Edlavitch  
*Conference Chair Emeritus*  
Monique Elseviers  
Sybil Eng  
Germano Ferreira  
Donnie Funch  
Kari Furu  
Joshua Gagne  
David Gagnon  
Christiane Gasse  
Tobias Gerhard  
Dina Gifkins  
Andrew Gilbert  
Earl Goehring  
Jean-Pierre Gregoire,  
FISPE  
Patricia Grossman

Jose Pedro Guerreiro  
Jeff Guo  
Lia Gutierrez  
Gillian Hall, FISPE  
Joseph Hanlon  
Spencer Harpe  
Kevin Haynes  
Eibert Heerdink  
Sean Hennessy, FISPE  
Sonia Hernandez-Diaz,  
FISPE  
Richard Hill  
Michie Hisada  
Alan Hochberg  
Laura Horne  
Amalia Issa  
Jessica Jalbert  
Yonghua Jing  
Catherine Johannes  
Judith K. Jones, FISPE  
Judith Kelly  
Mirjam-Colette Kempf  
Farhad Ali Khan  
Alena Khromava  
Victor Kiri  
Olaf Klungel  
Scott Korn  
Kate L. Lapane, FISPE  
Tamar Lasky  
Deborah Layton  
Charles Leonard

James D. Lewis, FISPE  
Geoffrey Liu  
Sandra Lopez Leon  
Jeanne Loughlin  
Kimberly Lowe  
Marie-Josée Martel  
Ramona Mateos-Campos  
Jay McDonald  
Anita McGrogan  
Hans-Ulrich Melchert  
Dominique Milea  
Daniel Mines  
Eileen Ming  
Allen Mitchell, FISPE  
Jingping Mo  
Nicholas Moore, FISPE  
Elaine Morrato  
Jonathan Morris  
Cristiano Moura  
Pavel Napalkov  
C. Ineke Neutel, FISPE  
Herbert Noack  
Niklas Noren  
Mette Norgaard  
Anthony Nunes  
Jude Nwokike  
Fredrik Nyberg  
Susan Oliveria  
Sallie Pearson  
Susana Perez Gutthann,  
FISPE

Ingemar Persson  
Jennifer Polinski  
Brian J. Quilliam  
Jeremy Rassen  
Joe Reilly  
Margaret (Meg) Richards  
Roelof Risselada  
Elena Rivero, FISPE  
Lewis Roht, FISPE  
Annalisa Rubino  
Stefan Russmann  
Susan Sacks, FISPE  
Patricia Saddier  
Maribel Salas  
Nancy Santanello  
Delphine Saragoussi  
Bill Saunders  
Hedi Schelleman  
Sebastian Schneeweiss,  
FISPE  
Marieke Schoonen  
Glenn Schumock  
John Seeger  
Harry Seifert  
Sarah Sellers  
Soko Setoguchi  
Gloria Shalviri  
Mary Lou Skovron  
Emily Somers  
Paul Stang, FISPE  
Michael Steinbuch

Monika Stender  
Til Stürmer, FISPE  
Bharat Thakrar  
Paula Thompson  
Thierry Trenque  
Gianluca Trifiro  
Ilse Truter  
Jerzy Tyczynski  
Marianne Ulcickas Yood  
Cristina Varas  
Zdravko Vassilev  
Priscilla Velentgas  
Patrice Verpillat  
Steven Vlad  
Vera Vlahovic-Palcevski  
Peter Wahl  
Alexander M. Walker,  
FISPE  
Alex Ward  
Li Wei  
Michael Wess  
Sue L. West, FISPE  
Jim Wilson  
Fei Xue  
Yu Yan  
Rong-Yuan Zheng  
Wei Zhou

August 19-22, 2010 | Hilton Brighton Metropole | Brighton, England, UK

## 26th ICPE

International Conference  
on Pharmacoepidemiology &  
Therapeutic Risk Management

The online abstract site will be  
operational by mid-December 2009.

Abstract Submission Deadline:  
February 10, 2010

Meeting information will be posted at [www.pharmacoepi.org](http://www.pharmacoepi.org)



# Meeting At-A-Glance

## Tuesday, August 18, 2009

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	
7:00am - 6:00pm Registration Open 3rd Floor Foyer													
7:30am - 5:00pm Speaker Ready Room 553B													
10:30-11:00am Break/Posters/Exhibits Hall B											← Sponsored by CSD-EPIC		
7:00-8:00am Poster Session B Set-Up Continental Breakfast Hall B	8:00am - 6:00pm Exhibitors/Poster Session B Hall B		11:00am - 12:30pm Anti-Infectives 552B		12:30 - 2:00pm Lunch/Poster Walks/ Poster Session B/ Exhibits Hall B		2:00 - 3:30pm Cancer All Over the Place! 551A		3:30-4:00pm Break/Posters/Exhibits Hall B		4:00 - 5:30pm Symposia & Workshops CIOMS VIII Report 557		
7:00 - 8:00am CERT's Breakfast Roundtable 557	8:00 - 9:15am Plenary Session: National Pharmaceutical Policy Imperatives Ballroom A		9:15 - 10:30am Annual Meeting of ISPE Members & Awards Ceremony Ballroom A		11:00am - 12:30pm Information as a Basis for Risk Mgmt. Ballroom D		12:30 - 2:00pm ISPE Committee/Council Meetings Bylaws and Policies 554A		2:00 - 3:30pm Cardiovascular Disease Ballroom D		4:00 - 5:30pm Conflict of Interest 552A		
				11:00am - 12:30pm Measurement Methods Ballroom B		12:30 - 2:00pm Global Development 554A		2:00 - 3:30pm Potpourri Session Ballroom B		4:00 - 5:30pm Guidance for Non-Randomized Studies of Comparative Effectiveness Ballroom B		5:30 - 6:30pm Biologics 551A	
				11:00am - 12:30pm The Spectrum of Anti-Inflammatory Therapies 552A		12:30 - 2:00pm Membership 554B		2:00 - 3:30pm Risk Factors, Surveillance, and Comorbidity Burden 551B		4:00 - 5:30pm ISPE Public Policy Forum-Communication Ballroom D		5:30 - 6:30pm Database 551B	
				11:00am - 12:30pm Use and Risks of Psychotropics in Elderly Persons 557		12:30 - 2:00pm Publications 558B		2:00 - 3:30pm To Do No Harm...? 557		4:00 - 5:30pm Providing Data for Drug Regulatory Decision Making Ballroom A		5:30 - 6:30pm Drug Utilization/Health Services Research Ballroom B	
						1:00 - 2:00pm Public Forum on Core Competencies for Pharmacoeconomics Ballroom A				4:00 - 5:30pm Who is a Patient's Main Prescriber and How Should Clustering Influence Analyses? 552B		5:30 - 6:30pm Medications in Pregnancy 552A	
											7:30pm - Midnight Evening at the Waterplace Restaurant		

## Wednesday, August 19, 2009

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm										
7:30am - 5:00pm Registration Open 3rd Floor Foyer																						
7:30am - 3:30pm Speaker Ready Room 553B																						
10:00-10:30am Break/Posters/Exhibits Hall B											10:30am - Noon Symposia & Workshops Assessment of Prenatal Exposure to Medications 552B											
7:30-8:30am Poster Session C Set-Up Continental Breakfast Hall B											8:00am - 1:45pm Exhibitors/Poster Session C Hall B		RMP, RiskMAP, and REMS: The Challenges of Epidemiology Ballroom D									
7:00 - 8:00am 2010 ICPE Scientific Program Committee Meeting 557											8:30 - 10:00am Analysis Methods II Ballroom B		10:00am - 11:00am Benchmarking Databases to Improve Harmonization 551A		12:00 - 1:30pm Lunch/Poster Walks/ Poster Session C/ Exhibits Hall B		1:30 - 3:00pm Invited Plenary FDA's Sentinel Initiative Project Ballroom A		3:30 - 4:30pm Hot Topics Session: Clopidogrel: Has the Pharmacogenetics Era Arrived? Ballroom A		4:30-5:00pm The Final Word: • Poster Awards • ICPE 2010 • Adjournment	
	8:30 - 10:00am Diabetes From Legs to Death 551A		10:00am - 11:00am Assessing the Association of Pharmacotherapeutics and Suicidal Behavior 551B		12:00 - 1:30pm ISPE Board of Directors Luncheon 554B																	
	8:30 - 10:00am Drug Utilization-II 551B		10:00am - 11:00am Safety Assessment and Risk Mgmt. of Biologics (Biologics SIG) Ballroom B																			
	8:30 - 10:00am Medications in Pregnancy and Birth Outcomes II 552A		10:00am - 11:00am The Future of Epidemiology 557																			
	8:30 - 10:00am Psychotropics II: Safety of Psychotropics 552B		10:00am - 11:00am Using Databases for both Hypothesis Generating and Hypothesis Confirmation 552A																			

# ISPE Exhibitors & Sponsors (as of July 30, 2009)



ISPE gratefully acknowledges the generous support of the following organizations and institutions. Their contributions helped to enhance the scientific program content and increase attendance at the ICPE 2009. *Thank you*

## Exhibitors

- \* Analysis Group
- \* APCER  
Pharma Solutions
- \* Aris Global
- \* Covance
- \* DrugLogic
- \* Exponent
- \* GPRD/MHRA
- \* HealthCore
- \* i3 Drug Safety
- \* IMS Health
- \* Kendle
- \* LA-SER
- \* Lovelace Respiratory  
Research Institute
- \* MedMining, a Geisinger  
System Business
- \* National Death  
Index, NCHS
- \* Outcome
- \* Phase Forward
- \* Premier Inc.
- \* PPD
- \* ProSanos
- \* REGISTRAT-MAPI
- \* RTI Health Solutions
- \* The Degge Group
- \* The Mattson  
Jack Group
- \* The Uppsala  
Monitoring Centre
- \* Thomson Reuters
- \* TCC llc
- \* United BioSource  
Corporation
- \* Wiley-Blackwell
- \* Wolters Kluwer Health

## ISPE Sponsors

### Corporate Benefactor

- \* Astra Zeneca R & D
- \* Pfizer

### Annual Meeting Sponsor

#### Platinum: \$12,500

- \* Pfizer
- \* Wiley-Blackwell

#### Gold: \$6,500

- \* Amgen
- \* Celegene Corporation
- \* Cephalon, Inc.
- \* Covance
- \* Eli Lilly & Company
- \* GlaxoSmithKline
- \* Genentech
- \* HealthCore
- \* i3 Drug Safety
- \* IMS Health
- \* Outcome
- \* Phase Forward
- \* PPD
- \* ProSanos
- \* REGISTRAT-MAPI
- \* Roche
- \* RTI Health Solutions
- \* The Degge Group
- \* The Mattson  
Jack Group
- \* United BioSource  
Corporation

#### Bronze: \$1,500

- \* Analysis Group, Inc.
- \* CSD-EPIC
- \* EpiSource
- \* PharmIdeas
- \* WHISCON

## Academic Showcase/ Welcome Reception

- \* Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- \* Center for Drug Safety, School of Pharmacy, University of Maryland
- \* Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida
- \* Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- \* Program in Pharmacoepidemiology and Pharmacoeconomics, College of Pharmacy, University of Rhode Island
- \* Program in Pharmacoepidemiology, Department of Epidemiology, UNC Gillings School of Global Public Health University of North Carolina at Chapel Hill

# ISPE Supporters

## Organizational & Institutional Members

### Corporate Benefactors

(10-year membership)

- ✱ Astra Zeneca R & D ✱ Pfizer

### Members

#### Pharmaceuticals

- ✱ Roche
- ✱ Sanofi-Aventis

#### Service Provider

- ✱ RTI Health Solutions

### Academic Programs

- ✱ Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- ✱ Center for Drug Safety, School of Pharmacy, University of Maryland
- ✱ College of Pharmacy, University of Texas at Austin
- ✱ Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- ✱ Harvard School of Public Health
- ✱ McGill Pharmacoepidemiology & Research Unit, McGill University
- ✱ Program in Pharmacoepidemiology and Pharmacoeconomics, College of Pharmacy, University of Rhode Island
- ✱ Program in Pharmacoepidemiology, Department of Epidemiology, UNC Gillings School of Global Public Health University of North Carolina at Chapel Hill
- ✱ Slone Epidemiology Center, Boston University

## \$25 for 25th (ICPE) Campaign (as of July 30, 2009)

The Society expresses its sincere appreciation to those supporters listed below for their contribution in honor of ISPE's 25th Annual Meeting (ICPE).

- |                             |                         |                                  |
|-----------------------------|-------------------------|----------------------------------|
| Edgar Adams                 | Kjell Hermann Halvorsen | Hans Petri                       |
| Michael Adena               | Abraham Hartzema        | Cynthia Phillips                 |
| Anna Birna Almarsdóttir     | Klaas Heinemann         | Richard Platt                    |
| Susan Andrade               | Deborah Hennessey       | Mary Prince Panaccio             |
| Daniel Ankrah               | David Henry             | Brian J. Quilliam                |
| Maurits Arbouw              | Ishan Hirji             | June Raine                       |
| Felix Arellano, FISPE       | Zhiping Huang           | Joe Reilly                       |
| Janet Arrowsmith            | Jacqueline Hugtenburg   | Maria Elena Rivero Ferrer, FISPE |
| Annlouise Assaf             | Anders Hviid            | Noah Robinson                    |
| Anita Assmann               | Michael Iskedjian       | Daniel Rosenberg                 |
| Elenie Bartzokis            | Betsey Jackson          | Annalisa Rubino                  |
| Keith Beard, FISPE          | Derek Johnson           | Ken Rothman, FISPE               |
| Ulf Bergman, FISPE          | Eric Johnson            | Leo Russo                        |
| Harshvinder Bhullar         | Yea-Huei Kao Yang       | Susan Sacks, FISPE               |
| Sebastien Bineau            | William Kelly, FISPE    | Deborah Saltman                  |
| Stella Blackburn, FISPE     | Farhad Ali Khan         | Lloyd Sansom                     |
| William Blumentals          | Ju-young Kim            | Cees Schep, FISPE                |
| Rhonda Bohn, FISPE          | Stephen Kimmel, FISPE   | Robert Schirmer                  |
| Alison Bourke               | Brice Kitio Dschassi    | Markus Schuerch                  |
| Elliot Brown                | Olaf Klungel            | Harry Seifert                    |
| Rudolf Bruppacher, FISPE    | James Kotsanos, FISPE   | Saad Shakir, FISPE               |
| Claudia Cabrera-Moksnes     | Gottfried Kreutz        | Gloria Shalviri                  |
| Suzanne Cadarette           | Kiyoshi Kubota          | Rosemarie Sift Carter            |
| Stella Chang                | Anais Lacasse           | Daniel Solomon                   |
| Robert Chen, FISPE          | Nancy Lass              | Patrick Souverain                |
| Lyn Colvin                  | Deborah Layton          | Tommasco Staniscia               |
| Anne Costello               | Joongyub Lee            | Miriam CJM Sturkenboom           |
| Suellen Curkendall          | Samuel Lesko            | Shinji Suzuki                    |
| Marie-Christine Cyr         | Linda Levesque          | Martina Teichert                 |
| Andrzej Czarniecki, FISPE   | James D. Lewis, FISPE   | Bharat Thakrar                   |
| Hilda de Jong               | Michael Lewis, FISPE    | Sengwee Toh                      |
| Lolkje de Jong-van den Berg | Jeanne Loughlin         | Marianne Ulcickas Yood           |
| Frank De Vries              | Malcolm Maclure         | John Urquhart, FISPE             |
| Dabashish Dey               | Milada Mahic            | Carla Van Bennekom               |
| Nancy Dreyer, FISPE         | William Maier           | Zdravko Vassilev                 |
| David Dore                  | Marie-Josée Martel      | Patrice Verrillat                |
| William Eastmann            | Colleen Maxwell         | Peter Wahl                       |
| Carol Fairchild             | Frank May, FISPE        | Alexander M. Walker, FISPE       |
| Sarah Frise                 | Giampiero Mazzaglia     | Mari-Ann Wallander, FISPE        |
| Genevive Gabb               | Andrew McAfee           | Douglas Watson                   |
| Helga Gardarsdottir         | Anita McGrogan          | Sue L. West, FISPE               |
| Churn-Shiouh Gau            | Joseph McLaughlin       | James Wilson                     |
| Brian Godman                | Dominique Milea         | Almut Winterstein                |
| Jean-Pierre Gregoire, FISPE | David Miller            | Fenglong Xie                     |
| Lamiaë Grimaldi-Bensouda    | Allen Mitchell, FISPE   | Songlin Xue, FISPE               |
| Zhenchao Guo                | Jocelyne Moisan, FISPE  | Shu-yu Yang                      |
| Flora Haaijer-Ruskamp       | Yola Moride, FISPE      |                                  |
| James Haddox                | C. Ineke Neutel, FISPE  |                                  |
| Gillian Hall, FISPE         | Anthony Nunes           |                                  |
| Jesper Hallas               | Axel Olsen              |                                  |
|                             | Byung-Joo Park, FISPE   |                                  |
|                             | Inger Nordin Olsson     |                                  |

## In This Program

### 25th ICPE Agenda

Saturday, August 15 .....	9
Sunday, August 16 .....	10
Monday, August 17 .....	12
Tuesday, August 18 .....	22
Wednesday, August 19 .....	32

### 25th ICPE Posters

Poster-Presentation Guidelines .....	38
Poster Session A .....	40
Poster Session B .....	48
Poster Session C .....	57

Abstract Index .....	64
Advertisers Index .....	70

# Meeting Information Future Meetings

## Badges

All attendees at ICPE 2009 must wear their name badges to all events.

A badge will be needed for admission to meeting related functions, such as the scientific sessions, the exhibit/poster hall, and social events. Badges will be included in the registration packet material. In some cases, tickets for admission will be required.

### Badge Legend

- Student – YELLOW
- One Day Attendee – RED
- New Member – BLUE
- Local Host Comm.–GREEN

## Rhode Island Convention Center (RICC)

All Pre-ICPE courses, the ICPE 2009, and ISPE Committee, Council and SIG meetings will be held at the Rhode Island Convention Center, One Sabin Street, Providence, RI, except otherwise listed. Food/beverage will be available at all committee meetings.

2009

### ISPE'S Fourth Asian Meeting

(Asian Conference on Pharmacoepidemiology)

Convened in conjunction with the Pharmaceutical Society of Taiwan

- October 23-25, 2009
- National Cheng Kung University, Tainan, Taiwan

2010

### ISPE Mid-Year Meeting

- April 10-12, 2010
- Marriott Raleigh City Center, Raleigh, North Carolina

### 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management


- August 19-22, 2010
- Hilton Brighton Metropole, Brighton, England, UK

### 5th Asian Conference on Pharmacoepidemiology

- October 29-31, 2010
- Tokyo, Japan

### ISPE Mid-Year Meeting

- April TBD, 2010
- Florence, Italy



RTI HEALTH SOLUTIONS®

RISKS AND BENEFITS:

**Define. Measure. Evaluate. Communicate.**

At RTI Health Solutions we provide full-service solutions for your international epidemiological, safety, and risk management needs. Visit our exhibit booth to learn how we can help you *define, measure, evaluate* and *communicate* the risks and benefits of your products.

Research Triangle Park • Ann Arbor • Barcelona • Manchester • Ottawa • Wallingham

ENTER  
TO WIN  
our daily  
book draw!

[www.rtihs.org](http://www.rtihs.org)

LEADING RESEARCH...  
MEASURES THAT COUNT®

# Agenda - Saturday, August 15

**8:30am-5:00pm**  
**ISPE Board of Directors Meeting**  
(Westin Providence-Bristol/Kent)

(Open to ISPE members; notify staff if you plan to attend)

**11:30-5:00pm**  
**Registration**  
(Third Floor Foyer)

New Course!

\* On Saturday afternoon (Day 1), there will be didactic teaching. On Sunday morning (Day 2) participation is optional, but there will be a small group workshop that will use real pharmacogenetic case studies catering to both novice and advanced participants.

[Note: There is no separate registration for Part 2 only; you must register for Part 1 to take Part 2].

## Pre-Conference Educational Sessions (RICC)

**1:00-5:00pm**  
**Introduction to Pharmacoepidemiology**  
(Room 555AB)

[\*Included as part of the full meeting registration; Registration required.]

**Chair: Andrew McAfee**

**Syed Rizwanuddin Ahmad**, FDA,  
*Spontaneous Reporting*

**Andrew McAfee**, i3 Drug Safety,  
*Cohort Studies*

**Yu-Xiao Yang**, University of Pennsylvania,  
*Case-Control Studies*

**Anita McGrogan**, University of Bath,  
*Confounding and Bias*

**1:00-5:00pm**  
**Introduction to Pharmacogenetics – Part 1\*** (Room 554AB)

[\*Admission by ticket only. Tickets will be included in registration materials for those that registered for this session.]

### Educational Objectives

- Understand the genetic and pharmacogenetic terminology and how cellular and molecular biology informs pharmacogenetic studies at analysis
- Appreciate the challenges of utilizing biospecimens
- Know the study design and methodologic approaches, their strengths and weakness used in pharmacogenetic epidemiology
- Understand statistical approaches used in Pharmacogenetics
- Understand how pharmacogenetics relates to current focus of Personalized Medicine
- Have an overview of clinical utility of pharmacogenetics and associated regulatory issues.

**Co-Chairs: Geoffrey Liu & Anke-Hilse Maitland**

**Leah Sansbury**, National Institutes of Health,  
*Pharmacogenetic Terminology: The Basics*

**Geoffrey Liu**, Alan Brown Chair in Molecular Genomics, CCO Chair in Population Studies and Experimental Therapeutics, University of Toronto, *Biospecimen Issues for Pharmacoepidemiologists*

**Wei Zhou**, Senior Epidemiologist, Merck Pharmaceuticals, *Biospecimen Databases*

**Anke-Hilse Maitland-van der Zee**,

Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht University,  
*Pharmacogenetics Methods I*

**Efrosini Setakis**, Division of General Practice Research Database, Medicines & Healthcare Products Regulatory Agency, UK,  
*Pharmacogenetic Methods II and Databases as Study Sources*

**Andrew Freedman**, National Institutes of Health, *Pharmacogenomics Translation: From Discovery to Confirmation to Clinical Utility*

**Stephen Kimmel**, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, *Warfarin as a Prototype Pharmacogenetic Example*

**5:00-7:00pm**

**Student Meet and Greet**

(Cuban Revolution Restaurant & Grill;  
50 Aborn Street)

- Organized by the ISPE Student Council

**5:15-6:30pm**

**Literature Review Journal Club**  
(Room 555AB)

- Open to Introduction to Pharmacoepidemiology Course participants as well as anyone who has registered to attend a Pre-ICPE course.
- Participants are encouraged to read the following article before attending this session: **Wayne Ray**, “**Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death**” (NEJM 2009;360:225-35)

**Panelists:**

**Alexander M. Walker**, FISPE, World Health Information Science Consultants

**Sean Hennessey**, FISPE, Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine

**Stephen Evans**, London School of Hygiene and Tropical Medicine

# Agenda - Sunday, August 16

7:30am-6:00pm  
Registration  
(Third Floor Foyer)

8:00-5:00pm  
Speakers'  
Ready Room  
(Room 553 B)

## Pre-Conference Educational Sessions (RICC)

### 8:30-Noon Regulatory Epidemiology/Public Health Decision Making\* (Room 555B)

#### Educational Objectives

- Understand the intent and structure of regulation to protect the Public Health
- Appreciate the challenges of decision making with weak data
- Know about practical approaches typically chosen by regulators
- Recognize the challenges epidemiology faces to provide sufficient information for public health decision making
- Have an overview of world wide challenges for drug regulatory agencies and variation in approaches
- Know about current strategies to strengthen regulation in the face of these challenges

#### Chair: Gerald Dal Pan

**Gerald Dal Pan**, US FDA, *Regulation & Challenges of Decision-Making with Weak Data*

**June Raine**, EMEA, *Regulatory Decision Making Approaches in Europe*

**Stephen Evans**, London School of Tropical Medicine, *An Epidemiologist's View of Public Health Decision Making*

**Ralph Edwards**, WHO Collaborating Centre for International Drug Monitoring, *Global Perspective on Regulatory Utilization of Pharmacovigilance Data*

### 8:30-Noon Introduction to Drug Utilization/Health Services Research\* (Room 555A)

#### Educational Objectives

- To explain the definition and scope of the eclectic discipline of Drug Utilization Research within the context of Pharmacoepidemiology.
- To motivate researchers providing international cross-national comparisons of national drug utilization data to cooperate on the collection of a minimal dataset of reliable and comparable drug utilization data in their country, in terms of volume, expenditures and quality of drug use.
- To explain the process of developing and validating prescribing quality indicators.
- To give an applied overview of methods useful for drug policy research (time series analysis)

**Co-Chairs: Robert Vander Stichele & Julie Zito, FISPE**

**Robert Vander Stichele**, *Course Objectives, Definitions of Research Fields and Methodological Framework*

**Marit Rønning**, *The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose: Classifying and Quantifying Drug Use for Cross National Comparison*

**Julie Zito**, *Overview of Drug Utilization Research in the US*

**Monique Elseviers**, *Using DUR – Data for Cross National Comparisons*

**Flora Haaijer-Ruskamp**, *Using DUR – Data to Create Valid Prescribing Quality Indicators*

**Colin Dormuth**, *Testing Interventions on Drug Utilization (Time Series Analysis and Other Methods)*

### 8:30-Noon Comparative Effectiveness Research\* (Ballroom D)



#### Educational Objectives

- Identify the differences between effectiveness and efficacy research and implications for improving routine care
- Understand the basic study design issues for non-randomized data recorded in routine care settings
- Recognize the advantages and limitations of a variety of data sources for comparative effectiveness research and how combining multiple sources can enhance the utility of a given dataset
- Have an overview of methodological challenges and proposed solutions in non-randomized effectiveness research
- Learn how to create and synthesize evidence with the decision maker in mind

**Co-Chairs: Sebastian Schneeweiss, FISPE, & Erick Johnson**

**Scott Smith**, AHRQ, *Objectives of CER*

**Eric Johnson**, Kaiser, *Cohort Studies*

**David Magid**, Kaiser, *Data Sources and Implications*

**Sebastian Schneeweiss**, Harvard, *Methodological Challenges in Non-Randomized CER*

**David Atkins**, Veteran's Administration, *Creating and Synthesizing Evidence with the Decision Maker in Mind*

#### \* NOTE FOR EDUCATIONAL SESSIONS:

Admission by ticket only. Tickets will be included in registration materials for those who registered for this session.

# Agenda - Sunday, August 16

8:30-Noon

## Introduction to Pharmacogenetics\* – Part 2 (Room 556A)



Must register for Part 1; attendance at Part 2 is optional.

- Speakers will lead small discussion groups addressing real life pharmacogenetic examples.

**Co-Chairs: Geoffrey Liu & Anke-Hilse Maitland**

**Leah Sansbury**, National Institutes of Health

**Geoffrey Liu**, University of Toronto

**Wei Zhou**, Merck Pharmaceuticals

**Anke-Hilse Maitland-van der Zee**,  
Utrecht University

**Efrosini Setakis**, Medicines & Healthcare  
Products Regulatory Agency, UK

**Andrew Freedman**, National Institutes of  
Health, USA

**Stephen Kimmel**, Center for Clinical Epi-  
demiology and Biostatistics, University of  
Pennsylvania School of Medicine

8:30-12:00pm

## Students Only – Special Skills Workshop: From Writing an Abstract to Planning a Career: Skills You Can Use (Room 554A)

[\* Included as part of full meeting registration; registration required]

- Organized by ISPE Student Council

Noon -1:30pm

## Lunch on your own.

Noon-1: 30pm

## Luncheon for New Members/Student Prize Winners/Scholarship Recipients (Westin Providence Waterplace Ballroom)

- By Invitation

1:30-6:00pm

## Advanced Topics in Pharmacoepidemiology\* (Ballroom D)

**Chair: James D. Lewis, FISPE**

**Sander Greenland**, *Bayesian Methods for Observational Research*  
**Tom MacDonald, FISPE**, *Clinical Trials or Observational Studies for Drug Safety Assessment?*

**Joanna Haas**, *Unique Aspects of Studying Biologics*

**Daniel Heitjan**, *Methods for Handling Missing Data*

1:30-6:00pm

## Introduction to Risk Management\* (Room 557)

**Co-Chairs: Elizabeth Andrews, FISPE & Carla van Bennekom**

**Elizabeth Andrews, FISPE**, *Overview of Risk Management and the Role of Evaluation*

**Mary Willy**, *US Regulatory*

**Stella Blackburn, FIPSE**, *EU Regulatory*

**Carla van Bennekom**, *Isotretinoin*

**Judith Jones, FISPE**, *Workshop for Participants to Develop an Evaluation Plan*

6:00-7:30pm

## Welcome Reception/Academic Showcase (Rhode Island Statehouse)

- Admission by badge or ticket. Cash Bar

### Welcome

**Kate Lapane, FISPE**, Chair, 2009 Scientific Program Committee

**Miriam Sturkenboom**, ISPE President

### Academic Showcase

- Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- Center for Drug Safety, School of Pharmacy, University of Maryland
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- Program in Pharmacoepidemiology and Pharmacoeconomics, College of Pharmacy, University of Rhode Island
- Program in Pharmacoepidemiology, Department of Epidemiology, UNC Gillings School of Global Public Health University of North Carolina at Chapel Hill

# Agenda - Monday, August 17

7:00-8:00am

## ISPE Committee Meeting

- Open to all participants.
- Breakfast will be available in meeting rooms

• **Education Committee** (Room 551B)

• **Finance Committee** (Room 551A)

7:00-5:00pm

## Speakers' Ready Room (Room 553B)

7:00-8:00am

## Poster Session A Set-up (Hall B)

## Continental Breakfast (Hall B))

7:00-6:00pm

## Registration (Third Floor Foyer)

8:00-6:00pm

## Exhibits/Posters (Hall B)

8:00-10:00am

## Opening Session (Ballroom A)

### • Welcome

**Kate L. Lapane, FISPE**, Chair, 2009 Scientific Program Committee, & Co-Chair, 25th Anniversary Committee

**Brian J. Quilliam**, Chair, 2009 Local Host Committee

### • Presidential Address

**Miriam CJM Sturkenboom**, ISPE President

### • Keynote Address

*Accounting for Uncertainty About Investigator Bias*

**Sander Greenland**, Professor of Epidemiology, UCLA School of Public Health, and Professor of Statistics, UCLA College of Letters and Science

### • Special Anniversary Presentation

**Susan Sacks, FISPE**, Co-Chair, 25th Anniversary Committee

**Thomas MacDonald, FISPE**, ISPE Poet Laureate

10:00am -10:30am

## Break/Posters/Exhibits (Hall B)

10:30am-12:00pm

## Concurrent Sessions: Contributed Papers

### Drug Utilization-I (Room 552AB)

**Moderators: Jurgen Dinger & Julie Zito, FISPE**

10:30am

• **Understanding the Prescribing Patterns of Lipid-Lowering Agents in the United States and Canada [1]**  
Matthew W Reynolds, Yola Moride. (United States)

10:45am

• **Comparison of Prescription Patterns of Statins in Primary Care in Five European Countries: Results from the LIPIDE Observational Survey [2]**  
Gaelle Desamericq, Laurent Laforest, Marie-Sophie Schwalm, Philippe Moulin, Emilie Michel, Caroline Eteve, Gabriel Coffin, Cecile Ritleng, Eric Van Ganse. (France)

11:00am

• **Variation in Initiation of Angiotensin Blocking Agents, Beta Blockers and Statins after Hospitalization for Acute MI in British Columbia [3]**  
Andrea V Margulis, Sebastian Schneeweiss. (United States)

11:15am

• **An Intervention To Increase Statin Tablet Splitting among General Practitioners [4]**  
Jennifer Polinski, Sebastian Schneeweiss, Malcolm Maclure, Sam Ramsden, Blair Marshall, Colin Dormuth. (United States)

11:30am

• **Pattern of Utilization of Pegfilgrastim (PEGFIL) in Patients with Chemotherapy-Induced Neutropenia: A Retrospective Analysis of Administrative Claims Data [5]**  
AT Skarin, F Vekeman, F Laliberté, O Afonja, MH Lafeuille, V Barghout, MS Duh. (United States)

11:45am

• **Is Low Use of Inhaled Corticosteroids among Asthmatic Patients Due to Inappropriate Prescribing or Low Patients' Adherence? [6]**  
Lucie Blais, Marie-France Beauchesne, Catherine Lemièrre, Sylvie Perreault. (Canada)



You will notice that the "ICPE 25th Anniversary" logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.



***Working together for a healthier world™***



## **Pfizer Epidemiology: Committed to Patient Safety**

Pfizer, Inc. discovers, develops, manufactures, and markets leading prescription medicines for humans and animals.

With 2008 actual spending of \$7.9 billion in research & development (R&D), Pfizer has the industry's largest pharmaceutical R&D organization.

Our search for new treatments spans hundreds of research projects across fifty-six major disease groups in 10 therapeutic areas.

We build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues.

Every year we help 150 million patients, utilize the skills of medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses – adding both years to life, and life to years.

The Epidemiology Group at Pfizer partners with development teams to bring new medicines to patients and to evaluate the safety of our medicines.

We are committed to the conduct of research meeting the highest scientific and ethical standards to assess the benefits and risks of our medicines.

Pfizer Epidemiology is proud to support the 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management and welcomes the opportunity for the open exchange of scientific ideas and research findings in order to advance the fields of pharmacoepidemiology and risk management.

# Agenda - Monday, August 17

## Early Detection In Pharmacovigilance (Room 555AB)

**Moderators:** Andrej Czarnecki, FISPE, & M. Miles Braun, FISPE

**10:30am**

- ★ **A Comparison of MedDRA and WHOART for Signal Detection on a Database of Spontaneous Adverse Drug Reaction Reports [7]**  
Richard Hill, Kristina Star, G Niklas Norén. (Sweden)

**10:45am**

- ★ **Using Regression To Find Otherwise Undetected Drug Safety Issues [8]**  
Ola Caster, Kristina Star, Richard Hill, G Niklas Norén. (Sweden)

**11:00am**

- ★ **Comparison of Adverse Drug Reaction (ADR) Reports Submitted to the FDA by Consumers and Healthcare Professionals (HCPs) [9]**  
Thamir M Alshammari, Syed Rizwanuddin Ahmad, Lynette Swartz, Tarek A Hammad. (United States)

**11:15am**

- ★ **Using the Capture-Recapture Method To Assess the Incidence of Drug-Induced Liver Injury in a French University Hospital [10]**  
Neda Tavassoli, Virginie Ramillon, Pauline Calvet, Laure Pourcel, Jean Louis Montastruc, Maryse Lapeyre-Mestre. (France)

**11:30am**

- ★ **Evaluation of Cardiovascular Diseases (CVDs) Risk in French Patients Receiving Milnacipran (MLN) Relative to Patients Receiving Other Antidepressants Therapies [11]**  
PJ Mease, MS Duh, F Vekeman, A Guérin, M Boerstoeel-Streefland, W Jiang, P Lefebvre, PJ Zimetbaum. (United States)

**11:45am**

- ★ **Near Real-Time Post-Marketing Surveillance: The Experience of the Vaccine Safety Datalink [12]**  
WK Yih, B Fireman, N Klein, M Kuldorff, E Lewis, T Lieu, E Weintraub, R Platt. (United States)

Phase III/Phase IV Studies • Registries and Observational Studies • Risk Management/REMS  
Product Safety and Pharmacovigilance • Patient-Reported Outcomes and Health Economics Research

## Covance Periapproval Services. Designed for results.™

Be confident with Covance—the CRO that was specifically designed to meet every goal you target.  
Precisely why Covance Periapproval Services is the natural selection for all your post-approval needs.

THE AMERICAS | 888.COVANCE (1.888.268.2603) | 609.410.5340  
EMAIL [info@covance.com](mailto:info@covance.com) | WEB SITE [www.covance.com/periapproval](http://www.covance.com/periapproval)

**COVANCE**  
THE GREEN COMPANY. A SYSCO COMPANY.

# Agenda - Monday, August 17

## Effects of Cardiovascular Drugs (Room 556AB)

**Moderator:** Jennifer Christian & Michael Lewis, FISPE

**10:30am**

- ★ **Statins, Other Antihyperlipidemic Agents, and Psoriasis [13]**  
Yolanda B Brauchli, Susan S Jick, Christoph R Meier. (Switzerland)

**10:45am**

- ★ **Statin-CYP3A4 Inhibitor Drug Interaction Shows Differential Increased Risk for Adverse Events Depending on Statin Metabolism [14]**  
Christopher G Rowan, Steven M Brunelli, James Flory, Jeffrey Munson, Warren Bilker, Brian Strom. (United States)

**11:00am**

- ★ **Safety and Effectiveness of Bivalirudin in Routine Care of Patients Undergoing Percutaneous Coronary Intervention [15]**  
Jeremy A Rassen, Murray A Mittleman, Robert J Glynn, M Alan Brookhart, Sebastian Schneeweiss. (United States)

**11:15am**

- ★ **Association of Proton Pump Inhibitors with Clopidogrel Effectiveness in Elderly Stroke Patients [16]**  
Mi-Sook Kim, Sun-Young Jung, Ye-Jee Kim, Nam-Kyong Choi, Byung-Joo Park. (Republic of Korea)

**11:30am**

- ★ **Propranolol May Be Associated with Increased Risk of Hospitalized Myopathy: A Hypothesis Generated by Chemical Genomics [17]**  
Soko Setoguchi, John Higgins, Levin Raisa, Vamsi Mootha, Jerry Avorn. (United States)

**11:45am**

- ★ **Use of Organic Nitrates and the Risk of Hip Fracture: A Population-Based Case-Control Study [18]**  
Arief Lalmohamed, Sander Pouwels, Cyrus Cooper, Tjeerd van Staa, Bert Leufkens, Lars Rejnmark, Anthonius de Boer, Peter Vestergaard, Frank de Vries. (Netherlands)

## Hormones/Reproductive Agents (Room 554AB)

**Moderators:** Stephen Evans & Annlouise Assaf

**10:30am**

- ★ **Teen Pregnancy Rates Following Pharmacist-Initiated Emergency Contraceptives [19]**  
Vivian WY Leung, Judith A Soon, Marc Levine, Larry D Lynd, Carlo A Marra. (Canada)

**10:45am**

- ★ **An Internet-Based Prospective Study of Pregravid Oral Contraceptive Use and Time to Pregnancy [20]**  
Ellen M Mikkelsen, Lauren A Wise, Anders Riis, Elizabeth E Hatch, Henrik T Sørensen, Kenneth J Rothman. (United States)

**11:00am**

- ★ **Incident Anticoagulant Use among Users of Extended-Cycle Versus Conventional Oral Contraceptives [21]**  
Joshua J Gagne, Tarek A Hammad, Solomon Iyasu. (United States)

**11:15am**

- ★ **Extended Results on the Risk of Venous Thromboembolism (VTE), Myocardial Infarction (MI), and Stroke in Users of Transdermal Norelgestromin/Ethinyl Estradiol (Patch) [22]**  
David D Dore, Heather Norman, Clorinda Hoffman, Judy Wong, John D Seeger. (United States)

**11:30am**

- ★ **Oral Hormone Replacement Therapy: An Update Report from the EURAS-HRT Study on Cardiovascular Safety [23]**  
Anita Assmann, Juergen C Dinger. (Germany)

**11:45am**

- ★ **Risk of Cardiovascular Outcomes in Users of Estradiol/Dydrogesterone or Other HRT Preparations [24]**  
Cornelia Schneider, Susan S Jick, Christoph R Meier. (Switzerland)

# Agenda - Monday, August 17

## Medications in Pregnancy/Birth Outcomes – I (Ballroom B)

**Moderators:** Jennita Reefhuis & Lolkje de jong van den Berg

**10:30am**

★ **Pregnancy Exposure Registries: Challenges in Identifying Comparison Groups [25]**

Deborah L Covington, Susan S Roberts, Jessica Albano, Laura F McKain. (United States)

**10:45am**

★ **Can the General Practice Research Database Identify a Known Teratogenic Association? [26]**

Rachel A Charlton, John G Weil, Julia M Snowball, Marianne C Cunningham, Corinne S de Vries. (United Kingdom)

**11:00am**

★ **Valproic Acid Exposure & Specific Malformations [27]**

J Jentink, MA Loane, H Dolk, JK Morris, LTW de Jong-van den Berg, EUROCAT AED Working Group. (Netherlands)

**11:15am**

★ **Effect of Correct Folic Acid Use on Spina Bifida in Pregnancies Exposed to Valproic Acid or Carbamazepine in the Netherlands [28]**

J Jentink, MK Bakker, LTW de Jong-van den Berg. (Netherlands)

**11:30am**

★ **Serotonin Reuptake Inhibitor and Pregnancy: Risk of Gestational Hypertension? [29]**

Christine Damase-Michel, Veronique Duhalde, Caroline Hurault, Robert Bourrel, Jean Louis Montastruc. (France)

**11:45am**

★ **Use of Antidepressants during Pregnancy and the Risk of Pre-term Delivery and Fetal Growth Restriction [30]**

Sengwee Toh, Allen A Mitchell, Carol Louik, Martha M Werler, Christina D Chambers, Sonia Hernandez-Diaz. (United States)

Meet with  
**i3 Drug Safety experts**  
at our booth.

▶ **drug safety & epidemiology**

clinical research

biostatistics & data management

pharma informatics

staffing & outsourcing

health economics, outcomes,  
& late phase research

cardiology

central nervous system

oncology

respiratory & infectious disease

endocrinology & metabolic disease

**Our partnership.**  
**Their peace of mind.**

i3's full-spectrum functional and therapeutic expertise helps pharmaceutical companies gain sharper insights that lead to better patient care. Faster and more efficiently. With less risk and expense. For solutions that combine consulting-firm flexibility with the scientific depth of an integrated research organization, look to the specialists of i3. [www.i3global.com](http://www.i3global.com)



The company of specialists.

# Agenda - Monday, August 17

12:00pm-1:30pm

Lunch/Poster Session A/Exhibits/

Poster Walks (Hall B)

~Lunch Sponsored by UBC

Poster Walks/Moderators

- **Pharmacovigilance**, Harry Seifert & Keith Beard, FISPE
- **Medicines in Pregnancy/Birth Defects**, Lolkje T de Jong-van den Berg
- **Drug Utilization Studies**, Monique Elseviers
- **Uses of Linked Databases**, Matthew W. Reynolds

ISPE Committee/Council Meetings

- Open to all participants. (Lunches will be available in meeting rooms)
- **Development Committee** (Room 558B)
- **Fellowship & Awards Committee** (Room 558A)
- **Public Policy Committee** (Room 557)
- **Student Council** (Ballroom E)

1:30-3:00pm

Concurrent Sessions: Contributed Papers

Analysis Methods I (Ballroom B)

Moderators: Til Stürmer, FISPE & Marieke DeBruin

1:30pm

- **Estimating Absolute Risks in the Presence of Noncompliance: An Application to a Women's Health Initiative Randomized Trial [31]**

Sengwee Toh, Sonia Hernandez-Diaz, Roger Logan, James M Robins, Miguel A Hernan. (United States)

*Student Award Recipient - Best Methods Abstract*

1:45pm

- **Prior Event Rate Ratio Adjustment: A Magic Bullet or More of the Same? [32]**

Arlene Gallagher, Frank de Vries, Tjeerd van Staa. (Netherlands)

*Student Award Recipient - Best Drug Utilization Abstract*

2:00pm

- **Observed Performance of the High-Dimensional Propensity Score (hd-PS) Algorithm in Small Samples [33]**

Jeremy A Rassen, M Alan Brookhart, Sebastian Schneeweiss. (United States)

2:15pm

- **Applying Propensity Scores Estimated in a Full Cohort To Achieve Balance in Subgroup Analyses [34]**

Jeremy A Rassen, M Alan Brookhart, Sebastian Schneeweiss. (United States)

2:30pm

- **Bias from Excluded Event-Depleted Time in Cohort Studies [69]**

Frank Andersohn, Stefan N Willich. (Germany)

2:45pm

- **Confounder Summary Scores When Comparing the Effects of Multiple Drug Exposures [36]**

Suzanne M Cadarette, Joshua J Gagne, Daniel H Solomon, Jeffrey N Katz, Til Stürmer. (Canada)

# Agenda - Monday, August 17

## Gastrointestinal Drugs: Going Beyond the Intestine (Room 554AB)

**Moderator:** Dan Mines & Mari-Ann Wallander, FISPE

**1:30pm**

- **Prokinetic Drugs in Children; Drug Utilization and Safety [37]**  
S de Bie, KMC Verhamme, SMJM Straus, G Piceli, A Ceci, MCJM Sturkenboom. (Netherlands)

**1:45pm**

- **No Evidence for Association of Tegaserod with Adverse Cardiovascular Ischemic Events [38]**  
Jeanne Loughlin, Sherry Quinn, Elena Rivero, Heather Norman, David L Earnest, Judy Wong, John D Seeger. (United States)

**2:00pm**

- **Use of Protonpump Inhibitors and Risk of Hip Fracture [39]**  
Arief Lalmohamed, Sander Pouwels, Cyrus Cooper, Tjeerd van Staa, Bert Leufkens, Anthonius de Boer, Frank de Vries. (Netherlands)

**2:15pm**

- **The Role of Medical Comorbidities in the Association of Proton Pump Inhibitors [PPIs] and Fractures [40]**  
David R Gagnon, Jennifer R Fonda, Richard Scranton, Elizabeth V Lawler. (United States)

**2:30pm**

- **Use of Proton Pump Inhibitors and Histamine Type 2 Receptor Blockers Is Not Associated with Pneumonia Risk [41]**  
Sascha Dublin, Rod L Walker, Michael L Jackson, Jennifer C Nelson, Noel S Weiss, Lisa A Jackson. (United States)

**2:45pm**

- **Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Associated Diarrhea [42]**  
Amy Linsky, Kalpana Gupta, Elizabeth Lawler, Jennifer Fonda, John Hermos. (United States)

## Improving Linking Databases (Room 555AB)

**Moderators:** Thomas MacDonald, FISPE, & Earl Goehring

**1:30pm**

- **Automated Data Capture from Free Text Radiology Reports To Enhance Accuracy of Hospital Inpatient Stroke Codes [43]**  
Robert Flynn, Thomas MacDonald, Gordon Murray, Alexander Doney. (United Kingdom)

**1:45pm**

- **Linking Inpatient and Outpatient Data [44]**  
Suellen Curkendall, Daniel Huse. (United States)

**2:00pm**

- **Sensitivity and Specificity of Acute Renal Failure Medical Claims Validated against Electronic Medical Records [45]**  
Marc B Rosenman, Peter M Wahl, Gregory Daniel, J Marc Overhage, Patricia McGuire, Daniel Thompson, Keith Rodgers, Louise Short, Rhonda L Bohn, William M Tierney. (United States)

**2:15pm**

- **Effect of Extended Mortality Ascertainment in a Cohort Study of the Risk of Cancer in Regranex (Becaplermin) Users and Matched Comparators [46]**  
Najat Ziyadeh, Daniel Fife, John D Seeger. (United States)

**2:30pm**

- **Signal Detection Beyond Spontaneous Reports: An Example of Acute Adverse Event Detection in Large Claims Databases [47]**  
Zhenchao Guo, Gilbert J L'Italien, Jayanti Mukherjee, Hugh Kawabata, Andres Gomez Caminero. (United States)

**2:45pm**

- **Validation of Persistent Pulmonary Hypertension in the Newborn (PPHN) within the UK-Based General Practice Research Database (GPRD): Comparing Two Approaches [48]**  
Tarek A Hammad, Carol Pamer, Susan McCune, Sigal Kaplan, Hany Aly, Solomon Iyasu. (United States)



# Agenda - Monday, August 17

## Personalized Medicine: Molecular and Genetic Biomarkers of Efficacy and Toxicity (Room 552AB)

**Moderator:** Frederick Nyberg & Andrew Freedman

**1:30pm**

- **Cisplatin, Nucleotide Excision DNA Repair Pathway, and Esophageal Cancer Outcomes: A Pharmacogenetic Epidemiology Study [49]**

Penny Bradbury, Wei Zhou, Rihong Zhai, Kofi Asomaning, Li Su, David Christiani, Geoffrey Liu. (Canada)

**1:45pm**

- **CYP2C9, CYP2C19 and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity [50]**

Sean Hennessy, Charles E Leonard, Cristin M Palumbo, Joshua P Metlay, Xin Chu, Brian L Strom, Warren B Bilker. (United States)

**2:00pm**

- **Variation in Renin-Angiotensin System and Salt Sensitivity Genes and the Risk of Diabetes Mellitus Associated with the Use of Thiazide Diuretics [51]**

Ozlem Bozkurt, Anthonius de Boer, Diederik E Grobbee, Peter W de Leeuw, Abraham A Kroon, Paul Schiffrers, Olaf H Klungel. (Netherlands)

**2:15pm**

- **Single Nucleotide Polymorphisms in Genes That Are Associated with a Modified Response to Statin Therapy: The Rotterdam Study [52]**

Catherine E de Keyser, Mark Eijgelsheim, Albert Hofman, Eric JG Sijbrands, Anke-Hilse Maitland-van der Zee, Cornelia M van Duijn, Andre G Uitterlinden, Jacqueline CM Witteman, Bruno HCh Stricker. (Netherlands)

*Student Award Recipient - Best Molecular Epidemiology - Pharmacogenetics Abstract*

**2:30pm**

- **The Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients with Atrial Fibrillation [53]**

Amanda R Patrick, Jerry Avorn, Niteesh K Choudhry. (United States)

**2:45pm**

- **Mesothelin, a Biomarker of Pharmacologic Response in Malignant Pleural Mesothelioma, Evaluated in a Molecular Epidemiologic Study [54]**

Boming Yang, Paul Wheatley-Price, Deval Patel, Clement Ma, Natasha Leighl, Ron Feld, Marc de Perrot, Geoffrey Liu. (Canada)

## Vaccines (Room 556AB)

**Moderators:** M. Miles Braun, FISPE, & Robert Chen, FISPE

**1:30pm**

- **A Systematic Approach To Analyze Safety Data Clinical Trial Database [55]**  
Caroline Legendre, Alena Khromava, Gillis Carrigan. (France)

**1:45pm**

- **Active Safety Surveillance of DTaP Vaccines by Linkage of Immunization Registry and Claims Database in Korea [56]**  
Sun-Young Jung, Nam-Kyong Choi, Byung-Joo Park. (Korea)

**2:00pm**

- **The Risk of Seizures after Acellular Pertussis Vaccines in Early Childhood — United States, 2002-2006 [57]**  
Wan-Ting Huang, Paul Gargiullo, Irene Shui, Eric Weintraub, James Baggs, Karen Broder, John Iskander. (United States)

**2:15pm**

- **Effectiveness of the Pentavalent Rotavirus Vaccine in Preventing Gastroenteritis in the United States: A Claims-Based Analysis [58]**  
Florence T Wang, T Christopher Mast, Roberta J Glass, Jeanne Loughlin, John D Seeger. (United States)

**2:30pm**

- **Cautionary Example of Potential Exposure-Based Differential Misclassification in a Post-Marketing Vaccine Safety Study [59]**  
Nancy C Santanello, Christopher Mast, Jeanne Loughlin, John Seeger. (United States)

**2:45pm**

- **A Post-Marketing Surveillance Program for Pentavalent Rotavirus Vaccine [60]**  
Jeanne Loughlin, Wang Florence, P Mona Eng, T Christopher Mast, John D Seeger. (United States)

**3:00-3:30pm**

**Break/Posters/Exhibits (Hall B)**

# Agenda - Monday, August 17

3:30-5:00pm

## Concurrent Sessions: Symposia And Workshops

**Automated Data Sources for Pharmacoepidemiology in Asia-Pacific Region – Updates and Perspectives [61]**  
(Room 556AB)

- **Byung Joo Park, Yea Huei Kao Yang, Libby Roughead, Daisuke Koide, Jeff J Guo, Tomomi Kimura, Arnold K Chan, Judith K Jones, Brian L Strom.** (Japan)

**Can Registries Deliver? The Methods and Use of Registries for Biologics [62]**  
(Room 555AB)

*- Sponsored by the Biologics SIG*

- **Sean Zhao, Nancy Dreyer, Alex Cole, Annette Stemhagen, Nils Feltelius, Joanna Haas.** (United States)

**Confounding by Indication Studying Epoetin and Mortality [63]** (Ballroom B)

- **John Acquavella, Eric Weinhandl, Brian Bradbury, Alan Brookhart, Til Stürmer, Kenneth J Rothman.** (United States)

**Evaluating Study Designs for the Measurement of Drug Exposure in Pregnancy [64]** (Room 552AB)

*- Sponsored by the Medicines in Pregnancy SIG and the Teratology Society*

- **Elizabeth B Andrews, Lyn Colvin, Sonia Hernandez-Diaz, Lewis Holmes, Tina Chambers, Andrea Margulis, Allen Mitchell.** (United States)

**Pharmacoepidemiology, Medicines Policy and Health Outcomes: The Next Steps [65]**  
(Room 551AB)

- **Andrew L Gilbert, Richard Laing, Andreas Laupacis, Elizabeth Roughead, Kate L Lapane.** (Australia)



**The Past, Present and Future of Pharmacoepidemiology at CDER, FDA [66]** (Ballroom A)

- **Solomon Iyasu, Tarek A Hammad, Gerald J Dal Pan, Judy A Staff.** (United States)



**Is Accuracy at Odds with Privacy? Challenges and Solutions When Combining Data from Multiple Sources [285]** (Room 554AB)

- **Jeremy Rassen, Lang Chen, Miriam Sturkenboom, Sebastian Schneeweiss, Stephen Evans.** (United States)

5:00-6:00pm

## ISPE Council Meetings (Westin)

- Open to all interested participants
- **Academic Council** (Narragansett C)
- **Government/Regulatory Council** (Narragansett B)
- **Manufacturing/Service Providers Council** (Narragansett A)

5:15-6:15pm

## Fourth Asian Meeting Planning Committee (RICC-Room 554AB)

6:00-7:30pm

## PDS Editorial Board (Westin, Bristol Room, Third Floor)

- By Invitation

7:00pm- ?

## Student Social Event – A Night Out in Providence (Bravo Brasserie 123 Empire Street)

- Open to all students.
- Organized by the ISPE Student Council



Providence Skyline  
Photo credit: Providence/Warwick Convention & Visitors Bureau



You will notice that the “ICPE 25th Anniversary” logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.

# PDS Pharmacoepidemiology & Drug Safety

Official Journal of the International Society for Pharmacoeconomics

**Editor-in-Chief: Professor Ronald D. Mann**

*Pharmacoeconomics & Drug Safety* provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoeconomics.

- Free online access for ISPE members via the society website
- Latest Impact Factor: 2.516 (JCR® 2008)

## A selection of the top-downloaded papers from the 2008 Volume (17)

- Reliability of the assessment of preventable adverse drug events in daily clinical practice.  
*Jasperien E. van Doornaal, Peter G. M. Mol, et al. Volume 17, Issue 7, Pages 645-54*
- Association between serious ischemic cardiac outcomes and medications used to treat diabetes.  
*David J. Margolis, Ole Hoffstad, Brian L. Strom. Volume 17, Issue 8, Pages 753-59*
- Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.  
*Alexander M. Walker, Carol E. Koro, Joan Landon. Volume 17, Issue 8, Pages 760-68*
- A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.  
*Alexander Cobitz, Andrew Zambanini, et al. Volume 17, Issue 8, Pages 769-81*
- The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care.  
*Luis Alberto Garcia-Rodriguez, Elvira Luján Massó-González, Mari-Ann Wallander, Saga Johansson. Volume 17, Issue 10, Pages 943-52*



For more information on these top papers and other journal features, please visit

[www.interscience.wiley.com/journal/pds](http://www.interscience.wiley.com/journal/pds)

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2009 Volume: 18 • Frequency: Monthly

 **WILEY-BLACKWELL**

# Agenda - Tuesday, August 18

7:00-8:00am

**Annual Roundtable Discussion/  
Breakfast: Centers for Education and  
Research on Therapeutics [608]**  
(Room 557)

- Anne E Trontell, Mark Hornbrook, Stephen Crystal. (United States)

7:00-8:00am

**Poster Session B Set-up (Hall B)  
Continental Breakfast (Hall B)**

7:00-6:00pm

**Registration (Third Floor Foyer)**

7:30-5:00pm

**Speakers' Ready Room (Room 553B)**

8:00-6:00pm

**Exhibits/Posters (Hall B)**

8:00-9:15am

**Invited Plenary Session**

(Ballroom A)

**National Pharmaceutical Policy  
Imperatives: Implications for Pharma-  
coepidemiologists**

**Chair: Andrew Gilbert**

**Speaker: Lloyd Sansom**, Emeritus Professor;  
University of South Australia: Chair, Phar-  
maceutical Benefits Advisory Committee;  
Australian Government Department of Health  
and Aging

9:15-10:30am

**Annual Meeting Of ISPE Members, Awards  
Ceremony & Special Address (Ballroom A)**

- Open to all participants.



**Annual Meeting of ISPE Members**

- **Miriam CJM Sturkenboom, FISPE**, ISPE President
- **Nancy Dreyer**, ISPE Vice President Finance

**Awards Ceremony**

**ICPE 2009**

- **Presented by: Miriam CJM Sturkenboom**, ISPE President
- **Brian J. Quilliam**, Chair, Local Host Committee
- **Susan Sacks, FISPE**, Co-Chair, 25th Anniversary ICPE Committee
- **Kate Lapane, FISPE**, Chair, 2009 Scientific Program Committee & Co-Chair, 25th Anniversary ICPE Committee

**Student Awards**

- **Presented by: Kate Lapane, FISPE**, Chair,  
2009 Scientific Program Committee

*Best Drug Utilization Abstract: Arlene Gallagher*

*Best Molecular Epidemiology/Pharmacogenetics Abstract:  
Catherine de Keyser*

*Best Methods Abstracts: Sengwee Toh*

*Third Best Abstract: Nicole Pratt*

*Second Best Abstract: Mary Ritchey*

*Edlavitch Award (Best Student Abstract): Charlotte van Noord*

**Induction of ISPE Fellow (FISPE)**

- **Yola Moride, FISPE**, Chair, Fellowship & Awards Committee

*Inductees:*

- **Stella Blackburn, FISPE**
- **James D. Lewis, FISPE**

**Pharmacoepidemiology & Drug Safety**

**ISPE-PDS Prizes for Best Papers published in PDS Volume 17 (2008)**

- **Presented by, Brian Strom, FISPE**, Regional Editor for the Americas,  
**Joerg Hasford**, Regional Editor for Europe, and **Richard Hughes**,  
Managing Editor, PDS



**Special Anniversary Address**

- **25 Years in 25 Minutes**  
**Hugh Tilson**, Honorary Lifetime Fellow

10:30-11:00am

**Break/Posters/Exhibits (Hall B)**

*-Sponsored by CSD-EPIC*



You will notice that the "ICPE 25th Anniversary" logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.

# Agenda - Tuesday, August 18

11:00-12:30pm

## Concurrent Sessions - Contributed Papers

### Anti-Infectives (Room 552B)

Moderators: Patricia Saddier & Kerry LaPlante

11:00am

● **Effectiveness of an Information Technology Intervention To Improve Prophylactic Antimicrobial Use in the Post-Operative Period [227]**

Kevin Haynes, Darren Linkin, Neal Fishman, Warren Bilker, Eric Pifer, Sean Hennessy. (United States)

11:15am

● **Effectiveness of Palivizumab in Medicaid Infants [228]**

Almut G Winterstein, Christian Hampp, Arwa Saidi. (United States)

11:30am

● **Comparison of Infection-Related Hospitalization Risk among Patients Receiving Sargramostim, Filgrastim, and Pegfilgrastim for Chemotherapy-Induced Neutropenia [229]**

Mei Sheng Duh, Edmond L Toy, Francis Vekeman, Francois Laliberte, Bree L Dority, Daniel Perlman, Victoria Barghout, Mark L Heaney. (United States)

11:45am

● **Is Cigarette Smoking a Risk Factor for Subsequent Use of Antibiotics? [230]**

Hege S Blix, Vidar Hjellvik, Irene Litleskare, Marit Rønning, Aage Tverdal. (Norway)

12:00pm

● **Reporting of Hepatic Events in Patients Using Vancomycin from Clinical Studies: A Meta-Analysis [231]**

Yan Chen, Xiao Yan Yang, Michael Zeckel, Chris Killian, Kenneth Hornbuckle, Simon Voss. (United States)

12:15pm

● **Outcomes of Antibiotic Use for Respiratory Infections [232]**

Sharon B Meropol, A Russell Localio, Joshua P Metlay. (United States)

### Information as Basis for Risk Management (Ballroom D)

Moderators: Elizabeth Andrews, FISPE & Nataliya Volkova

11:00am

● **Determinants of Metabolic Testing for Patients Treated with Second-Generation Antipsychotics after the FDA Diabetes Warning [233]**

Elaine H Morrato, Benjamin Druss, Daniel M Hartung, Robert J Valuck, Deborah Thomas, Richard Allen, Elizabeth Campagna, John W Newcomer. (United States)

11:15am

● **Quantification of Patient Population Impact of Contra-Indications: Glaucoma Therapy [234]**

Andrew Maguire, Sharon MacLachlan (United Kingdom)

11:30am

● **Perceptions of Older Adults Regarding Information Obtained from Pharmacists and Medication Leaflets [235]**

Roberta Goldman, Anne L Hume, Brian J Quilliam, Pedro Pichardo, Devi Ross, Kate L Lapane. (United States)

11:45am

● **Opioid Analgesic Abuse Surveillance: Convergence of Poison Control Center Intentional Exposure Calls and Media Reports [236]**

John Brownstein, Richard Dart, Meredith Y Smith. (United States)

12:00pm


● **Evaluation of the Infliximab (Remicade®) Pediatric Crohn's Disease Educational Plan [237]**

Alejandro Arana, Sam Allen, Ola Ghatnekar, María T Rico, Nathalie Vanhaverbeke, Jörg Burkowitz, Charles E Wentworth, Valerio Fantoni, Max Brosa, Felix M Arellanom (Spain)

12:15pm

● **A Comparison of Health Outcomes and Healthcare Utilization during Episodes of Modified-Release Opioid Analgesic Therapy with and without Evidence of an Alcohol-Related Disorder [238]**

Meredith Y Smith, J David Haddock, Liisa Palmer. (United States)



# Agenda - Tuesday, August 18

## Measurement Methods (Ballroom B)

**Moderators:** Tobias Gerhard & Tamar Lasky

**11:00am**

- **Prescription Changes and Chronic Disease Score as Predictors for Hospitalization [239]**  
Carolien GM Sino, Rutger Stuffken, Eibert R Heerdink, Patrick C Souverein, Marieke J Schuurmans, Antoine CG Egberts. (Netherlands)

**11:15am**

- **Positive Predictive Value (PPV) of Commercial Health Insurance Claims Data for Identifying Acute Pancreatitis (AP) in Patients with Diabetes Mellitus (DM) [240]**  
David D Dore, Clorinda Hoffman, Sherry G Quinn, Saadia Chaudhry, John D Seeger. (United States)

**11:30am**

- **Impact of Exposure Data Sources on Risk Estimates in Etiological Studies: Application to Benzodiazepines in the Three-City (3C) Study [241]**  
Fabienne Bazin, Pernelle Noize, Antoine Pariente, Nicholas Moore, Annie Fourrier-Réglat. (France)

**11:45am**

- **The Validity of Mother-Reported Asthma and Asthma Medication Use in Children [242]**  
Kari Furu, Øystein Karlstad, Svetlana Skurtveit, Siri Haaberg, Per Nafstad, Stephanie London, Wenche Nystad. (Norway)

**12:00pm**

- **Impact of Missing Data on Potential Confounders in Perinatal Pharmacoepidemiologic Studies Using Administrative Databases [243]**  
Anick Bérard, Hamid R Nakhai-Pour, Sophie Kulaga. (Canada)

**12:15pm**

- **Risk of Hospitalization among Rheumatoid Arthritis Patients Initiating Treatment with TNF- $\alpha$ -Antagonists: Effect of Different Exposure Measurements and Propensity Score Estimates [244]**  
Carlos Grijalva, Lisa Kaltenbach, Patrick Arbogast, Edward Mitchel, Marie Griffin. (United States)

## The Spectrum of Anti-Inflammatory Therapies (Room 552A)

**Moderators:** Sean Hennessy, FISPE & C. Ineke Neutel, FISPE

**11:00am**

- **The Influence of CYP2D6, CYP3A4/3A5 and UGT2B7 Genetic Polymorphisms on Prescription of Other Analgesics in Codeine Users [245]**  
Monique J Bijl, Loes E Visser, Ron HN van Schaik, Mark Eijgelsheim, Albert Hofman, Andre G Uitterlinden, Arnold G Vulto, Teun van Gelder, Bruno HCh Stricker. (Netherlands)

**11:15am**

- **Risk of Serious Infections Among Patients with Rheumatoid Arthritis Initiating Treatment with Tumor Necrosis Alpha Antagonists [246]**  
Carlos Grijalva, Lisa Kaltenbach, Patrick Arbogast, Edward Mitchel, Marie Griffin. (United States)

**11:30am**

- **Changes in Overuse and Underuse of Prophylactic Strategies with NSAID Treatment over the Past Decade [247]**  
VE Valkhoff, EM van Soest, MCJM Sturkenboom, EJ Kuipers. (Netherlands)

**11:45am**

- **Concomitant Use of Gastroprotective Agents (GPAs) among NSAID/COX-2 Selective Inhibitor Users: A Hospital Register-Based Study [248]**  
Jarir Atthobari, Erna Kristin, Iwan Dwiprahasto. (Indonesia)

**12:00pm**

- **Randomized Controlled Trials on Cox-2 Inhibitors, Changes in Comparator Dose over Time [249]**  
G Stefansdottir, ML de Bruin, MJ Knol, DE Grobbee, HGM Leufkens. (Netherlands)

**12:15pm**

- **Association between Non-Steroidal Anti-Inflammatory Drugs and Keratinocyte Cancer Prevention: VATTTC Trial [250]**  
Anthony P Nunes, Kate L Lapane, Martin A Weinstock. (United States)

# Agenda - Tuesday, August 18

## Use and Risks of Psychotropics in Elderly Persons (Room 557)

Moderators: Vincent Mor & Lauri Daiello

11:00am

- **Socioeconomic Determinants of Psychotropic Drug Use Among Elderly [251]**  
Eva Lesén, Karolina Andersson, Max Petzold, Anders Carlsten. (Sweden)

11:15am

- **Antipsychotics and the Risk of Hip Fracture, Pneumonia and Stroke: Self-Controlled Case Series and Instrumental Variable Analysis Results [252]**  
Nicole Pratt, Elizabeth Roughead, Philip Ryan, Robert Peck, Andrew Gilbert. (Australia) *Student Award Recipient - Third Best Abstract*

11:30am

- **Antipsychotic Use and the Risk of Hip Fracture in Nursing Home Residents with Dementia [253]**  
Jessica J Jalbert, Susan C Miller, Charles B Eaton, Kate L Lapane. (United States)

11:45am

- **Factors Associated with Discontinuation of Cholinesterase Inhibitors in the Netherlands [254]**  
Edeltraut Kröger, Rob van Marum, Patrick Souverein, Toine Egberts. (Netherlands)

12:00pm

- **Impact of Non-Persistence to Cholinesterase Inhibitor Treatments in Demented Elderly [255]**  
Antoine Pariente, Annie Fourrier-Réglat, Alice Dragomir, Sylvie Perreault, Nicholas Moore, Yola Moride. (France)

12:15pm

- **Risk of Upper Gastrointestinal Bleeding and Degree of Serotonin Reuptake Inhibitions among Elderly Patients in Korea [256]**  
Ye-Jee Kim, Nam-Kyong Choi, Sun-Young Jung, Jong-Mi Seong, Joongyub Lee, Byung-Joo Park. (Republic of Korea)

## REGISTRAT·MAPI

A Global Late Phase CRO

A global, Late Phase CRO, REGISTRAT-MAPI has extensive experience in the design, implementation, and management of peri- and post-approval studies for biotechnology pharmaceutical and medical device clients. Operating as the only global, full-service Late Phase focused CRO, REGISTRAT-MAPI has offices in North America, Europe and Asia.

REGISTRAT-MAPI provides integrated clinical development services worldwide in 60 countries. For more information please do not hesitate to call Carolyn Maki in the US (+1-859-967-9329 Ext.545 ) and Hubert Mechin in Europe ((+33) 4 72 35 53 36).

### REGISTRAT-MAPI, North America

2343 Alexandria Drive - Suite 400  
Lexington KY 40504-3276 USA  
Tel : +1-800-381-7878  
Fax : +1-859-223-2005

### REGISTRAT-MAPI, Europe

27 rue de la Villette  
69003 Lyon FRANCE  
Tel : +33 4 72 13 66 66  
Fax : +33 4 72 13 59 62

# Agenda - Tuesday, August 18

12:30-2:00pm

Lunch/Poster Session B/Exhibits/  
Poster Walks (Hall B)

Poster Walks/Moderators

- **Pharmacovigilance**  
Harry Seibert
- **Molecular Epidemiology/  
Pharmacogenetics**  
Weu Zhou & David Miller
- **Drug Utilization Studies**  
Monique Elseviers
- **Biologics**  
Pavel Napalkov
- **Use of Linked Database**  
Matthew R. Reynolds

ISPE Committee/Council Meetings

- Open to all participants. (Lunches will be available in meeting rooms)
- **Bylaws and Policies Committee**  
(Room 558A)
- **Global Development Committee**  
(Room 554A)
- **Membership Committee** (Room 554B)
- **Publications Committee** (Room 558B)

1:00-2:00pm

Public Forum on Core Competencies  
for Pharmacoepidemiology (Ballroom A)

*Sponsored by ISPE Education Committee*

- *NOTE: Eat first—lunch will not be available at this session*

**Introduction**

- **James D. Lewis, FISPE**, Chair, Education Committee

**Moderator, Introduction**

- **Hugh Tilson, FISPE**

**Data Presentation**

- **Judith Jones, FISPE**

**Panel Comments**

- **Jennifer Polinski**, Student Council
- **Wei Dong**, Manufacturing/Service Provider Council
- **Anna Birna Almarsdóttir**, Academic Council
- **Richard Hill**, Government/Regulatory Council

**Open Discussion**

2:00-3:30pm

Concurrent Sessions - Contributed Papers

Cancer All Over the Place! (Room 551A)

Moderators: Annette Beiderbeck & Jim Kaye

2:00pm

- **Half of Breast Cancer Patients Starting on Tamoxifen Complete Five Years of Endocrine Treatment [257]**  
Myrthe PP van Herk-Sukel, Adri C Voogd, Grard AP Nieuwenhuijzen, Ron MC Herings, Jan Willem W Coebergh, Lonneke V van de Poll-Franse. (Netherlands)

2:15pm

- **Dose Response of Retinol and Isotretinoin in the Prevention of Non-Melanoma Skin Cancer Recurrence [258]**  
Mary C Clouser, Denise J Roe, Janet A Foote, Robin B Harris. (United States)

2:30pm

- **Incidence Rates of ARDS in Solid Tumor Cancer Patients in the THIN Database [259]**  
Victor Gastanaga, Chuck Wentworth, Anthony Yeo, Gail Hughes, William Haddock, Sean Zhao. (United States)

2:45pm

- **Patients (Pts) with Metastatic Renal Cell Carcinoma (mRCC) Receiving Angiogenesis Inhibitor (AI) Therapies: Treatment Efficacy and Safety in Clinical Practice [261]**  
David McDermott, Toni K Choueiri, Jessica Clement, Ashley J Brick, Christabel Kwabi, Karishma Shah, Lucia Antras, Sujata S Jayawant, Si-Tien Wang, Andi Luka, Mei Sheng Duh, Maureen Neary, William K Oh. (United States)

3:00pm

- **Pattern of Bevacizumab (BV) Use in 1st-Line Therapy Metastatic Colorectal Cancer (mCRC) in Real-Life Practice: Results of the ETNA Cohort Study [262]**  
A Fourrier-R[eaculte]glat, D Smith, A Ravaud, M Rouyer, A Balestra, D Jayles, N Moore, ETNA Study Group.

# Agenda - Tuesday, August 18

## Cardiovascular Disease (Ballroom D)

Moderators: Annlouise Assaf & Cristina Varas

2:00pm

★ **Antipsychotic Use and Myocardial Infarction in Demented Patients Treated with Cholinesterase Inhibitors [263]**

Antoine Pariente, Yola Moride, Alice Dragomir, Sylvie Perreault, Nicholas Moore, Annie Fourier-Réglat. (France)

2:15pm

★ **Do Selective Cyclooxygenase-2 Inhibitors and Nonselective Non-steroidal Antiinflammatory Drugs Increase the Risk of Cardiovascular Events and Death after Intracoronary Stenting? [264]**

M Schmidt, M Maeng, L Pedersen, JF Lassen, TT Nielsen, HT Sorensen. (Denmark)

2:30pm

★ **Evaluation of the Level of Anticoagulation Control in Patients with Non-Valvular Atrial Fibrillation [265]**

Bill Zang, Efrosini Setakis, Tjeerd P van Staa. (United Kingdom)

2:45pm

★ **Non-Selective  $\beta$ -Blockers Decrease Thrombotic Events in Patients with Heart Failure [266]**

Olav R De Peuter, Patrick C Souverein, Olaf H Klungel, Ton de Boer, Harry R Büller, Pieter-Willem Kamphuisen. (Netherlands)

3:00pm

★ **Oral Bisphosphonates and the Risk of Atrial Fibrillation in a Cohort of Older Adults [267]**

Linda Lévesque, Ana Blagojevic, Mahyar Etminan, James Brophy. (Canada)

3:15pm

★ **Case-Control Study: Use of Oral Contraceptives Containing Dienogest and Risk of Venous Thromboembolism [268]**

Juergen C Dinger, Kristina Voigt, Sabine Moehner. (Germany)

*minimized risk*

US +1 866 458 1095  
EU +44 (0) 207 299 4550  
[unitedbiosource.com](http://unitedbiosource.com)

**Safety & Risk Management**

UBC understands that the greatest risk is the unknown. We help clients assess, identify and plan for risk by developing and implementing Risk Evaluation and Mitigation Strategies (REMS), Risk Management Plans, epidemiology studies, registries and large simple safety studies globally. All of our solutions are designed and executed by industry-leading experts to assess and demonstrate product safety, mitigate risk and meet regulatory requirements.

UBC accelerates the generation, analysis and communication of real-world evidence by integrating scientific and operational expertise with innovative technology solutions to support the global development and commercialization of medical products for life science companies.

**UBC**  
United BioSource Corporation  
*Evidence Matters™*

# Agenda - Tuesday, August 18

## Potpourri Session (Ballroom B)

**Moderators:** Gianluca Trifiro and Rene Schade

**2:00pm**

● **Population-Based Studies of Antithyroid Drugs and Sudden Cardiac Death [609]**

Charlotte van Noord, Miriam CJM Sturkenboom, Sabine MJM Straus, Jacqueline CM Witteman, Bruno HC Stricker. (Netherlands)

*Student Award Recipient - Best Abstract*

**2:15pm**

● **Outcomes Following a Hip Fracture and Length of Hospitalization: The General Practice Research Database (GPRD) [610]**

Arlene Gallagher, Frank de Vries, Rinat Ariely, Tjeerd van Staa. (United Kingdom)

**2:30pm**

● **Polymorphisms in Two Regions of the Cyclo-Oxygenase-2 Gene Associated with Variation in Risk of Coronary Thrombosis with Cyclo-Oxygenase-2 Inhibitors [611]**

D Henry, L Lincz, J Attia, P McElduff, L Bisset, R Peel, S Hancock, K Henderson, D Whitaker, M Seldon, P McGettigan. (Canada)

**2:45pm**

● **Human Avian Influenza: Development of a Shoe-Leather Approach to Evaluating Treatment Effectiveness [612]**

W Adisasmito, M Zaman, P Chan, N Lee, V Gasimov, FF Aghayev, A Oner, E Bamgboye, N Dogan, K Starzyk, A Layton, R Coker, S Toovey, N Dreyer.

**3:00pm**

● **Gabapentin Use in the US Department of Veterans Affairs [613]**

JE Lavigne, D Ganoczy, KL Knox, M Valenstein.

**3:15pm**

● **Changing Rate of Blood-Stream Infection across Duration of Central Venous Access [614]**

Mary Ritchey, Michele Jonsson Funk, Stephen Marshall, Danica Marinac-Dabic, William Rutala, David Weber. (United States)

*Student Award Recipient - Second Best Abstract*



## Risk Factors, Surveillance, and Comorbidity Burden (Room 551B)

**Moderators:** Wei Dong & Brian J. Quilliam

**2:00pm**

● **Validation of the National Respiratory and Enteric Virus Surveillance System for the Detection of Respiratory Syncytial Virus Seasons [269]**

Christian Hampf, Almut Winterstein. (United States)

**2:15pm**

● **Heptitis C Virus Genotype and Basal Viral Load Distribution in Different Regions of Mexico [270]**

Ricardo Jimenez-Mendez, Felipe Uribe-Salas, Paulo Lopez-Guillen, Gilberto Castaneda-Hernandez. (Mexico)

**2:45pm**

● **Modifiable Risk Factors among Uninsured, Insured and Medicaid-Insured United States Adults Aged 18 to 64 Years [271]**

Margaret McDonald, Robin P Hertz, Michael B Lustik, Alan N Unger. (United States)

**3:00pm**

● **Type 2 Diabetes and Incidence of Urinary Tract Infections (UTIs). Experience from the General Practice Research Database (GPRD) [272]**

Ishan Hirji, Zhenchao Guo, Susan Andersson, Niklas Hammar, Andres Gomez Caminero. (United States)

**3:15pm**

● **Comorbidity in Patients with Non-Small Cell Lung Cancer (NSCLC) - The Cancer and Comorbidity (CACOM) Study [273]**

Fredrik Nyberg, Tobias Svensson, Helle Kieler, Mats Lambe, Anders Ekblom, Fredrik Granath. (Sweden)

**3:30pm**

● **Renal Cell Carcinoma Patients Are Twice as Likely To Develop Thromboembolic Events Compared to Cancer-Free Controls [274]**

Myrthe PP van Herk-Sukel, Sumitra Shantakumar, Mariel K Casparie, Page E Abrahamson, Fernie JA Penning-van Beest, Ron MC Herings. (Netherlands)

# Agenda - Tuesday, August 18

## To Do No Harm....? (Room 557)

**Moderators: Frank May, FISPE, & Yea-Huei Kao Yang**

### 2:00pm

- **Prevalence, Nature and Severity of Prescribing Errors in Hospital Inpatients: Prospective Study in 20 UK Hospitals [275]**

Darren M Ashcroft, Penny J Lewis, Emma Carter, David Taylor, Mary P Tully, Valerie Wass, Steven Williams, Timothy Dornan. (United Kingdom)

### 2:15pm

- **Prevalence, Clinical Profile, and Preventability of Drug-Related Hospital Admissions: Prospective Observational Study [276]**

Darren M Ashcroft, Chuenjid Kongkaew, Steven Williams, David Metcalfe, Jaydeep Mandal, Peter Noyce. (United Kingdom)

### 2:30pm

- **Computerized Clinical Decision Support during Medication Ordering for Long-Term Care Residents with Renal Insufficiency [277]**

Terry S Field, Paula Rochon, Monica Lee, Joann L Baril, Jerry H Gurwitz. (United States)

### 2:45pm

- **RCT of a Computer Hard Stop Order Alert vs Routine Practice To Prevent Concurrent Orders of Trimethoprim/Sulfamethoxazole and Warfarin [278]**

Brian L Strom, Rita Schinnar, Faten Aberra, Warren Bilker, Sean Hennessy, Charles E Leonard, Eric Pifer. (United States)

### 3:00pm

- **The Effectiveness of Collaborative Medicine Reviews in Delaying Time to Next Hospitalisation for Heart Failure Patients in the Ambulatory Setting: Results of a Cohort Study [279]**

Andrew L Gilbert, Elizabeth E Roughead, John D Barratt, Emmae Ramsey, Nicole Pratt, Phillip Ryan, Robert Peck, Graeme Killer. (Australia)

### 3:15pm

- **Quality of Consumer Generated Adverse Event Reports [280]**

Rose C Plummer, Elisa F Cascade. (United States)

## 3:30-4:00pm

### Break/Posters/Exhibits

## 4:00-5:30pm

### Concurrent Sessions: Symposia & Workshops

#### Practical Aspects of Signal Detection in Pharmacovigilance – The CIOMS VIII Report [469] (Room 557)

- **June M Raine, Gerald Dal Pan, Manfred Hauben, Atsuko Shibata.** (United Kingdom)

#### Conflict of Interest (COI) – What Is It? What Can Be Done To Minimize It? [282] (Room 552A)

- *Proposed by* **Wei Dong, Susan Oliveria, Robert F Reynolds, Pavel Napalkov, Paul Stang, Marianne Ulcickas Yood.** (United States)
- **Bob Levine**, Director of Law, Policy and Ethics, Yale University, An Overview and Theoretical Framework of COI
- **Jill Hartzler Warner**, Office of Policy, Planning and Preparedness/Office of the Commissioner, FDA, An Overview of Policies and Considerations from FDA
- **Stella Blackburn, FISPE**, EMEA, ENCePP's Perspective on COI
- **Cary Gross**, Division of Internal Medicine, Yale University, Considerations from Academia
- **Walter Straus**, Merck Research Laboratories, Considerations from the Industry

#### Developing Good Practice Guidance for Non-Randomized Studies of Comparative Effectiveness: A Workshop on Quality and Transparency [283] (Ballroom B)

- **Nancy Dreyer, Gilbert J L'Italien, Scott Smith, Sebastian Schneeweiss.** (United States)

#### How Should We Plan and Communicate Interim Results of Pharmacoepidemiology Studies? An ISPE Public Policy Forum [284] (Ballroom D)

- **Susana Perez-Gutthann, Til Stürmer, Richard Platt, Brian L Strom, Patricia Saddier, June Raine.** (Spain)

#### Providing Pharmacoepidemiological Data Intended for Drug Regulatory Decision Making [286] (Ballroom A)

- **Joanna F Haas, Sebastian Schneeweiss, Elizabeth B Andrews, Edward Bortnichak, Judith Jones, Gerald Dal Pan.** (United States)

#### Who Is a Patient's Main Prescriber and How Should Clustering Within Prescriber Influence Analyses? [67] (Room 552B)

- **Niteesh K Choudhry, Robert J Glynn, M Alan Brookhart, Jeremy A Rassen.** (United States)

# Agenda - Tuesday, August 18

5:30-6:30pm

## Special Interest Group (SIG) Meetings

- Open to all participants.

- **Biologics SIG** (Room 551A)
- **Database SIG** (Room 551B)
- **Drug Utilization/Health Services Research SIG** (Ballroom B)
- **Medications in Pregnancy SIG** (Room 552A)
- **Molecular Epidemiology/ Pharmacogenetics SIG** (Room 55B)



Brass Attack

7:30-Midnight

## Evening at the Waterplace Restaurant

Join your colleagues to help celebrate ISPE's Silver Anniversary ICPE on this special evening. Brass Attack, Southern New England's finest dance band, will provide the music. And ISPE will host a WaterFire – an award-winning sculpture by Barnaby Evans and truly an unforgettable sensory experience, at dusk.

Admission is by badge or ticket.  
Cash bar



Water Fire  
Photo credit: Providence/Warwick Convention & Visitors Bureau

## The Most Trusted Epidemiology Resources

Web-based | Easy-to-Use | Projections to 2030



Epi Database® is a global database that provides reliable, documented, and well-researched epidemiological estimates across therapeutic areas.

- Includes over 180 indications<sup>1</sup> and covers France, Germany, Italy, Spain, the United Kingdom, Japan, the United States, Brazil, Russia, India, and China
- Thoroughly researched in scientific literature, with fully documented sources that provide complete transparency
- Breakouts are provided by country, indication, and year, as well as gender, race, and age if applicable.<sup>2</sup>

<sup>1</sup> Indications may vary by country.

<sup>2</sup> Gender, age, and race breakouts may vary by indication and country.



CancerMPact® Patient Metrics module is a comprehensive resource for historical, current, and projected cancer epidemiology and treatment estimates.

Best-in-class information and proprietary calculations provide stage specific data on:

- Incidence
- Restaged 10-year prevalence
- Active Disease
- Treated patient populations by modality
- Treated patient populations by drug regimen
- Includes analysis of 30 tumor types by country for the U.S., France, Germany, Italy, Spain, the UK, and Japan

**MATTSON JACK**  
A Kinase Health Company

Visit our booth for a demonstration.

info@mattsonjack.com • www.mattsonjack.com

# Need Evidence?

Patient Registries	Comparative Effectiveness
Safety / Surveillance	Phase IIIB Expanded Access
Risk Management	Quality Measurement
Health Outcomes	Quality Improvement
Phase IV Studies	Health Interventions
Quality of Life	Observational Studies

**Talk to the Leader** in Real-World Research.

Visit us at the Annual ICPE Meeting in Providence.



[www.outcome.com](http://www.outcome.com) [evidence@outcome.com](mailto:evidence@outcome.com) 617-621-1600 +41 (0) 21 321 3560

© 2009 Outcome Sciences, Inc. All Rights Reserved

# Agenda - Wednesday, August 19

7:00-8:00am

2010 ICPE Scientific Program

Committee Meeting (Room 557)

- Open to interested ISPE members

7:30-8:30am

Poster Session C Set-up (Hall B)

Continental Breakfast (Hall B)

7:30-5:00pm

Registration

(Third Floor Foyer)

7:30-3:30pm

Speakers' Ready

Room (Room 553B)

8:00-1:45pm

Exhibits/Posters

(Hall B)

Diabetes From Legs To Death

(Room 551A)

**Moderators:** Niklas Hammar & Andrej Czarnecki, FISPE

8:30am

★ **Use of Thiazolidinediones and the Risk of Fracture in Patients with Type II Diabetes in Taiwan [444]**

Churn-Shiouh Gau, Yi-Shiu Lin. (Taiwan)

8:45am

★ **Thiazolidinediones and Fractures in Men and Women [445]**

Colin R Dormuth, Greg Carney, Bruce Carleton, Ken Bassett, James M Wright. (Canada)

9:00am

★ **Effect of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors on Limb Amputation [446]**

David Margolis, Ole Hoffstad, Tim Crombleholme. (United States)

9:15am

★ **Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators: A Retrospective, Cohort Study [447]**

David Dore, Gary Bloomgren, Ruth Patterson, Sherry Quinn, Clorinda Hoffman, Saadia Chaudhry, Rebecca Noel, Daniel Braun, John Seeger. (United States)

9:30am

★ **Adverse Cardiovascular Events during Treatment with Pioglitazone and Rosiglitazone [448]**

David N Juurlink, Tara Gomes, Lorraine L Lipscombe, Peter C Austin, Jan E Hux, Muhammad M Mamdani. (Canada)

9:45am

★ **Combination Therapy of Sulfonylureas and Metformin and the Risk of Death in Patients with Type 2 Diabetes [449]**

Laurent Azoulay, Verena Schneider-Lindner, Sophie Dell'Aniello, Alicia Schiffrin, Samy Suissa. (Canada)

8:30-10:00am

## Concurrent Sessions - Contributed Papers

Analysis Methods II (Ballroom B)

**Moderators:** John Seeger & Tomasz Dyszynski

8:30am

★ **Using Different Types of Priors in a Bayesian Hierarchical Model for the Analysis of Drug Adverse Events [438]**

David Prieto-Merino, Stephen JW Evans. (United Kingdom)

8:45am

★ **The Effect of Psychotropic Medication Among Children On Changes in Mental Health: A Comparison of Marginal Structural Models (MSM) with Standard Regression Adjustment [439]**

Shirley Wang. (United States)

9:00am

★ **Predictors of Nucleoside Reverse Transcriptase Inhibitor Use: Channeling Bias in HIV Clinical Care [440]**

Emily S Brouwer, Sonia Napravnik, Joseph J Eron Jr. (United States)

9:15am

★ **Hurdle or No Hurdle? Select Appropriate Statistical Methods for Modeling Rare Events [441]**

Liping Huang, George Quartey, Jamie Robinson. (United States)

9:30am

★ **Reporting of Case-Series in Drug Safety: A Review of Published Studies [442]**

Antoine Pariente, Claire Nour Abou Chakra, Marion Pinet, Nicola Moore, Yola Moride. (Canada)

9:45 am

★ **Significance of Incorporating Real World Clinical Non-Adherence and Drug Adverse Events Data into Pharmacoeconomic Models: Statins Example [443]**

Pendar Farahani, Gray Ellrodt. (United States)

# Agenda - Wednesday, August 19

## Drug Utilization: Session II (Room 551B)

Moderators: Andrew Gilbert & Monique Elsevier

### 8:30am

- **Is Persistence Fading? Time Trends and Determinants of Antibiotic Prescriptions in the Community for Children in the United Kingdom 1993-2007 [450]**

V Schneider-Lindner, S Dell'Aniello, A Kezouh, C Quach, J Hanley, S Suissa. (Canada)

### 8:45am

- **Off-Label Use of Antipsychotic Drugs in Privately and Publicly Insured Youth in the US [451]**

Stephen Crystal, Tobias Gerhard, Cecilia Huang, Mark Olfson. (United States)

### 9:00am

- **Physician Preference Motivates Use of Anti-TNF Therapy Independent of Clinical Disease Activity [452]**

Jeffrey R Curtis, Lang Chen, Leslie Harrold, Pongthorn Narongroeknawin, George Reed, Daniel H Solomon. (United States)

### 9:15am

- **Levetiracetam One Year Retention Rate in Real-Life Practice in France, Final Results of the EULEV Study [453]**

C Droz, C Dureau, H Vespignani, C Marchal, J Jové, N Moore, A Fourrier. (France)

### 9:30am

- **Use of Cardioprotective Drugs in Newly Treated Individuals with Type 2 Diabetes Aged Under 65 [454]**

Anis Ben Abdeljelil, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)

### 9:45am

- **Polypharmacy in Chronic Diseases in the Elderly: Evidence-Based or Potentially Inappropriate Prescribing? [455]**

Gillian Caughey, Agnes Vitry, Andrew Gilbert, Elizabeth Roughead. (Australia)

Think tank



Thinking helps.

Our innovations help millions of people by alleviating their suffering and improving their quality of life. We give them hope.



*We Innovate Healthcare*

# Agenda - Wednesday, August 19

## Medications in Pregnancy and Birth Outcomes II (Room 552A)

Moderators: Janneke Jentink & Sara A. Ephross

8:30am

- ★ **Descriptive Study of the Administration of Category X Medications during Pregnancy Using an Outpatient Electronic Health Record [456]**

Brian L Strom, Rita Schinnar, Joshua Jones, Warren Bilker, Mark Weiner, Sean Hennessy, Charles E Leonard, Peter Cronholm, Eric Pifer. (United States)

8:45am

- ★ **Trimethoprim Use Prior to Pregnancy and Risk of Congenital Malformation: A Register Based Nationwide Cohort Study [457]**

Jon T Andersen, Morten Petersen, Jeppe N Rasmussen, Nadia LT Andersen, Christian Torp-Pedersen, Henrik E Poulsen. (Denmark)

9:00am

- ★ **Linking a Pharmaceutical Claims Database with a Birth Defects Registry To Investigate Birth Defect Rates of Known Teratogens [458]**

Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)

9:15am

- ★ **Maternal Use of Bupropion and Risk for Congenital Heart Defects [459]**

Sura Alwan, Jennita Reefhuis, Lorenzo Botto, Adolfo Correa, Sonja Rasmussen, Jan Friedman. (United States)

9:30am

- ★ **Early-Pregnancy Opioid Analgesic Treatment and Risk for Congenital Heart Defects [460]**

CS Broussard, SA Rasmussen, J Reefhuis, JM Friedman, MW Jann, MA Honein. (United States)

9:45am

- ★ **Does Decongestant Use during Pregnancy Reduce Preterm Delivery? [461]**

Rohini K Hernandez, Allen A Mitchell, Martha M Werler. (United States)

## SAFETYWORKS

Rapid. Observational. Pharmacovigilance.

From ProSanoS Corporation

### Signal Detection and Evaluation in any Observational Database

- » Standardized Approach
- » Robust and Transparent Analytic Methodology
- » Interactive Workflow
- » Familiar Vocabulary
- » Saves Time and Money



FOR MORE INFORMATION, PLEASE VISIT US TODAY AT [WWW.PROSANOS.COM](http://WWW.PROSANOS.COM)

# Agenda - Wednesday, August 19

## Psychotropics II: Safety of Psychotropics (Room 552B)

**Moderators:** James Wilson & Jessica Jalbert

**8:30am**

- **General Population Risk of Suicide Attempt Compared to Depressed Untreated and Antidepressant Treated Populations [462]**

Robert J Valuck, Heather D Orton, Anne M Libby. (United States)

**8:45am**

- **Use of Antiepileptic Drugs in Epilepsy and the Risk of Self Harm and Suicidal Behaviour [463]**

Frank Andersohn, René Schade, Carlos Martinez, Stefan N Willich, Edeltraut Garbe. (Germany)

**9:00am**

- **Use of Dopaminergic Drugs and Risk of Hip or Femur Fracture: A Population-Based Case-Control Study [464]**

Maurits Arbouw, Kris Movig, Tjeerd van Staa, Toine Egberts, Patrick Souverein, Frank de Vries. (Netherlands)

**9:15am**

- **Renal Outcomes in People with Bipolar Disorder Treated with Lithium: A Retrospective Cohort Database Study [465]**

Joe Reilly, Helen Close, John Main, Mukesh Kripalani, Pali Hungin, Douglas Wilson, James Mason. (United Kingdom)

**9:30am**

- **Effects of Preexisting Cardiovascular Risk Factors on Initiation of Stimulants in Adults Newly Diagnosed with ADHD [466]**

Tobias Gerhard, Almut Winterstein, Mark Olfson, Arwa Saidi, Stephen Crystal. (United States)

**9:45am**

- **Extensive Psychotropic Drug Use among Icelandic Children: A Nationwide Population Based Study [467]**

Helga Zoega, Gísli Baldursson, Birgir Hrafnkelsson, Anna B Almarsdóttir, Unnur Valdimarsdóttir, Matthías Halldórsson. (Iceland)

**10:00-10:30am**

**Break/Posters/Exhibits (Hall B)**

**10:30-Noon**

## Concurrent Sessions: Symposia & Workshops

### Assessment of Prenatal Exposure to Medications [616] (Room 552B)

- Lyn Colvin, Sonia Hernandez-Diaz, Elizabeth Andrews, Allen Mitchell, Tina Chambers, Pamela E Scott, Richard Hill. (United States)

*Sponsored by the Medicines in Pregnancy SIG and the Teratology Society*

### RMP, RiskMAP and REMS: The Challenges of Epidemiology [470] (Ballroom D)

- Patricia Saddier, Susana Perez-Gutthann, Annette Stemhagen, Rekha Garg, Stella Blackburn, Gerald Dal Pan. (United States)

### Benchmarking of Healthcare Databases To Improve Harmonization [468] (Room 551A)

- Miriam Sturkenboom, Martijn Schuemie, Gianluca Trifiro, Annie Fourier, Preciosa Coloma, Jeffrey Brown, BJ Park, Helle Kieler, Ron Herings. (Netherlands)

### Assessing the Association of Pharmacotherapeutics and Suicidal Behavior: Lessons from the Front [281] (Room 551B)

- Jamie Geier, Juhaeri Juhaeri, Daniel Mines, Andrew Mosholder, Madhukar Trivedi, Sybil Eng, Mary Lou Skovron, Paul Stang, Nataliya Volkova. (United States)

### Safety Assessment and Risk Management of Biologics—Challenges and Opportunities (Biologics SIG) [471] (Ballroom B)

- Thijs J Giezen, Brigitte Keller, Anders Sundstrom, Aaron S Kesselheim, Wei Dong, Judith K Jones, Hans Petri. (Netherlands)

### The Future of Epidemiology [472] (Room 557)

- Ken Rothman, Gerald Dal Pan, Stephen Evans, Paul Stang, Judith Jones, Til Sturmer. (United States)



### Using Databases for both Hypothesis Generating and Hypothesis Confirmation: One Database or Two? [473] (Room 552A)

- Larry Gould, Alec Walker, Patrick Ryan, Sebastian Schneeweiss, Nancy Santanello, Susan Sacks. (United States)



You will notice that the "ICPE 25th Anniversary" logo has been appended to selected sessions. These sessions have been selected because the topics are broad and reach into the future of our field.

# Agenda - Wednesday, August 19

**Noon-1:30pm**

**Lunch/Poster Session C/Exhibits/ Poster Walks (Hall B)**

**Poster Walks/Moderators**

- **Pharmacovigilance** –Harry Seifert
- **Use of Linked Databases** – Matthew R.Reynolds
- **Biologics** – Pavel Napalkov
- **Drug Utilization Studies** – Monique Elseviers

**ISPE Board of Directors Luncheon (Room 554AB)**

- Meeting open to all members; check with staff if you wish to attend

**1:30-3:00pm**

## *Invited Plenary*

**FDA's Sentinel Initiative Project**  
(Ballroom A)

**Chair: Scott Smith**, Agency for Healthcare Research & Quality

**Panelists:**

- **Richard Platt**, Harvard University
- **Mark McClellan**, Engelberg Center for Health Care Reform, The Brookings Institution
- **Invited**, FDA
- **Miriam CJM Sturkenboom**, Erasmus University Medical Center

**3:00-4:30pm**

## *Hot Topics Session:*

**Clopidogrel: Has the Pharmacogenetics Era Arrived?**  
(Ballroom A)

**Chair: Leah Sansbury**, National Cancer Institute, National Institutes of Health

**Panelists:**

- **Jessica Mega**, Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard Medical School; *Clopidogrel Pharmacogenetics: Overview of The TIMI*

**Study Results**

- **O.H. Klungel**, Department of Pharmaceutical Sciences, Utrecht University; *Methodological Aspects of Clopidogrel Pharmacogenetics*
- **Alan R. Shuldiner**, Professor of Medicine, University of Maryland School of Medicine; *Perspective on Potential Clinical Utility of Clopidogrel Pharmacogenetics (Recent MI, Recent Stroke or Established Peripheral Arterial Disease)*
- **Bonny Lewis Van**, Pharmacogenetic Epidemiologist; *Potential Clinical Utility with Coronary Stents/ Summary Perspective of Future Direction of Pharmacogenetic Epidemiology.*

**4:30-5:00pm**

## *The Final Word* (Ballroom A)

**Moderator**

**Kate L. Lapane, FISPE**, Chair, 2009 Scientific Program Committee

**Poster Awards**


- **Wei Dong**, Chair, Poster Awards Committee

**ICPE 2010 Brighton, England, UK**

- **Corinne de Vries**, Chair, 2010 Scientific Program Committee

**5:00pm**

**Adjournment of ICPE 2010**



*International Conference  
On Pharmacoepidemiology &  
Therapeutic Risk Management*

LATE-STAGE RESEARCH

EPIDEMIOLOGY

In drug safety, you need the perspective  
of a team with a proven track record.

DRUG SAFETY

RISK MANAGEMENT

## Join PPD & WHISCON at ICPE.

When it comes to identifying benefits and risks in late-stage research, you need the perspective of a team of experts who has been there before. PPD, in collaboration with WHISCON, brings knowledge gained from thousands of clinical trials and hundreds of safety studies to help you confidently manage your product's safety.

Visit PPD's booth at ICPE to gain insight from David Brown, executive director of epidemiology at PPD, and Alec Walker and Deb Hennessey, founders of WHISCON.

Visit [www.ppd.com/services/post\\_approval](http://www.ppd.com/services/post_approval) and [www.WHISCON.com](http://www.WHISCON.com) to learn more.

**Gain insight from Alec Walker  
at the following events:**

**15 Aug:** Journal Club panel  
**19 Aug:** "Using Databases for  
Both Hypothesis Generating  
and Hypothesis Confirmation:  
One Database or Two?"

Helping you Advance the Science of Safety

**PPD**


PRECLINICAL/PHASE I > PHASE II-III > POST-APPROVAL > LABS

[www.ppd.com](http://www.ppd.com)

© 2009 Pharmaceutical Product Development, Inc. All Rights Reserved. PPD is a trademark of PPD. Other marks are the property of their respective owners.

# Rhode Island Convention Center


## Third Level



Skybridge to Dunkin Donuts Center



## Fifth Level



Rhode Island Convention Center

# Poster Session Guidelines

## Overview

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

## Poster Session

Posters will be displayed in Hall B of the Rhode Island Convention Center (RICC) August 17-19. Each day will have a separate poster session. All posters for a specific day's session must be removed that day.

- **Monday, August 17** ..... Poster Session A
- **Tuesday, August 18**..... Poster Session B
- **Wednesday, August 19**.. Poster Session C

### 1. Set Up

- **Monday & Tuesday** ..... 7:00-8:00am
- **Wednesday** ..... 7:30-8:30am

### 2. Hours

- **Hall B will be open for the attendees from:**  
8:00am-6:00pm ..... Monday and Tuesday  
8:00am-1:45pm ..... Wednesday

### 3. Discussion Time

- **General:** Presenters should be at their posters between 12:15-1:15pm (Monday & Wednesday), and 12:45-1:45pm on Tuesday.
- **Poster Walks** – organized by the ISPE Special Interest Groups (SIG)  
**Monday:** *Pharmacovigilance; Medicines in Pregnancy/Birth Defects; Drug Utilization Studies; & Uses of Linked Database*  
**Tuesday:** *Pharmacovigilance; Molecular Epidemiology/Pharmacogenetics; Drug Utilization Studies; Biologics; and Uses of Linked Database*  
**Wednesday:** *Pharmacovigilance; Uses of Linked Databases; Biologics; and Drug Utilization Studies*

The poster walks offer selected presenters the opportunity to present their work and to discuss their results with an audience. Participants in these categories should be at their posters between 12:15-1:15pm (Monday & Wednesday), and 12:45- 1:45 (Tuesday). When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research

### 4. Poster Prizes

A group of judges will select the best posters of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The best posters will be announced at The Final Word session at 4:30pm, August 19.

### 5. Take Down

All posters must be taken down by 6:30 pm on Monday and Tuesday; posters must be taken down by 5:00pm on Wednesday.

## Numbering System

- Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the Final Program, which will be available at the ISPE Registration Desk (3rd Floor Foyer/RICC). The poster number is the first number listed. Please note the number may differ from that shown in the preliminary program. The abstract number, for use in locating abstracts in the Final Program and the special issue of Pharmacoeconomics and Drug Safety, is in brackets [ ] after the title of the abstract.

## Poster Specifications

1. Posters must be designed to fit a space 4 feet HIGH by 8 feet WIDE; POSTER ORIENTATION: LANDSCAPE. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board
2. Posters may be attached to the boards using Velcro. All poster presenters are encouraged to bring their own supplies.
3. **Disclosure Statement**  
A disclosure statement must accompany each abstract submission and each presentation. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the 1-year period before the ICPE. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed.

**NOTE:** ISPE and the RICC are not responsible for any poster that is left up overnight or is lost or damaged.

# Poster Session A: Monday, Aug. 17

8:30am–6:00pm

## Analysis Methods

- 1 **The Need for Right Censoring for Identification of Secondary Care Outcomes in THIN – A UK GP Database [68]**  
*Alison Bourke, Michelle Hards, Hassy Dattani. (United Kingdom)*
- 2 **Withdrawn by author [35]**
- 3 **Absence of Evidence and Evidence of Absence in Population-Based Studies [69.5]**  
*Zuleika Aponte, Marco Pavesi, Swati Basu. (Spain)*
- 4 **Bayesian Prescribing Model for Cox-2 Selective NSAIDs [70]**  
*Margaret R Stedman, MA Brookhart. (United States)*
- 5 **Bridging Cardiovascular Risk from Clinical Trials to Real Life Population [71]**  
*ASY Chain, C Vannoord, JP Dieleman, M Danhoff, MCJM Sturkenboom, O Della Pasqua. (Netherlands)*
- 6 **Validation of Ischemic Cerebrovascular Diagnoses in the Health Improvement Network (THIN) [72]**  
*Ana Ruigómez, Elisa Martín-Merino, Luis A García Rodríguez. (Spain)*
- 7 **Automated Selection of Interaction Terms for Poisson Regression Models with Many Dichotomous Variables from Large Scale Observational Databases [73]**  
*Alan M Hochberg. (United States)*
- 8 **Compliance Bias in a Cohort Study of Older Adults Treated with Oral Bisphosphonates [74]**  
*Linda Lévesque, Ana Blagojevic, Mahyar Etminan, James Brophy. (Canada)*
- 9 **Advantages of Mapping ICD-9-CM into SNOMED CT Concepts and Hierarchy [75]**  
*Hoa V Le, Kathleen J Beach. (United States)*

- 10 **Data-Driven Analysis of All Recorded Comorbidities in Persons with a Diagnosis of Rheumatoid Arthritis (RA) in MarketScan US Claims Database [76]**  
*Hans Petri, Debra Maldonato, Noah Robinson. (United Kingdom)*
- 11 **Meta-Analysis for Drug Development and Risk Management [77]**  
*Matthew W Reynolds, Tamar Lasky, FDA Representative. (United States)*
- 12 **Comparison of Alpha-Spending Plans for Influenza Vaccine Safety Surveillance [78]**  
*SK Sandhu, D Burwen, T MaCurdy, J Gibbs, E Rusev, B Garcia, C Sholley, D Marston, K Elmo, H Izurieta, R Ball. (United States)*
- 13 **Abstract Withdrawn by Author [79]**

## Cancer

- 14 **Update on the Absence of Interaction between Tamoxifen and the SSRI Citalopram with Respect to Protection Against Breast Cancer Recurrence [80]**  
*Deirdre Cronin-Fenton, Timothy L Lash, Lars Pedersen, Thomas P Ahern, Carol L Rosenberg, Rebecca A Silliman, Kathy L Lunetta, Stephen Hamilton-Dutoit, Jens P Garner, Marianne Ewertz, Henrik T Sørensen. (Denmark)*
- 15 **Enhanced Oncology Applications of Health Insurance Claims Data through Clinical Data Linkage [81]**  
*David D Dore, Andrew T McAfee, Ruby K Woo, John D Seeger. (United States)*
- 16 **Treatment (Tx) and Dosing Patterns for Angiogenesis Inhibitor (AI) Therapies in Patients (Pts) with Metastatic Renal Cell Carcinoma (mRCC) [82]**  
*Toni K Choueiri, Ashley J Brick, David McDermott, Jessica Clement, Christabel Kwabi, Karishma Shah, Lucia Antras, Kristina Chen, Sujata S Jayawant, Mei Sheng Duh, Andi Luka, Maureen Neary, William K Oh. (United States)*
- 17 **Completeness of Recorded Cancer Incidence in the Health Improvement Network [83]**  
*Kevin Haynes, Kimberly Forde, Rita Schinar, Patricia Wong, Brian Strom, James Lewis. (United States)*
- 18 **Incidence of Malignancy in Patients with Rheumatoid Arthritis [84]**  
*Helen Huang, Jamie Laudati, Zhiping Huang. (United States)*
- 19 **Abstract Withdrawn by Author [85]**
- 20 **Prenatal Exposure to Medicines and the Risk of Childhood Brain Tumor [86]**  
*Karin Stålberg, Bengt Haglund, Helle Kieler. (Sweden)*
- 21 **An Observational Follow-Up Study of Patients Previously Enrolled in Exubera Controlled Clinical Trials (FUSE): Design and Rationale [87]**  
*Nicolle M Gatto, Daniel O Koralek, Joanna Lem, Neville Jackson. (United States)*
- 22 **Survival of Malignant Mesothelioma in a Retrospective Survey in the West Part of Japan [88]**  
*Shuko Nojiri, Tsugumichi Sato, Takuhiro Yamaguchi, Kenichi Gemba, Keisuke Aoe, Katsuya Kato, Takumi Kishimoto, Kiyoshi Kubota. (Japan)*
- 23 **Hfs 14: A Specific Quality of Life Instrument for Patients with Hand-Foot Syndrome [89]**  
*Charles Taieb. (France)*
- 24 **The Risk of Cancer Associated with Anti-Diabetic Agents [90]**  
*Hui-Talia Zhang, Tarek A Hammad, David Christiani, Edward Giovannucci. (United States)*

# Poster Session A: Monday, Aug. 17

## CNS/Neurological

- 25 Suicidality in Patients Treated with Antiepileptic Drugs [91]**  
*Alejandro Arana, Charles E Wentworth III, José Luis Ayuso-Mateos, Janet Price, Felix M Arellano. (Spain)*
- 26 Distribution of Cases of Progressive Multifocal Leukoencephalopathy: Analysis of the French National Hospital Discharge Registry [92]**  
*Marion Pinet, Nadia Foskett, Anthony Amey, Jamie Robinson. (United Kingdom)*
- 27 Incidence of Progressive Multifocal Leukoencephalopathy (PML) in Patients with Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) from MarketScan Claim Database [93]**  
*Nadia Foskett, Liping Huang, Hans Petri, Pavel NAPALOKOV, Philip Watson, Elena Fischeleva, Ravi RAO, Sophie Banzet, Noah Jamie Robinson. (United Kingdom)*
- 28 Individual-Level Time Series Analysis of Antidepressant and Antipsychotic Drug Use Around Varenicline Initiation [94]**  
*Joshua J Gagne, Tarek A Hammad, Solomon Iyasu. (United States)*
- 29 Incidence of Urinary Tract Infection in Subjects with Type 2 Diabetes. Experience from Adverse Event Reporting in Diabetes Clinical Trials [95]**  
*Niklas Hammar, Bahman Farahmand, Susan Andersson, Svante Joelson, Mikael Gran. (Sweden)*
- 30 Exploratory Analysis of the Relationship between Antipsychotic Use and the Incidence of Seizures among Patients with Schizophrenia in the UK General Practice Research Database (GPRD) [96]**  
*Meghan E Jones, Lamiya A Rizvi, Indiana Strombom, Frank DeLisle, Ludmila Kryzhanovskaya, Joachim Wernicke, Bruce J Kinon. (United States)*
- Community Pharmacies Network: Results 2005-2007 of the OSIAP Europe Survey [97]**  
*Ulf Bergman, Alfonso Carvajal, Anita Conforti, Rob Heerdink, Maryse Lapeyre-Mestre, Diego Macias, Robert Vander Stichele. (France)*
- 32 Antidepressant Selection Associated with Prior Use of Hypnotics/Anxiolytics in Patients with Major Depressive Disorder [98]**  
*Xianchen Liu, Wenyu Ye, Madelaine M Wohreich, Stacey Bledsoe. (United States)*
- 33 Maternal Use of Antibiotics during Pregnancy and Risk of Epilepsy in Childhood: A Danish Population-Based Cohort Study [99]**  
*Mette Nørgaard, Vera Ehrenstein, Leiv Bakketeig, Henrik T Sørensen, Lars Pedersen. (Denmark)*

## Advancing science. Serving patients.



Amgen, a biotechnology pioneer, discovers, develops and delivers innovative human therapeutics. Our medicines have helped millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses.

With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

To learn more about Amgen, our vital medicines, our pioneering science, and our career opportunities, visit [www.amgen.com/careers](http://www.amgen.com/careers).

**AMGEN**

Pioneering science delivers vital medicines™

[www.amgen.com/careers](http://www.amgen.com/careers)

As an EEO/AAE employer, Amgen values a diverse combination of perspectives and cultures. M/F/D/V.

# Poster Session A: Monday, Aug. 17

## 34 Identifying Intentional Self-Harm Hospitalizations when E-Codes Are Incompletely Recorded [100]

Amanda R Patrick, Matthew Miller, Catherine W Barber, Philip S Wang, Claire F Canning, Sebastian Schnee-weiss. (United States)

## 35 Predictors of 60 Day Mortality after Aneurysmal Subarachnoid Haemorrhage [101]

R Risselada, H Lingsma, E Steyerberg, M Sturkenboom. (Netherlands)

## 36 The Acute Effect of Alcohol on Psychomotor Performance in Healthy Korean Men with ALDH2 Variations [102]

Hee-Young Shin, Kyung-Lyung Bae, Sung-Wan Kim, Il-Seon Shin, Tak Youn, Jin-Sang Yoon. (Korea)

## Coverage Without Evidence

## 37 Systematic Review of Observational Research Studying Long-Term Use of Antithrombotic Medicines Following Haemorrhagic Stroke [103]

Robert Flynn, Thomas MacDonald, Gordon Murray, Alexander Doney. (United Kingdom)

## 38 Pragmatic Randomized Trial of Continuing Cholinesterase Inhibitors among Indeterminate Responders [104]

Malcolm Maclure, Carolyn J Green, Claudia Jacova, Robin G-Y Hsiung. (Canada)

## Devices

## 39 Measuring the Use of Medical Devices Dispensed According to the PNPCD [105]

Carolina Monteiro. (Portugal)

## Disease Epidemiology/ Burden of Illness

## 40 Characteristics of Patients with Diabetic Macular Edema, Retinal Vein Occlusion, and Uveitis [107]

Kandace L Amend, Najat Ziyadeh, Suresh Mahabhashyam, John Seeger. (United States)

## 41 A Two-Stage Sampling Cohort Study on the Risk of Perinatal Mortality Associated with Asthma during Pregnancy [108]

Marie-Claude Breton, Marie-France Beauchesne, Catherine Lemiere, Ev-elyne Rey, Amelie Forget, Lucie Blais. (Canada)

## 42 Investigation of Pediatric Crohn's Disease Burden in Multiple Data Sources [109]

Kristen Butterfield, Meighan Cappello, Erica Velthuis, Margaret Richards, Joanna Haas, Melynda Holmes. (United States)

## 43 Longitudinal Changes in Lower Urinary Tract Symptoms in Men Managed for Benign Prostatic Hyperplasia [110]

Wendy J Carman, John Wei, Martin Miner, David Pasta, Raymond Rosen, Claus Roehrborn, Allen Seftel. (United States)

## 44 The Incidence of Guillain Barre Syndrome in the United Kingdom [111]

Gillis Carrigan, Germano Ferreira, Alena Khromava.

## 45 The Risk of Suicidal Behavior among Patients with Diabetic Peripheral Neuropathic Pain, Low Back Pain, Fibromyalgia, or Osteoarthritis [112]

Yingkai Cheng, Dale Marmaduke, Antonio Crucitti, Sharon Hoog, Indiana Strombom, Kenneth Hornbuckle. (United States)

## 46 Incidence Rate of Febrile Convulsions in Toddlers – A Database Study in the United Kingdom [113]

Germano Ferreira, Gillis Carrigan, Alena Khromava. (France)

## 47 Heart Failure, Myocardial Infarction and Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease [114]

Luis A Garcia Rodríguez, Mari-Ann Wallander, Elisa Martín-Merino, Saga Johansson. (Spain)

## 48 Predictors of Uncontrolled Asthma in Adult and Pediatric Patients: Results from the Asthma Control Characteristics and Prevalence Survey [un [115]

Alicia Gilsenan, Richard Stanford, Christine Bui, Ryan Ziemicki, Hector Ortega. (United States)

## 49 Validation of Diabetic Macular Edema (DME) through Claims Profile Review [116]

Earl L Goehring Jr, Bao-Anh Nguyen-Khoa, Winifred Werther, Judith K Jones. (United States)

## 50 Cardiovascular Disease and Risk Factors in Patients with Ankylosing Spondylitis [117]

Katherine L Gooch, David L Laitinen, Robert L Wong, Oscar A Hayes. (United States)

## 51 Changes in Prevalence and Healthcare Use and Costs of Breast Cancer among 21- to 64-Year Old Female Recipients in a Fee-for-Service State Medicaid Program: 2000-2005 [118]

Rahul Khanna, S Suresh Madhavan, Abhijeet Bhanegaonkar. (United States)

## 52 Drug-Related Poisonings in the Brazilian General Population from 1996 to 2005 [119]

Daniel M Mota, Jose RR Melo, Daniel RC Freitas, Márcio Machado. (Canada)

## 53 Longitudinal Assessment of Smoking in the Health Improvement Network (THIN) Database [120]

Aditya A Marfatia, Mary Maneno, Jie Li, Judith K Jones. (United States)

## 54 Myocardial Infarction and Cerebrovascular Accident in Patients with Diabetic Macular Edema [121]

Bao-Anh Nguyen-Khoa, Earl L Goehring Jr, Winifred Werther, Judith K Jones. (United States)

# Poster Session A: Monday, Aug. 17

- 55 Incidence of Oropharyngeal Conditions in Patients with Influenza in the GPRD [122]**  
*Michael M Peng, Anthony Amey, Jamie Robinson. (United States)*
- 56 Treatment Patterns in Depressed Elderly and Younger Adult Patients in the U.S. [123]**  
*Thibaut Sanglier, Dominique Milea, Delphine Saragoussi, Jean-paul Auray, Marie Tournier. (France)*
- 57 Characteristics of Depressed Elderly Patients Compared with Younger Depressed Adult Patients: An Assessment Based on a Large U.S. Insurance Claims Database [124]**  
*Thibaut Sanglier, Delphine Saragoussi, Dominique Milea, Jean-Paul Auray, Marie Tournier. (France)*
- 58 Risk of Serious Skin Reactions Associated with Carbamazepine and Phenytoin: A Signal Detection from Thai-vigibase [125]**  
*Pakawadee Sriphomya, Sareeya Wechwithan. (Thailand)*
- 59 Incidence of Chlamydia Diagnoses, Tests, and the Use of Antibiotics [126]**  
*Ann Vanrolleghem, Eva M van Soest, Ingrid van den Broek, Miriam CJM Sturkenboom. (Netherlands)*
- 60 Prescribing Guidelines Concerning Analgesics – Geographic Variations and Adherence [127]**  
*Magnus AB Axelsson, Lena Gustafsson, Susanna M Wallerstedt. (Sweden)*
- 61 Factors Associated with Changes in Management of Benign Prostatic Hyperplasia: Longitudinal Data from the BPH Registry [128]**  
*Wendy J Carman, Martin Miner, John T Wei, David J Pasta, Raymond Rosen, Claus G Roehrborn, Allen D Seftel. (United States)*
- 62 Prevalence of Drug-Drug Interactions among Epileptic Patients Receiving Antiepileptic Drugs and Oral Anticancer Drugs at a Cancer Centre: A Retrospective Study [129]**  
*Yin Ting Cheung, Alexandre Chan, Wai Keung Chui. (Singapore)*
- 63 Levetiracetam Effectiveness in Real-Life Practice in France, Final Results of the EULEV Study [130]**  
*C Droz, C Dureau, A Alperovitch, H Vespignani, C Marchal, J Jové, N Moore, A Fourier. (France)*
- 64 Trends in Outpatient Drug Utilization Patterns in the U.S. Pediatric Population: Y2002 – Y2008 [131]**  
*Patty Greene, Laura Governale, Vicky Borders-Hemphill, Hina Mehta, David Moeny. (United States)*
- 65 Assessment of Orphan Drugs Developed and Drug Utilization Under the Orphan Drug Act: A Descriptive Empirical Study [132]**  
*Erin McErlane, Jeff J Guo, Pankaj Desai, William Sietsema, Christina ML Kelton. (United States)*
- 66 Treatment Status and Treatment Changes in a Dutch Type 2 Diabetes Cohort [133]**  
*Jaco Voorham, Petra Denig, Ronald P Stolk, Bruce HR Wolffenbuttel, Dick De Zeeuw, Flora M Haaier-Ruskamp, GIANTT Group. (Netherlands)*
- 67 Adherence to Pharmacotherapy Guideline in Depression and Anxiety: Preliminary Results [134]**  
*Pierre M Bet, Jacqueline G Hugtenburg, Brenda WJH Penninx, Ton van Balkom, Witte JH Hoogendijk. (Netherlands)*
- 68 Lipid-Regulating Drugs in Japanese Psychotic Inpatients [135]**  
*Ataru Inagaki, Toshiaki Itoh, Kazumi Tsukada. (Japan)*
- 69 Drug Concurrency Patterns among Asthma Patients Using Single-Ingredient LABA: A Claims Data Study [136]**  
*Sigal Kaplan, Yulan Ding, Andrew Mosholder. (United States)*
- 70 Predictors of Treatment Failure in Trigeminal Neuralgia [137]**  
*Joseph SHA Koopman, Jeanne P Dieleman, Frank J Huygen, Marissa de Mos, Miriam CJM Sturkenboom. (Netherlands)*
- 71 Increasing Prevalence and Incidence of Drug Use in Sweden – Data from the National Prescribed Drug Register [138]**  
*Andrejs Leimanis, Örjan Ericsson, Michael Fored, Niklas Hammar, Björn Wettermark. (Sweden)*
- 72 Prevalence and Persistence of TNF Inhibitors in Norway 2004-2008 [139]**  
*Milada Mahic, Svetlana Skurtveit, Randi Selmer, Kari Furu. (Norway)*
- 73 Driving Impairing Medication Use in the Netherlands [140]**  
*S Ravera, ST Visser, JJ de Gier, LTW de Jong-van den Berg. (Netherlands)*
- 74 Utilization of Behavioral Medication in a Medicaid Population Pre and Post Formulary Implementation [141]**  
*Jason C Simeone, Rita M Marcoux, Brian J Quilliam. (United States)*
- 75 Off-Label Use of Oncology Drugs in a Community Oncology EMR Database [142]**  
*Reejeis Stephen, Kevin Knopf, Matthew Reynolds, Weixiu Luo, Kathy Fraeman. (United States)*
- 76 Comparison of Outpatient Utilization of Psychopharmaceuticals between Zagreb and Scandinavian Countries (2001-2006) [143]**  
*Danijela Stimac, Albert Cattunar, Zvonimir Šostar. (Croatia)*
- 77 Adjusting the Nicotine Dose: The Key to a Successful, “Tailored” Method of Quitting Smoking [144]**  
*Charles Taieb. (France)*

## Drug Utilization Studies

# Poster Session A: Monday, Aug. 17

## Measurement Methods

- 78 Assessment of Drug Exposure in Etiological Studies: A Review from Pharmacoepidemiology and Drug Safety [145]**  
*Pernelle Noize, Fabienne Bazin, Antoine Pariente, Nicholas Moore, Annie Fourier-Réglat. (France)*
- 79 Constructing Drug Treatment Episodes from Individual Dispensed Prescriptions: The Influence of the Gap-Length [147]**  
*Helga Gardarsdottir, Eibert R Heerdink, Toine CG Egberts. (Netherlands)*
- 80 Impact of Exposure Data Sources on Risk Estimates in Etiological Studies: Application to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Three-City (3C) Study [148]**  
*Fabienne Bazin, Pernelle Noize, Antoine Pariente, Nicholas Moore, Annie Fourier-Réglat. (France)*
- 81 Providers' and Administrators' Perceived Value of the UMWA Health and Retirement Funds MineRx Program [149]**  
*Eric P Jack, MP Powell, Jeroan J Allison, Kenneth G Saag, Norman W Weissman. (United States)*
- 82 Evaluation of Current Practices in Drug Adverse Event Reporting Rates: A Methodological Approach for Estimating the Denominator [150]**  
*Sigal Kaplan, Lois La Grenade, Carol Pamer, Ann Corken Mackey. (United States)*
- 83 Reliability and Convergent Validity of the Perceived Stress Scales 4 and 10 Items: Results from the Antidepressants in Pregnancy Discontinuation Study [151]**  
*Fatiha Karam, Anick Bérard. (Canada)*
- 84 Systematic Process for Coding Definition/Algorithm Development in Database Analyses [152]**  
*Bob LoCasale, Vinay Mehta, Lucy Alderton, Ed Bortnichak, Matt Reynolds, Reejis Stephen, Natalie Jones, Carol Ware. (United States)*
- 85 Comparison of Treatment Utilization of Intravenous Bisphosphonates (IVBIS) in an Electronic Medical Records (EMR) and Administrative Claims Database [153]**  
*Vinay Mehta, Bob Locasale, Chuck Wentworth, Reejis Stephen, Beth Nordstrom, Kathy Fraeman. (United States)*



**We discover the value within.**

**IMS helps you realize the potential of your products.**

Combining commercial insight with scientific evidence is required to maximize market access. That's why IMS has built a global team of more than 200 HEOR experts and the world's most extensive databases.

Our team combines rigorous scientific research — evidenced by more than 200 publications in 2008 alone — with commercially savvy consulting to help determine, demonstrate, communicate and realize product value.

We have unparalleled claims, medical, hospital and patient-centered pharmaceutical databases. Our HEOR experts use them to create an Evidence-Based Consulting<sup>SM</sup> powerhouse.

So the next time you're thinking about product value, find out what we're thinking.

Contact our consulting team at +1.703.286.2862 or visit [www.imshealth.com/heor](http://www.imshealth.com/heor)

**ims** INTELLIGENCE. APPLIED.

© 2009 IMS Health Incorporated or its affiliates. All rights reserved.

# Poster Session A: Monday, Aug. 17

- 86 Reliability of Patients and Physicians Information on Drug Exposure: A Study in the Systematic Case-Referent PGRx Database [154]**  
*Lamiae Bensouda-Grimaldi, Michel Rossignol, Elodie Aubrun, Constance Charveriat, Nabil El Kerri, Richard Goudreau, Fanny Depont-Hebert, Benoit David, Lucien Abenheim. (Canada)*
- 87 Validation of Claims-Based Diagnostic and Procedure Codes for Serious Adverse Events in a Commercially-Insured Population [155]**  
*Peter M Wahl, Keith Rodgers, Sebastian Schneeweiss, Brian F Gage, Louise J Short, Rhonda L Bohn. (United States)*
- 88 A Novel Method for Assessing Dose-Response Relationships Using Meta-Analytic Techniques [156]**  
*Catherine J Williams, Matthew W Reynolds, Weixiu Luo, Kyle Fahrbach, Jenna Collins. (United States)*
- 89 Population-Based Surveillance System on Medicine Use during Pregnancy in Finland [157]**  
*Miia Artama, Mika Gissler, Annukka Ritvanen, Heli Malm. (Finland)*
- 90 Fluoxetine Use during Pregnancy and the Risk of Major Congenital Malformations [158]**  
*Anick Bérard, Martin St-André. (Canada)*
- 91 Gestational Exposure to Antidepressants and the Risk of Miscarriage: A Review [159]**  
*Perrine Broy, Anick Bérard. (Canada)*
- 92 Birth Outcome in Women Exposed to Anti-Inflammatory Drugs for Ulcerative Colitis [160]**  
*Gabriella Bröms, Fredrik Granath, Olof Stephansson, Helle Kieler. (Sweden)*
- 93 Antispasmodics in Pregnancy: A Study in EFEMERIS Database [161]**  
*Christine Damase-Michel, Isabelle Lacroix, Caroline Hurault, Jean-Louis Montastruc. (France)*
- 94 What Mothers Think: Trends in Perceptions of Medications as a Teratogens [162]**  
*LTW de Jong-van den Berg, C Louik, M Malone-Moses, AA Mitchell. (Netherlands)*
- 95 Outcome of Infants Exposed In Utero to More Than One Antidepressant during Pregnancy: A Prospective Comparative Study [163]**  
*Adrienne Einarson, Jacqueline Choi, Thomas Einarson, Gideon Koren. (Canada)*
- 96 A Pilot Study To Investigate Drug Prescribing among Pregnant Women in Tayside, Scotland [164]**  
*Robert Flynn, Linda Irvine, Iain Crombie, Gillian Libby, Josie Evans. (United Kingdom)*
- 97 Use of Opioids in Mothers and Fathers before and during Pregnancy—2004-2006 [165]**  
*Marte Handal, Anders Engeland, Svetlana Skurtveit, Kari Furu. (Norway)*
- 98 Carbamazepine Exposure & Specific Malformations [166]**  
*J Jentink, H Dolk, MA Loane, JK Morris, LTW de Jong-van den Berg, EUROCAT AED Working Group. (Netherlands)*
- 99 Preterm Delivery in HIV+ Pregnant Women on Protease Inhibitors [167]**  
*Derek Johnson, Olufemi Ogundeji, Kartikey Acharya, Bachmann Laura, Sturdevant Marsha, Mirjam Kempf. (United States)*
- 100 Prescriptions Filled for Drugs with Embryotoxic, Fetotoxic or Teratogenic Potential during Pregnancy [168]**  
*Sophie N Kulaga, Amir Zargarzadeh, Anick Bérard. (Canada)*
- 101 Benzodiazepine Use during Pregnancy and the Risk of Major Congenital Malformations [169]**  
*Sophie N Kulaga, Sheehy Odile, Perrine Broy, Anick Bérard. (Canada)*
- 102 Drug Utilization of Pregnancy Category D or X Drugs among Child-Bearing Age Women with Depression or Bipolar Disorder in Medicaid [170]**  
*Xing Li, Jeff J Guo, Patricia R Wigle, Christina ML Kelton, Yonghua Jing. (United States)*
- 103 Development of a Pregnancy Registry in Herceptin (H) Treated Breast Cancer (BC) Patients (pts)-MOTHER: The Herceptin Pregnancy Registry [171]**  
*Wang Lisa, Cochran Colette, Brannan Carol, Shing Mona, Dong Wei. (United States)*
- 104 Use of Teratogenic Ingredients Across Different Ethnic Groups among Pregnant Women [172]**  
*Pubali D Mattoo, Somnath Pal. (United States)*
- 105 Exposure to Hydroxyurea and Pregnancy Outcomes [173]**  
*William F McCarthy, Samir K Ballas, Nan Guo, Bruce A Barton. (United States)*
- 106 Statins and Pregnancy Outcomes: A Cohort Study in the GPRD [174]**  
*Anita McGrogan, Julia Snowball, Corinne S de Vries. (United Kingdom)*
- 107 Exposure to Herbal Products during Pregnancy and the Risk of Low Birth Weight [175]**  
*Krystal Moussally, Gideon Koren, Anick Berard. (Canada)*
- 108 Antihypertensive Medication Use during Pregnancy and the Risk of Major Congenital Malformations or Small-for-Gestational-Age Newborns [176]**  
*Hamid Reza Nakhai-Pour, Evelyne Rey, Anick Bérard. (Canada)*
- 109 Antidepressant Medication Use during Pregnancy and the Risk of Miscarriage [177]**  
*Hamid Reza Nakhai-Pour, Perrine Broy, Anick Bérard. (Canada)*
- 110 Paternal Exposures and Birth Defects: Overlooked or Unnecessary? [178]**  
*Susan S Roberts, Laura F McKain, Deborah L Covington, Jessica D Albano. (United States)*

## Medications in Pregnancy/ Birth Defects

# Poster Session A: Monday, Aug. 17

**111 Exposure to Anti-Infective Drugs during Pregnancy and the Risk of Prematurity [179]**

*Fabiano Santos, Anick Bérard. (Canada)*

**112 Utilisation of Psychotropic Medicines in Pregnancy [180]**

*Irini-Alexia Terzakis, Julia M Snowball, Anita McGrogan, Corinne S de Vries. (United Kingdom)*

## Pharmacovigilance

**113 Abstract Withdrawn by Author [181]**

**114 Performance of Screening Multiple Observational Databases for Active Drug Safety Surveillance [182]**

*Patrick B Ryan, Gregory E Powell, Ed N Pattishall, Kathleen J Beach. (United States)*

**115 Active Safety Surveillance of the Risk of Acute Pancreatitis (AP) Associated with Exenatide or Sitagliptin Compared to Metformin or Glyburide [183]**

*David D Dore, John D Seeger, K Arnold Chan. (United States)*

**116 Review of Evidence Related to the Abuse of Tramadol [184]**

*Edgar H Adams. (United States)*

**117 Reporting Rates of Hemorrhagic/ Necrotizing Pancreatitis (HNP) in Association with Selected Newer Antidiabetics [185]**

*Syed Rizwanuddin Ahmad, Joslyn Swann. (United States)*

**118 Considerations When Using FDA AERS Data for Data Mining Purposes [186]**

*Keith L Altman. (United States)*

**119 Use of the Multi-Item Gamma Poison Shrinker (MGPS) Algorithm in Retrospective Screening of Spontaneous Data of Withdrawn Marketed Products [187]**

*Jacinta U Anigolu. (United States)*

**120 Second Generation Antipsychotics and Adverse Drug Reactions – A Comparison between Children and Adults [188]**

*Gertrud Brunlöf, Anders Sundström, Marie-Louise Johansson, Susanna M Wallerstedt. (Sweden)*

**121 Uterine Perforation in Women Using Intrauterine Devices: Interim Results from the EURAS-IUD Study [189]**

*Juergen C Dinger, Anita Assmann, Mathias Altmann. (Germany)*

**122 Incidence Rates of Thromboembolic Events in Solid Tumor Cancer Patients in the THIN Database [190]**

*Victor Gastanaga, Chuck Wentworth, Anthony Yeo, Gail Hughes, Ming Ji, Sean Zhao. (United States)*

**123 Does Pharmacy Students' Education in Postmarketing Adverse Drug Reaction Reporting Influence Post-Graduate Drug Safety Surveillance Training Plans? [191]**

*Jean Kim, Nicole L Perna, Yvonne Viteri, Anthony G Oladipo. (United States)*

**124 Pharmacovigilance Training Needs: An International Survey of Drug Safety Scientists [192]**

*D Layton, R Walker, E Lynn, SAW Shakir. (United Kingdom)*

**125 Lessons Learned from Celecoxib Familial Adenomatous Polyposis (FAP) Registry Study [193]**

*Joanna Lem, Evelyn Moy, Carla Yunis, Kui Huang. (United States)*

**126 Case Reports of Suspected Adverse Drug Reactions: An Evaluation of the Efficiency of Search Strategies in MEDLINE and EMBASE [194]**

*Shannon Michels, Alex Ward. (United States)*

**127 Analysis of Adverse Events Related to Ziconotide Intrathecal Administration: Utilization of the FDA AERS Database [195]**

*Marie Lou Munson, Vivek Saharan, Soares George. (United States)*

**128 Evaluation of a Community Based Pharmacovigilance Program in Nepal [196]**

*Subish Palaian, Mohamed Izham, Pranaya Mishra. (Nepal)*

**129 Abstract Withdrawn by Author [197]**

**130 Publication of Dear Doctor Letters and Reporting Patterns of the AEs of Concern [198]**

*Bharat T Thakrar, Marianne Gerber, Noah Jamie Robinson. (Switzerland)*

**131 Selective Serotonin Reuptake Inhibitors (SSRIs) and Hyperprolactinemia [199]**

*Emmanuelle Herlem, Fany Oger, Marie Laure Germain, Thierry Trenque. (France)*

**132 Epidemiologic Study of Antipsychotic Use and the Incidence of Suicide Events [200]**

*M Ulcickas Yood, G DeLorenze, C Quesenberry Jr., S Phillips, A Tsai, V Willey, S Niemcryn, K Wells, ML Skovron, M Cziraky, W Carson, S Oliveria. (United States)*

**133 Frequency and Characteristics of Pediatric Adverse Drug Reactions Reported to a Major Poison Control Center over a 9-Year Period [201]**

*Zdravko P Vassilev, Alvin F Chu, Steven M Marcus. (United States)*

## Psychotropics

**134 The Risk of Institutionalization with the Concurrent Use of Cholinesterase Inhibitors (ChEIs) and Potentially Contraindicated Medications in Alzheimer's Disease (AD) [202]**

*Alison L Supina, David B Hogan, Scott B Patten, Braden J Manns, Winanne Downey, Patty Beck, Colleen J Maxwell. (Canada)*

**135 Utilization of Antidepressants among Young Adults in Sweden [203]**

*Karolina Andersson, Mika Gissler, Max Petzold, Margda Waern. (Sweden)*

**136 Priapism Associated with Antipsychotics: Role of Alpha-1 Adrenoceptor Affinity [204]**

*Frank Andersohn, Niklas Schmedt, Stefan Weinmann, Stefan N Willich, Edeltraut Garbe. (Germany)*

**137 Hepatic Events in Duloxetine Users Compared to Other Depressed and Non-Depressed Subjects [205]**

*Fei Xue, Indiana Strombom, Bruce Turnbull, Shao Zhu, John D Seeger. (United States)*

# Poster Session A: Monday, Aug. 17

- 138 Patterns of Psychotropic Drug Use: A Comparative Study in Alzheimer's Disease and Community-Dwelling Elderly Populations [206]**  
*Sarah-G Beland, Antoine Pariente, Djamel Berbiche, Michel Preville, Yola Moride. (Canada)*
- 139 Association between Benzodiazepine Use and Individual Components of Sleep in the Community-Dwelling Elderly Population [207]**  
*Sarah-Gabrielle Beland, Michel Preville, Marie-France Dubois, Philippe Voyer, Dominique Lorrain, Yola Moride. (Canada)*
- 140 Effects of Cholinesterase Inhibitors on Visual Attention in Mild Alzheimer's Disease [208]**  
*Lori A Daiello, Brian R Ott, Elena K Festa, William C Heindel. (United States)*
- 141 Factors Associated with Suboptimal Benzodiazepine Use in Older Adults [209]**  
*Sascha Dublin, Tingting Li, Shelly L Gray, Jennifer C Nelson, Noel S Weiss, Eric B Larson. (United States)*
- 142 Sickness Leave Patterns and Characteristics of Users of Antidepressants in 2004 [210]**  
*Christiane Gasse, Delphine Saragoussi, Dominique Milea, Preben B Mortensen. (Denmark)*
- 143 Analysis of Potential Drug-Drug Interaction Pairs Associated with Antipsychotics among Medicaid Patients with Schizophrenia or Bipolar Disorder [211]**  
*Jeff J Guo, Nick C Patel, Yonghua Jing, Christina ML Kelton, Paul C Keck. (United States)*
- 144 Hemoglobin A1C Level in Relation to Olanzapine, Quetiapine, and Risperidone in a Claims Database [212]**  
*Zhenchao Guo, Andrei Pikalov, Edward Kim. (United States)*
- 145 Association between Maternal Exposure to Antidepressant Drugs and Persistent Pulmonary Hypertension of the Newborn (PPHN) in the Mother-Baby Linked Records in the UK-Based General Practice Research Database (GPRD): Preliminary Results [213]**  
*Tarek A Hammad, Carol Pamer, Susan McCune, Sigal Kaplan, Hany Aly, John Yap, Solomon Iyasu. (United States)*
- 146 Suboptimal Prescribing of Antidepressants in Older Veteran Nursing Home Patients [214]**  
*Joseph Hanlon, Xiaoli Wang, Nick Castle, Roslyn Stone, Steven Handler, Todd Semla, Mary Jo Pugh, Dan Berlowitz, Maurice Dysken. (United States)*
- 147 Increasing Antidepressant Use in Older Nursing Home Patients [215]**  
*Joseph Hanlon, Steven Handler, Nick Castle. (United States)*
- 148 BZD Use in the Entire Norwegian Population According to Age, Gender and Disability Pension Status-A Register Linkage Study [216]**  
*Ingeborg Hartz, Aage Tverdal, Svetlana Skurtveit. (Norway)*
- 149 Disability Pension as Predictor of Continued Use of Benzodiazepines [217]**  
*Ingeborg Hartz, Aage Tverdal, Svetlana Skurtveit. (Norway)*
- 150 Weight Gain in Autic Children using Risperidone and Haloperidol in Thailand [218]**  
*Chutima Pasook, Tita Apichathajutapan, Nakarin Insorn, Penkam Kanjanarat, Wirat Niwatananan, Nootjaree Kamduang. (Thailand)*
- 151 Adolescent Cannabis Use and Prescribed Benzodiazepine Anxiolytic Use in Early Adulthood [219]**  
*Hege Kornør, Willy Pedersen, Jørgen G Bramness. (Norway)*
- 152 Impact of Drug-Drug Interactions on Compliance among Elderly Antidepressant Users [220]**  
*Tami L Mark, Vijay N Joish, Joel Hay, David Sheehan, CJ Choi, Stephen Johnston, Cao Zhun. (United States)*
- 153 Benzodiazepines's Utilization and Forecast in Portugal Mainland [221]**  
*Mafalda Ribeirinho, Carolina Monteiro, Rosália Oliveira. (Portugal)*
- 154 Abstract Withdrawn by Author [222]**
- 155 Antidepressant Discontinuation and Risk of Suicide Attempt [223]**  
*Robert J Valuck, Heather D Orton, Anne M Libby. (United States)*
- 156 Psychiatrist's Awareness of Schizophrenic Patients' Weight When Prescribed Antipsychotics: The EPIONE Survey [224]**  
*E Van Ganse, L Laforest, R Arnaud, JL Eychenne, MA Geoffroy, JY Loze, A Dillenschneider, F Rouillon. (France)*
- 157 Cardiovascular Events in Duloxetine Users Compared to Other Depressed and Non-Depressed Subjects [225]**  
*Fei Xue, Indiana Strombom, Bruce Turnbull, Shao Zhu, John D Seeger. (United States)*
- 158 Autistic Disorder and Asperger's Disorder: Contrasting Psychotropic Patterns in U.S. Medicaid-Insured Youth [226]**  
*Julie M Zito, Daniel J Safer, James J Korelitz, James F Gardner, Diane McNally. (United States)*

End Session A

***Celgene Corporation  
is proud to sponsor  
ICPE's 25th  
Anniversary event***

*Committed to  
improving the lives of  
patients worldwide*

***Celgene shares ISPE's  
dedication to enhancing  
public health through the  
creation of critical and  
innovative safety and risk  
management programs in areas  
of great medical need***

[www.celgene.com](http://www.celgene.com)



# Poster Session B: Tuesday, Aug. 18

8:30am–6:00pm

## Cardiovascular Drugs

- 1 Use of Statins and the Risk of Rheumatoid Arthritis [287]**  
*H de Jong, O Klungel, L van Dijk, R Vandebriel, H Leufkens, JW Cohen Tervaert, H van Loveren. (Netherlands)*
- 2 Risk of Incident Atrial Fibrillation in Users of Antihypertensive Drugs [288]**  
*Beat A Schaer, Cornelia Schneider, Susan S Jick, David Conen, Stefan Osswald, Christoph R Meier. (Switzerland)*
- 3 Quality Prescribing of Anti Hypertensives Drugs in Indonesian Hospital [289]**  
*Jarir Atthobari, Erna Kristin, Khairul I Bin Zulkifli, David B Wibowo, Iwan Dwiprahasto. (Indonesia)*
- 4 Synergistic Effect of Statins and Postmenopausal Hormone Therapy in Prevention of Skeletal Fractures [290]**  
*Ludmila N Bakhireva, Michael Shainline, Shelley Carter, Scott Robinson, Sally Beaton, James Nawarskas, Margaret Gunter. (United States)*
- 5 Antiplatelet Therapy for Secondary Prevention after Ischemic Stroke among Elderly in Taiwan [291]**  
*Ching-Lan Cheng, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)*
- 6 Reducing Co-Payments of Essential Cardiovascular Medications [292]**  
*Niteesh K Choudhry, Sebastian Schneeweiss, Michael Fischer, Jun Liu, Joyce Lii, Daniel Solomon, Alan Brookhart, Jerry Avorn, William Shrank. (United States)*
- 7 Effects of Phytosterols on Pattern and Effectiveness of Statin Use: Preliminary Results of a Post-Marketing Study [293]**  
*Simone Eussen, Menno van der Elst, Cathy Rompelberg, Johan Garssen, Henk van Loveren, Marcel Bouvy, Marco Oosterveld, Anthonius de Boer, Johan de Gier, Olaf Klungel. (Netherlands)*
- 8 Antithrombotic Prescribing Patterns Following Intracerebral Haemorrhage in the Tayside Stroke Cohort (TSC) [294]**  
*Robert Flynn, Thomas MacDonald, Gordon Murray, Alexander Doney. (United Kingdom)*
- 9 Heart Failure Medication Use in Older Home Care Clients [295]**  
*Andrea Foebel, John Hirdes, George Heckman, Erin Tjam, Suzanne Tyas, Colleen J Maxwell. (Canada)*
- 10 Rate of Bleeding Events and Comorbidities among Atrial Fibrillation Patients Treated with or without Warfarin [296]**  
*S Ghatge, J Biskupiak, J Casciano, M Hagan, D Brixner. (United States)*
- 11 Is Hyperlipidemia or its Treatment Associated with Erectile Dysfunction? Results from the Boston Area Community Health (BACH) Survey [297]**  
*Susan A Hall, Varant Kupelian, Raymond C Rosen, Thomas G Trivison, Carol L Link, Martin M Miner, Peter Ganz, John B McKinlay. (United States)*
- 12 Influence of Proton Pump Inhibitors on the Antiplatelet Properties of Two Clopidogrel Dosing Regimens and the Role of CYP2C19 Genotype [298]**  
*Ankie M Harmsze, Jochem W van Werkum, Vera HM Deneer, Henk J Ruven, Olaf H Klungel, Chris M Hackeng, Jurrien M Ten Berg, Antonius De Boer. (Netherlands)*
- 13 Persistence of Antihypertensive Therapy by Socioeconomic Status [299]**  
*Vidar Hjellvik, Randi Selmer, Hege S Blix, Solveig Sakshaug, Aage Tverdal. (Norway)*
- 14 Persistence of Statin Treatment by Socioeconomic Status [300]**  
*Vidar Hjellvik, Solveig Sakshaug, Randi Selmer, Hege S Blix, Aage Tverdal. (Norway)*
- 15 Use of Spironolactone in the Treatment of Congestive Heart Failure [301]**  
*Lachaine Jean, Beauchemin Catherine, Ramos Élodie. (Canada)*
- 16 Predicting the Risk of Hyperkalemia in Patients with Kidney Disease Starting Angiotensin-Converting Enzyme Inhibitors [302]**  
*Eric S Johnson, Jessica R Weinstein, Micah L Thorp, Robert W Platt, Amanda F Petrik, Xiuhai Yang, Sharon Anderson, David H Smith. (United States)*
- 17 Increasing Incidence of Statin Treatment among the Elderly and Those without Previous Cardiovascular Conditions. A Nation Wide Register Study [303]**  
*Helle Wallach Kildemoes, Morten Andersen. (Denmark)*
- 18 Carvedilol Is Effective for Preventing Rehospitalizations in Elderly Heart Failure with Diabetic Patients – Using Korea Health Insurance Review and Assessment Database [304]**  
*Ju-Young Kim, Hong-Ji Song, Hwa-Jung Kim, Sun-Young Jung, Byung-Joo Park. (Korea)*
- 19 A Randomized Controlled Trial of Copayment Reductions for Blood Pressure Medication: The CHORD Trial [305]**  
*Stephen E Kimmel, Andrea B Troxel, Judith Long, Said Ibrahim, Dina Appleby, J Otis Smith, Jane Jaskowiak, Marie Helweg-Larsen, Jalpa Doshi, Kjell Enge, Kevin G Volpp. (United States)*
- 20 Cost Analysis of Blood Pressure Lowering Drugs Utilization in an Indonesian Private Hospital: An Observational Study Using Claimed Prescribing Database [306]**  
*Hasnul Hayat Sofaruddin, Jarir At Thobari, Erna Kristin, Iwan Dwiprahasto. (Indonesia)*
- 21 Dual Pharmacological Effect of Simvastatin in a Cohort of Romanian Women [307]**  
*Victor Dumitrascu, Anca Alexandra Matusz, Daliborca Cristina Vlad, Adelina Cheveresan, Daniela Cipu. (Romania)*
- 22 Secondary Medication Prevention of Patients with Stable Angina Pectoris at the Level of Primary Health Services [308]**  
*Tolkun M Murataliev, Rasim Kutlu. (Kyrgyzstan)*

# Poster Session B: Tuesday, Aug. 18

- 23 Use of Oral Anticoagulants and Risk of Subarachnoid Haemorrhage. A Population Based Case-Control Study [309]**  
*Morten Olsen, Martin Johansen, Steffen Christensen, Henrik T Sørensen. (Denmark)*
- 24 More Than 50% of High Risk Patients Are Not Prescribed Statins [310]**  
*Pieter van den Haak, Edith Heintjes, Arian Plat, Miriam Sturkenboom, Fernie Penning-van Beest, Ron Herings. (Netherlands)*
- 25 THE Role of LDL-Levels in Initiating Statin Treatment [311]**  
*Edith Heintjes, Arian Plat, Miriam Sturkenboom, Fernie Penning-van Beest, Ron Herings. (Netherlands)*
- 26 Does Serum Potassium Monitoring Protect against Hyperkalemia? [312]**  
*Marsha Raebel, Colleen Ross, Stan Xu, Craig Cheetham, Douglas Roblin, Chris Blanchette, Gwyn Saylor, David Smith. (United States)*
- 27 Abstract Withdrawn by Author [313]**
- 28 Fibrate or Statin Initiation in Warfarin Users and GI Bleeding Risk [314]**  
*Hedi Schelleman, Warren B Bilker, Colleen M Brensinger, Yu-Xiao Yang, Sean Hennessy. (United States)*
- 29 Use of Antiplatelet Drugs and Risk of Subarachnoid Hemorrhage. A Population-Based Case-Control Study [315]**  
*Morten Schmidt, Martin B Johansen, Steffen Christensen, Christian F Christiansen, Henrik Toft Sørensen. (Denmark)*
- 30 Trends in Persistence of Evidence-Based Medications after Heart Failure Hospitalization in the Elderly [316]**  
*Soko Setoguchi, Niteesh K Choudhry, Raisa Levin, William Shrank, Wolfgang C Winkelmayr. (United States)*
- 31 Angiotensin Receptor Blockers (ARBs) and the Reduced Risk of Erectile Dysfunction [317]**  
*Hong Ji Song, Hwa Jung Kim, Ju Young Kim, Sun Young Jeong, Byung-Joo Park. (Korea)*
- 32 Abstract Withdrawn by Author [318]**



**Providing clarity on the value and safety of health care decisions.**

A fully evolved research environment:

- The HealthCore Integrated Research Database (HIRD™)
- A diverse and highly experienced research staff
- Collaborations with clinicians, academia, government and managed care

## HealthCore™

**Safety & Epidemiology Research**  
**Prospective Effectiveness Research**  
**Health Economics & Outcomes Research**

800 Delaware Avenue / Fifth Floor / Wilmington, DE 19801  
P 302.230.2156 / F 302.230.2046  
info@healthcore.com / www.healthcore.com

Visit us in the Exhibit Hall

To learn about our new  
HealthCore Safety Sentinel System™  
contact Peter Wahl at  
pwahl@healthcore.com

# Poster Session B: Tuesday, Aug. 18

## Drug Utilization Studies

- 43 Herbal Beverages: Perceptions and Knowledge among General Public towards Its Safety and Efficacy [319]**  
*Mohamed Azmi Ahmad Hassali, Asrul Akmal Shafie. (Malaysia)*
- 44 Trends in Potentially Inappropriate Prescribing among the Elderly in Taiwan: Population-Based Study [320]**  
*Chia-Hsien Chang, Yea-Huei Kao Yang. (Taiwan)*
- 45 Prevalence of Asthma, Diabetes Mellitus and Essential Hypertension and Association of Health Insurance with Diagnosis Specific Prescribed Medication [321]**  
*Ravi Y Dalwadi, Conrad W Dhing. (United States)*
- 46 Levetiracetam One Year Retention Rate in Real-Life Paediatric Practice in France, the EULEVp Study [322]**  
*C Dureau, C Droz, JM Pédespan, G Lavernhe, M Mann, J Jové, N Moore, A Fourier. (France)*
- 47 Differences in Drug Use by Race/Ethnicity in a Population-Based Sample [323]**  
*Susan A Hall, Gretchen R Chiu, David W Kaufman, Judith P Kelly, Carol L Link, Varant Kupelian, John B McKinlay. (United States)*
- 48 Effect of Health Literacy on Adherence in Heart Failure Patients [324]**  
*Aaron J Katz, Dan Morrow, Wanzhu Tu, Jingwei Wu, Michael D Murray. (United States)*
- 49 First Line Use of Pain Medication in Neuropathic Facial Pain [325]**  
*Joseph SHA Koopman, Frank J Huygen, Jeanne P Dieleman, Marissa de Mos, Miriam CJM Sturkenboom. (Netherlands)*
- 50 The Prescribing Pattern of Bone Specific Drugs among Taiwan Elderly Women with Established Hip/Vertebral fractures [326]**  
*Tzu-Chieh Lin, Yea-Huei Kao Yang. (Taiwan)*
- 51 Antipsychotic Use among Nursing Home Residents [327]**  
*Judith Lucas, John Bowlblis, Tobias Gerhard, Sujoy Chakravarty, Stephen Crystal. (United States)*
- 52 Epidemiology of Glaucoma and Drug Utilization in UK Primary Care [328]**  
*Andrew Maguire, Mary Thompson. (United Kingdom)*
- 53 Use of Anxiolytic and Hypnotic Drugs in Extremadura. (Spain) 2003- 2005 [329]**  
*Nuria González-Bermejo, Diana González-Bermejo, Javier García del Pozo, Ramona Mateos-Campos. (Spain)*
- 54 An Analysis of the Length of Hospital Stay for Patients with Potential Drug Interactions [330]**  
*Cristiano S Moura, Francisco A Acurcio, Najara O Belo, Ludmila S Tavares, Jessica O Bomfim, Luana A Santos. (Brazil)*
- 55 The Effect of Treatment Guidelines on the Initial Management of Idiopathic Pulmonary Fibrosis [331]**  
*Jeffrey C Munson, Maryl Kreider, Jason D Christie, Stephen E Kimmel. (United States)*
- 56 Age- and Sex-Related Differences in Use of Tertiary Medical Prophylaxis among Patients with Ischemic Stroke in Denmark: A Nationwide Follow-Up Study [332]**  
*Kaare D Palnum, Grethe Andersen, Frank Mehnert, Søren P Johnsen. (Denmark)*
- 57 Attitudes in Antibiotic Use by General Population in Greece [333]**  
*Paraskevi Papaioannidou, Fotios Tsanakalis, Panagiotis Akritopoulos. (Greece)*
- 58 Changing Trends in Thiazolidinedione Use in TRICARE [334]**  
*Kate A Stewart, Brenda M Natzke, Thomas Williams, Elder Granger, S Ward Casscells, Thomas W Croghan. (United States)*
- 59 Adherence to Prescription Guidelines in General Practice: Inter-Doctor Variation and Trends over Time [335]**  
*Liset Van Dijk, Judith D de Jong, Peter Spreeuwenberg, Michael van den Berg, Gert P Westert, Dinny H De Bakker. (Netherlands)*
- 60 Impact of Recent European Reforms To Encourage Prescribing of Generic Statins [336]**  
*Björn Wettermark, Brian Godman, Jaana Martikainen, Arash Ghaffarian Samavarchi, Vera Vlahovic Palcevski. (Sweden)*

## Economics

- 61 Economic and Clinical Impact of Formularies on Pneumonia Admissions [337]**  
*Godofreda V Dalmacion, Hilton Y Lam, Noel Juban, Nina C Carandang, Carlo Panelo. (Philippines)*
- 62 Anxiety Disorders – Cost of Illness and Treatment Patterns Analysis from a Retrospective US Claims Database [338]**  
*Clément François, Nicolas Despiéglé, Khaled Maman, Delphine Saragoussi, Pascal Auquier. (France)*
- 63 Application of Principals of Pharmacoepidemiology, Clinical Pharmacology and Therapeutics in Pharmacoeconomics [339]**  
*Pendar Farahani. (United States)*
- 64 Impact of Adalimumab (HUMIRA®) on Work Productivity in Patients with Psoriatic Arthritis: Results from ACCLAIM [340]**  
*Dafna D Gladman, Fotoula Psaradelis, Marie-Josée Martel, Olivier Illouz, Benoit Guerette, John S Sampalis. (Canada)*

## Effectiveness Research

- 65 The Effect of an Advice To Read the Medicine/Patient Information Leaflet among Patients in Ghana: A Cross-Sectional Survey [341]**  
*Daniel N Ankrah, Charles N Ofei. (Ghana)*

# Poster Session B: Tuesday, Aug. 18

- 66 A Systematic Review on Kushenin Versus Western Medicines for the Patients of Chronic Hepatitis B [342]**

Boyang Bian, Rong Shao, Yongfa Chen, Ying Xia. (United States)

- 67 Effect of Compliance to Statins on the Risk of Non-Fatal Coronary Events in Primary Prevention [343]**

Salvatore Mannino, Alfredo Cocci, Silvia Lucchi, Marco Villa. (Italy)

- 68 The Impact of Comparative Effectiveness Information on Prescribing Patterns: A Case Study [344]**

Tami L Mark. (United States)

- 69 Safety Promoting Behaviors: An Innovative and Feasible Method To Determine the Effectiveness of a Pharmacy Benefit Management Program [345]**

MP Powell, Jeroan J Allison, Kenneth G Saag, Norman W Weissman. (United States)

- 70 Definition of the Risk-Window for the Outcomes of the LIVE Study by Minimization of the Mean Squared Error (MSE) of the Estimator [346]**

Marco Villa, Salvatore Mannino, Silvia Lucchi, Kenneth J Rothman. (Italy)

## Emerging Epidemics

- 71 Incidence of Endophthalmitis after Intravitreal Injection Procedures in the General Population of the United States of America [347]**

Alejandro Arana, Felix M Arellano, Elena Rivero, Joan Fortuny, Charles W Wentworth. (Spain)

## Endocrine/Diabetes

- 72 Prevalence of Diabetes in Hepatitis C Population [348]**

Shirin Ahmed, Helen Huang, Pat Chandra. (United States)

- 73 Study of Hypoglycemia in Veteran Diabetes Patients [349]**

Donald R Miller, Madhuri Palnati, Graeme Fincke, Jean-Philippe Lafrance, Cindy Christiansen. (United States)

- 74 Evaluation of Thiazolidinedione Related Risk of Fracture [350]**

Joongyub Lee, Nam-Kyong Choi, Sun-Young Jung, Ye-Jee Kim, Jong-Mi Seong, Byung-Joo Park. (Republic of Korea)

- 75 A Comparison of Pioglitazone vs Rosiglitazone for Heart Failure in Elderly Type 2 Patients [351]**

Jong-Mi Seong, Nam-Kyong Choi, Sun-Young Jung, Ye-Jee Kim, Joongyub Lee, Byung-Joo Park. (Republic of Korea)

- 76 Predictive Value of ICD and CPT Codes for Identifying Osteonecrosis of the Jaw (ONJ) [352]**

Patricia Tennis, Athanasios Zavras, Constantinos Laskarides, Hiangkiat Tan. (United States)

- 77 LDL-C Goal Attainment According to Prescribed Lipid-Lowering Therapy: Results from the LIPIDE European Survey [353]**

Gaelle Desamericq, Laurent Laforest, Marie-Sophie Schwalm, Philippe Moulin, Emilie Michel, Caroline Eteve, Gabriel Coffin, Cecile Rittleng, Eric Van Ganse. (France)

## Gastrointestinal

- 78 No Evidence for Association of Tegaserod with Suicide-Related Outcomes [354]**

Jeanne Loughlin, Sherry Quinn, Elena Rivero, Heather Norman, David L Earnest, Judy Wong, John D Seeger. (United States)

- 79 Ventricular Arrhythmia and Sudden Unexpected Death and Domperidone [355]**

Charlotte van Noord, Jeanne P Dieleman, Katia Verhamme, Miriam CJM Sturkenboom. (Netherlands)

- 80 Abstract Withdrawn by Author [356]**

- 81 Thiazolidinedione Use and Ulcerative Colitis-Related Flares: An Analysis of Administrative Data [357]**

Jennifer L Lund, Til Stürmer, Carol Q Porter, Robert S Sandler, Michael D Kappelman. (United States)

- 82 Prevalence of Concomitant Proton Pump Inhibitor Prescription Medication Use in the US Population [358]**

Shan Cai, Sonia Hernández-Díaz. (United States)

- 83 Use of Selective Serotonin Reuptake Inhibitors and Upper GI Bleeding [359]**

Michael Dall, Ove B Schaffalitzky de Muckadell, Annmarie Touborg Lassen, Jane Møller Hansen, Jesper Hallas. (Denmark)

## Hematological

- 84 Association between Immune Thrombocytopenic Purpura and Vaccines, in the PGRx Database [360]**

Lamia Bensouda-Grimaldi, Michel Rossignol, Bertrand Godeau, Marc Michel, Jean Francois Viillard, Maya Hacini, Benoit David, Lucien Abenhaim. (France, Metropolitan)

- 85 The Effect of Increased Altitude on Achieved Hematocrit and EPO Dosing in End-Stage Renal Disease [361]**

Maurice A Brookhart, Brian Bradury, Wolfgang Winkelmayr. (United States)

- 86 Risk of Hematological Malignancy among Persons with Chronic Idiopathic Thrombocytopenia [362]**

Cheryl Enger, Dimitri Bennett, Ulla Forssen, Andrew T McAfee. (United States)

- 87 Factors Associated with Receipt of Splenectomy for Patients with Chronic Idiopathic Thrombocytopenic Purpura – A Nationwide Cohort Study [363]**

Mette Nørgaard, Annette Ø Jensen, Dora K Farkas, Lars Pedersen, Jon P Fryzek, Sean Zhao, Henrik T Sørensen. (Denmark)

- 88 Validation of TTP Diagnostic Codes in a Commercially Insured Population [364]**

Peter M Wahl, Keith Rodgers, James N George, Deirdra R Terrell, Lynne Uhl, Spero Cataland, Rhonda L Bohn. (United States)

# Poster Session B: Tuesday, Aug. 18

## Hormones/ Reproductive Agents

- 89 **The Effects of Hormone Contraceptive Use on Immune Reconstitution in HIV Positive Women on Antiviral Medication [366]**  
*Derek Johnson, Sadeep Shrestha. (United States)*
- 90 **Results from the European Active Surveillance Study in Italy (EURAS-OC Italy) [367]**  
*Kristina Voigt, Assmann Anita, Moehner Sabine, Dinger Juergen. (Germany)*
- 91 **Potential for Decreasing Breast Cancer with Decreasing Hormone Replacement Therapy (HRT) [368]**  
*C Ineke Neutel, Howard Morrison. (Canada)*

## Molecular Epidemiology/ Pharmacogenetics

- 92 **CYP2D6 Genotypes, Depression, and Antidepressant Discontinuation during Pregnancy: Results from the Antidepressants in Pregnancy Discontinuation Study [369]**  
*Anick Bérard, Fatiha Karam, Andrea Gaegick, Odile Sheehy, Sylvie Perreault. (Canada)*
- 93 **Understanding the Clinical Utility and Adoption of Pharmacogenomics: A Quantitative Analysis of Patient Decision-Making [370]**  
*Amalia M Issa, Janis Hutchinson, Waqas Tufail, Jose Tenorio. (United States)*
- 94 **CYP2C19\*2 Is Associated with Increased Survival in Breast Cancer Patients Using Tamoxifen [371]**  
*Tanneke R Ruiter, Monique J Bijl, Albert Hofman, Ron HN van Schaik, Loes E Visser, Bruno HCh Stricker. (Netherlands)*
- 95 **K-Ras Mutation among Colorectal and Non-Small Cell Lung Cancer Patients [372]**  
*Wei Zhou, Holly Brown, Melissa Tice. (United States)*

- 96 **Interaction between the G894T eNOS Gene Variant and Calcium Antagonists on the Risk of Myocardial Infarction [373]**  
*Diane BMA van Wieren-de Wijer, Anke Hilde Maitland-van der Zee, Anthonius de Boer, Abraham A Kroon, Peter W de Leeuw, Paul Schiffers, Rob GJH Janssen, Bruce M Psaty, Cornelia M van Duijn, Bruno HCh Stricker, Olaf H Klungel. (Netherlands)*
- 97 **Pharmacogenetic Determinants for Discontinuation of Non-Ergoline Dopamine Agonists in Parkinson's Disease [374]**  
*Maurits Arbouw, Kris Movig, Toine Egberts, Petra Poels, Jeroen van Vugt, Judith Wessels, Tahar van der Straaten, Cees Neef, Henk-Jan Guchelaar. (Netherlands)*
- 98 **Transcription Factor 7-Like 2 (TCF7L2) Polymorphism and Retinal Vascular Signs in African American and Caucasian Adults: The Atherosclerosis Risk in Communities (ARIC) Study [375]**  
*Yu Yan, Ronald Klein, Gerardo Heiss, Cynthia J Girman, Ethan M Lange, Barbara E Klein, Kathryn M Rose, Suzanne L West, Eric Boerwinkle, James S Pankow, Frederick L Brancati, Christie M Ballantyne, Anna Köttgen, Kari E North. (United States)*

## Pharmacovigilance

- 99 **A Review of Amputation and Gangrene Adverse Events for Injected Promethazine [376]**  
*Keith L Altman. (United States)*
- 100 **Performance of a Semi-Automated Process for Estimation of Risk in a Claims Database [377]**  
*Kathleen Beach, Hoa V Le, Gregory Powell, Ed Pattishall, Patrick Ryan, Robertino Mera. (United States)*
- 101 **Adverse Drug Reaction (ADR) Monitoring in Patient Receiving Oncologic Medications: A 3 Months Study [378]**  
*Kanwalpreet Kaur, Pipasha N Biswas. (United Kingdom)*

- 102 **Consequences of the Exclusion of Known Adverse Drug Reactions in a Spontaneous Reporting System on the Possibility to Detect Unknown Drug/ADR Combinations [379]**  
*Sander Borgsteede, Eugene van Puijenbroek, Kees van Grootheest. (Netherlands)*
- 103 **Variation in ICD-9 Diagnosis Coding of Potential Adverse Events [380]**  
*Kristen Moore, Jeffrey Brown. (United States)*
- 104 **Detection of Adverse Drug Reaction Signals in the Thai FDA Database: Comparison between Reporting Odds Ratio and Bayesian Confidence Propagation Neural Network Methods [381]**  
*Waranee Bunchuailua, Ilene H Zuckerman, Vithaya Kulsomboon, Wimon Suwankeawong. (Thailand)*
- 105 **Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION [382]**  
*Ulka B Campbell, Kenneth R Petronis, Brian J Klee, Francesca Kolitsopoulos, Alexander M Walker, Jingping Mo. (United States)*
- 106 **The Completeness of Data in the Food and Drug Administration' Adverse Event Reporting System from 1998 to 2007 [383]**  
*Yan Chen, Alice Russell, Patrick DeLisle, Yingkai Cheng, Indiana Strombom, Jennifer Bardos, Stephen Motsko, Kenneth Hornbuckle. (United States)*
- 107 **The Validity of Physician-Reported Hospitalized Infections in a US Rheumatoid Arthritis Cohort [384]**  
*Archana Jain, Nivedita Patkar, Jeffrey Greenberg, Daniel H Solomon, Jeffrey R Curtis. (United States)*
- 108 **Results from a German/Finnish Case-Control Study of Breast Cancer Risk for Levonorgestrel-Releasing Intrauterine Devices [385]**  
*Juergen C Dinger, Sabine Moehner, Kristina Voigt, Anita Assmann. (Germany)*

# Poster Session B: Tuesday, Aug. 18

**109 Drug-Induced Hepatic Injury in Children: Analysis of Spontaneous Adverse Event Reports of WHO Database [386]**

*Carmen Ferrajolo, Katia Verhamme, Martijn Schuemie, Annalisa Capuano, Francesco Rossi, Bruno Stricker, Miriam Sturkenboom. (Italy)*

**110 Mortality Due to Ischaemic Heart Disease in 15,659 Patients Prescribed Vardenafil in General Practice in England (2005): Results from a Prescription-Event Monitoring (PEM) Study [387]**

*L Hazell, V Cornelius, L Wilton, S Shakir. (United Kingdom)*

**111 The Impact of Patient Access Pathways on Post Marketing Drug Safety Studies Using Cancer Registry Data [388]**

*Kirk Midkiff, Alicia Gilsenan, Rebecca D Martin, Yun Wu, Daniel N Masica, Elizabeth B Andrews. (United States)*

**112 Hidden Partial Non-Compliance with Antidepressants and its Effect on Treatment Response [389]**

*Margareta Reis, Lars von Knorring, Ann-Charlotte Åkerblad, Lisa Ekse-lius. (Sweden)*

**113 No Evidence of a Strong Association between Orlistat and Pancreatitis. Results from a Study Using the UK General Practice Research Database (GPRD) [390]**

*Markus Schuerch, Noah J Robinson. (Switzerland)*

**114 Abstract Withdrawn by Author [391]**

**115 Impact of a Safety Issue on the Number and Type of Publications: The Example of Sertindole [392]**

*Frederieke H van der Baan, Mirjam J Knol, Marie L de Bruin, Bert GM Leufkens, Olaf H Klungel, Toine CG Egberts. (Netherlands)*

**116 Andrographolide: Thailand Epidemiological and Safety Profile [393]**

*Sareeya Wechwithan. (Thailand)*

## Regulatory Issues/ Drug Policy

**117 The Unintended Consequences of Good Intentions [394]**

*Edgar H Adams. (United States)*

**118 Abstract Withdrawn by Author [395]**

**119 Patterns of Reported Exposures to Cough and Cold Medications among Children Following the Release of an FDA Public Health Advisory [396]**

*Alvin F Chu, Zdravko P Vassilev, Steven M Marcus, Bruce Ruck. (United States)*



**Empirica™**  
Safety Suite

**Innovative Pharmacovigilance  
& Risk Management Solutions**

**Empirica™ Study**  
Clinical Trials Signal Detection

**Empirica™ Trace**  
Adverse Event Management

**Empirica™ Signal**  
Data Mining & Signal Detection

**PHASE•FORWARD.**

[www.phaseforward.com](http://www.phaseforward.com)

Copyright © 2009 Phase Forward Incorporated. All rights reserved. Phase Forward, Empirica, and the Phase Forward logo are trademarks or registered trademarks of Phase Forward Incorporated in the U.S., Patent and Trademark Office and other jurisdictions. Other marks may be trademarks or registered trademarks of their respective owners.

# Poster Session B: Tuesday, Aug. 18

- 120 Methodological and Regulatory Challenges in the Assessment of Long-Term Drug Safety [397]**  
*Marie L De Bruin, Ingemar Persson, Sebastian Schneeweiss, Tjeerd P van Staa, Hubert GM Leufkens. (Netherlands)*
- 121 The Role of Epidemiology in New Drug Development [398]**  
*Jeff J Guo, Christina ML Kelton. (United States)*
- 122 Social Cost of Adherence to Philippine Generics Prescribing (PGP) [399]**  
*Hilton Y Lam, Godofreda V Dalmaçion, Noel R Juban, Nina C Carandang, Carlo A Panelo. (Philippines)*
- 123 The Financially Tolerable Dose: A New Concept in Cancer Trial Design [400]**  
*Sallie-Anne Pearson, Melvin Chin, Robyn Ward. (Australia)*
- 124 Post Marketing Surveillance: What Is the Potential for Harm When Use Is Not Consistent with the Trial Population in People Receiving Cholinesterase Inhibitors for Treatment of Alzheimer's Dementia? [401]**  
*Ann Leverton, Debra S Rowett, Maxine Robinson, V Mabbott. (Australia)*
- 125 Differential Effects of Drug Cost Sharing Policies on Adherence to Angiotensin Blockers in Patients with and without Heart Failure [402]**  
*Soko Setoguchi, Amanda R Patrick, Colin Dormuth, Malcolm Maclure, Canning F Claire, Robert J Glynn, Sebastian Schneeweiss. (United States)*
- 127 Impact of Modified-Release Versus Other Opioid Formulations on Health Outcomes during Episodes of Opioid Treatment in Patients with Alcohol-Related Disorders [404]**  
*J David Haddox, Liisa Palmer. (United States)*
- 128 Development of a Regulatory Post-Marketing Studies Database [405]**  
*Martine Caron, Julie Mouchet, Marie-Pierre Emery, Juliette Longin, William C Maier. (France)*
- 129 Atomoxetine (ATO) Use and Central Nervous System Stimulants (CNSS) Use during Physician-Office Visit for Attention Deficit/Hyperactivity Disorders (ADHD) after the Discussion on ATO Related Suicidal Risk [406]**  
*C-Y Chen, AG Winterstein. (United States)*
- 130 Projected Exposure to Drugs on FDA's Watch List [407]**  
*Suellen Curkendall, Leigh Hansen, Stella Chang, Tami L Mark. (United States)*
- 131 Thiazolidinediones and Bone Loss: A Systematic Review [408]**  
*Gaurav Deshpande, Sheila Weiss-Smith. (United States)*
- 132 Evaluation of Current Risk Evaluation and Mitigation Strategies [409]**  
*Alicia Gilsenan, Elizabeth B Andrews, Brian Calingaert, Debra Crozier, Abenah Vanderpuije. (United States)*
- 133 Overview and Comparison of Post-Marketing Drug Safety Surveillance in Developing Countries and Other Well Developed Regions [410]**  
*Sampada S Vaidya, Jeff J Guo, Pamela C Heaton, Michael Steinbuck. (United States)*
- 134 Feasibility Study: Linkage of Prescribing and Dispensing Data To Generate Non-Adherence Alerts to Practitioners' Computer Systems [411]**  
*Jeff Harrison, Ramy Burjony, Khalid Ghanima, Sara Higgins, Ziyen Lam, Sam Pang. (New Zealand)*
- 135 Medical Practices' Awareness and Perceptions of the UMWA Health and Retirement Funds MineRx Program [412]**  
*Eric P Jack, MP Powell, Jeroan J Allison, Kenneth G Saag, Norman W Weissman. (United States)*
- 136 Implications of the Withdrawal of Exubera on the Exubera Large Simple Trial (Volume) [413]**  
*Nicolle M Gatto, Francesca M Koltisopoulos. (United States)*
- 137 Patient Counseling Efforts in U.S. Community Pharmacies: Associations to Pharmacy and Personnel Attributes [414]**  
*Stephan Linden, Carole Kimberlin, Almut G Winterstein. (United States)*
- 138 Estimating the Magnitude of Increased False Risks Due to Stimulated Adverse Event Awareness [415]**  
*T Christopher Mast, Nancy Santanello. (United States)*
- 139 Changes in Topical Calcineurin Use Following Regulatory Actions in the US [416]**  
*David Moeny, Lois La Grenade, Allen Brinker. (United States)*
- 140 A Decade of Dear Doctor Letters. A Systematic Review [417]**  
*Peter Mol, Sabine Straus, Jonie de Vries, Menno van der Elst, Fakhredin Tabatabaei, Pieter de Graeff, Flora Haaijer-Ruskamp. (Netherlands)*
- 141 Metabolic Risk Mitigation in Children Receiving Antipsychotics [418]**  
*Elaine H Morrato, Ginger Nicol, Benjamin Druss, Daniel M Hartung, Robert J Valuck, Richard Allen, Elizabeth Campagna, John W Newcomer. (United States)*
- 142 Low Birth Weight Paradox in Distrito Federal (DF), Brazil, 2005 [419]**  
*Aline Silva, Larissa Naves, Elisa Araújo, Elisabete Duarte. (Brazil)*
- 143 Emergency Department Visits Associated with Nonmedical Use of Hydrocodone/Acetaminophen: 2004-2007 [420]**  
*Meredith Y Smith, Andrea Best, Rita Jain. (United States)*

## Risk Management/ Communication

- 126 Survey on Specific Regulations and Requirements for Risk Management Plans in Countries outside the EU and the US [403]**  
*Patrice Verpillat, Sandrine Valiere, Christine Dutar, Laurent Auclert. (France)*

# Poster Session B: Tuesday, Aug. 18

- 144 Usefulness of Consumer Medication Information (CMI) [421]**  
*Almut G Winterstein, Stephan Linden, Erica Fernandez, Abigail Lee, Carole Kimberlin. (United States)*

## Use of Linked Databases

- 145 Assessment of Data Quality in Health Care Databases [422]**  
*Piotr Juszczak, Tim Williams, Tjeerd van Staa. (United Kingdom)*

- 146 Combining Data from Healthcare Databases in Europe: A Study of Dopamine Agonists [423]**  
*Cynthia de Luise, Gianluca Trifiro', Ron Herings, Jeanne Dieleman, Eva van Soest, Katia Verhamme, Giampiero Mazzaglia, Miriam Sturkenboom. (United States)*

- 147 Opportunity in Diversity: Merging Healthcare Databases in Europe for Safety Signal Detection in Pharmacovigilance [424]**  
*Preciosa Coloma, Martijn Schuemie, Gianluca Trifiro', Ron Herings, Julia Hippisley-Cox, Rosa Gini, Mariam Molokhia, Giampiero Mazaglia, Carlo Giaquinto, Giovanni Corrao, Lars Pedersen, Miriam Sturkenboom, Johan van der Lei. (Netherlands)*

- 148 An Audit of Completeness of Recording over Time of Key Variables in THIN – A UK General Practice Database [425]**  
*Alison Bourke, Mary Thompson, Fiona Hill. (United Kingdom)*

- 149 The Use of Prescribed Medications among Residents of Quebec Covered by a Private Drug Insurance Plan: Results from the reMed Pilot Study [426]**  
*Marie-Christyne Cyr, Lucie Blais, Marie-France Beauchesne, Lyne Lalonde, Jocelyne Moisan, Sylvie Perreault, Elham Rahme. (Canada)*

- 150 Innovative Data Tools and Techniques That Combine Claims and EMR-Based Data Sources [428]**  
*Vik Kherterpal, Stella Chang, Stacey Long. (United States)*

- 151 Are the Prescription Claims Data Reliable Despite the Over-the-Counter Drug Usage in Dealing with Misclassification Bias? [429]**  
*Hwa J Kim, Moo-song Lee, Seol-ryoung Kil, Hong-ji Song, Byoung-joo Park. (Republic of Korea)*



## THE DEGGE GROUP, LTD.

Drug Safety Research and Information

Risk Management  
Risk Evaluation & Mitigation Strategies  
Program Evaluation  
Spontaneous Reports & AERS  
Pharmacovigilance  
Comprehensive Literature Reviews  
Safety & SOP Audits

Pharmacoepidemiology  
Registries (Drug, Disease, AE)  
Natural History of Disease  
Phase IV Studies  
CRO Oversight  
Scientific Advisory Panel /  
Adjudication Panel Management

Stop by our Booth to find out how we may help you, or visit our website: [www.deggegroup.com](http://www.deggegroup.com)

We are proud to announce the re-launch of DGI, Inc.'s

**B.R.I.D.G.E. TO DATA<sup>SM</sup>**

Your connection to healthcare databases worldwide<sup>SM</sup>

[www.bridgetodata.org](http://www.bridgetodata.org)



# Poster Session B: Tuesday, Aug. 18

**152 Assessing the Feasibility of Applying a Validated ICD-9-CM Coding Algorithm To Identify Hypoglycemic Events in Hospitalized Pediatric Patients with Diabetes [430]**  
*Zhiwen Liu, Cynthia J Girman. (United States)*

**153 The Workplace Burden of Smoking in the United States [431]**  
*Tami L Mark, Zhun Cao, Stephen Johnston. (United States)*

**154 Outpatient Continuation of Inpatient Antipsychotic Prescriptions: A Linked Data Analysis [432]**  
*Tami L Mark, Stella Chang. (United States)*

**155 A Comparison of MedDRA® Code Assignments in Two Databases: Effect on the Safety Profile of a Product [433]**  
*Marie Lou G Munson, Vivek Saharan. (United States)*

**156 COPD Classification Based on Medical Codes and Spirometry — A Comparison [434]**  
*Robert Y Suruki, Hana Muellerova, Richard Baxter, Kourtney J Davis. (United States)*

**157 Availability of Spirometry Records in Patients with COPD in the General Practice Research Database [435]**  
*Robert Y Suruki, Hana Muellerova, Richard Baxter, Kourtney J Davis. (United States)*

**158 Predictive Value of Coding of Diagnoses in the Charlson Comorbidity Index in the Danish National Registry of Patients [436]**  
*Sandra K Thygesen, Christian F Christiansen, Timothy L Lash, Steffen Christensen, Henrik T Sorensen. (Denmark)*

**159 New Opportunities for Drug Outcomes Research in Cancer Patients: The Linkage of the Eindhoven Cancer Registry and the PHARMO Network [437]**  
*Myrthe PP van Herk-Sukel, Lonneke V van de Poll-Franse, Valery EPP Lemmens, Gerard Vreugdenhil, Johannes FM Pruijt, Jan Willem W Coebergh, Ron MC Herings. (Netherlands)*

*End Session B*

## Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that bring population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:

- Analyzing the occurrence and distribution of diseases, including underlying disease process
- Determining the burden of illness and unmet medical need
- Exploring traditional and new risk factors for diseases
- Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug uses and adverse events
- Detecting opportunities for possible new drug uses and new paths of drug development

Please visit our website at <http://epidemiology.gsk.com/organization.html> to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

*Developing talent through equality of opportunity*



# Poster Session C: Wednesday, Aug. 19

8:30am–2:00pm

## Analgesics/Anti-Inflammatory Agents

- 1 **Survival Analysis of Australian Veterans using COX-2 Selective or Non-Selective NSAIDs [474]**  
*Stephen J Kerr, Geoffrey P Sayer, Susan D Whicker, Debra S Rowett, Andrea Mant. (Australia)*
- 2 **Analgesic/Antipyretic Use of Children and Adolescents in Germany – Results of the KiGGS-Study [475]**  
*Hildtraud C Knopf, Yong Du. (Germany)*
- 3 **The SOS Project: Cardiovascular and Gastrointestinal Safety of NSAIDs. Preliminary Results of a Systematic Review of Epidemiological Studies [476]**  
*Nuria Riera-Guardia, Ceri Hirst, Jordi Castellsague, Cristina Varas-Lorenzo, Antoine Pariente, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)*
- 4 **The SOS Project (Safety of NSAIDs): Preliminary Results of Published Meta-Analyses Review [477]**  
*Francesco Salvo, Antoine Pariente, Sinem E Gulmez, Yannick Guillaume, Castellsague Jordi, Miriam C Sturkenboom, Mendel Haag, Nicholas Moore, Annie Fourier-Réglat. (France)*
- 5 **Dose Variations in NSAID Prescriptions for Children – An Analysis of Electronic Patient Records [478]**  
*Kristina Star, Andrew Bate, Ola Caster, Ralph Edwards. (Sweden)*

## Analysis Methods

- 6 **Validation of Claims Databases for the Ascertainment of Adverse Events: From Descriptive to Predictive Methodologies [479]**  
*Claire N Abou Chakra, Yola Moride, Brain Greenfield, Larry Lynd, Colleen Metge, Marie Tournier. (Canada)*
- 7 **Spontaneous Report Safety Signals Profile and Comparative Bayesian Analysis of ADHD Medication in Children in the UK [480]**  
*Raphaëlle Beau, Ian Douglas, Liam Smeeth, Stephen JW Evans. (United Kingdom)*
- 8 **The Pattern of Risk of Myocardial Infarction in Patients Taking Asthma Medication: A Study with the UK General Practice Research Database (GPRD) [481]**  
*Bill Zhang, Frank de Vries, Erosini Setakis, Tjeerd-Pieter van Staa. (United Kingdom)*
- 9 **Medical Record Abstraction To Supplement Covariate Data in Health Insurance Claims: The Case of Diabetes and Acute Pancreatitis (AP) [482]**  
*David D Dore, Saadia Chaudhry, Sherry G Quinn, John D Seeger. (United States)*
- 10 **Length of Follow-up Periods in Safety Studies Can Affect Chance Findings [483]**  
*Xiaoming Li, Ivan SF Chan, Bruce H Fireman, Lawrence A Gould, Eric Maiese, Roger Baxter, Patricia Saddier. (United States)*
- 11 **Implications of Censoring in Studies of Medication Adherence [484]**  
*Amanda R Patrick, M Alan Brookhart. (United States)*
- 12 **Effects of Different Groupings of Drug Adverse Events in the Detection of Signals Using Bayesian Analyses [485]**  
*David Prieto-Merino, Stephen JW Evans. (United Kingdom)*
- 13 **Dealing with Unmeasured Confounding Using Instrumental Variables [486]**  
*George Quartey, Loic Yengo, Liping Huang, John Weil. (United Kingdom)*
- 14 **Data Mining on Electronic Health Record Databases for Signal Detection in Pharmacovigilance: Which Events To Monitor? [487]**  
*Gianluca Trifirò, Antoine Pariente, Preciosa M Coloma, Jan A Kors, Giovanni Polimeni, Ghada Miremont-Salamé, Maria Antonietta Catania, Francesco Salvo, Anaëlle David, Nicholas Moore, Achille P Caputi, Miriam Sturkenboom, Mariam Molokhia, Julia Hippisley Cox, Carlos Diaz, Johan van der Lei, Annie Fourier-Reglat. (Netherlands)*

## Anti-Infectives

- 15 **The Risk of Hospitalization or Emergency Care Following Out-patient Treatment of Community-Acquired Pneumonia (CAP) with Levofloxacin Versus Moxifloxacin [488]**  
*James E Signorovitch, Anna Gu, Anirban Sengupta, Monika Raut, Samir H Mody, Richard Grant, Jeff Schein, Alan C Fisher, Daniel Ng, Mei Sheng Duh. (United States)*
- 16 **Effectiveness of Linezolid among a National Cohort of Patients Infected with Methicillin-Resistant Staphylococcus aureus (MRSA) [489]**  
*Aisling R Caffrey, Brian J Quilliam, Kerry L LaPlante. (United States)*
- 17 **Daily Practice of Oral Antibiotic Therapy: Problems in at Least 30% of the Children [490]**  
*Josta de Jong, Mirthe L Niehoff, Tjalling W de Vries, Lolkje TW deJong-van den Berg. (Netherlands)*
- 18 **Antibiotic Usage, Dosage and Course Length in Children between 0 and 4 Years [491]**  
*Josta de Jong, Paul B van den Berg, Sipke T Visser, Tjalling W de Vries, Lolkje TW de Jong-van den Berg. (Netherlands)*
- 19 **Evolution of Hospital Prescriptions of Antibiotics Dispensed in Community Pharmacies in 2006-2007 in France [492]**  
*Adeline Gallini, Maryse Lapeyre-Mestre, Florence Taboulet. (France)*
- 20 **Differences in Pharmacotherapy Adherence on Weekends Versus Weekdays [493]**  
*Marcus Bachhuber, Warren B Bilker, Hao Wang, Robert Gross. (United States)*
- 21 **Misuse of Antibiotics among Non Prescription Dispensing [494]**  
*Rajesh Kumar. (India)*
- 22 **An Updated Cohort Study on the Risk of Cholestatic Liver Disease and Flucloxacillin Using Data from the UK General Practice Research Database [495]**  
*Lin Li, Hershel Jick, Susan S Jick. (United States)*

# Poster Session C: Wednesday, Aug. 19

**23 Comparison of Fluoroquinolone and Macrolide Resistance in *Campylobacter* from Retail Chicken Meat in Pennsylvania with National Data [496]**

*Nkuchia M M'ikanatha, Sonya Bodeis-Jones, Ebbing Lautenbach, Shaohua Zhao, Jason P Folster, Felicita M Medalla, A Russell Localio, Anthony T Russo, Stanley Reynolds, Patrick F McDermott. (United States)*

## Cardiovascular Disease

**24 Differences in Risk of ST Segment Elevation Myocardial Infarction (STEMI) or Non STEMI Associated with NSAIDs Use. A Study with the PGRx Database [497]**

*Lamiae Bensouda-Grimaldi, Michel Rossignol, Nicolas Danchin, Jean Dal-longeville, Gabriel Ph Steg, Sandra Da Cruz, Benoit David, Lucien Abenhaim. (France, Metropolitan)*

**25 Prevalence and Predictors of Low HDL Cholesterol in US Population: NHANES 2005–2006 [498]**

*Jennifer B Christian, Nancy E Bourgeois. (United States)*

**26 Risk of Thromboembolic Events among Persons with Chronic Idiopathic Thrombocytopenia Purpura [499]**

*Cheryl Enger, Dimitri Bennett, Ulla Forssen, Andrew T McAfee. (United States)*

**27 Abstract Withdrawn by Author [500]**

**28 First-Listed Diagnostic Codes Functioned Well To Identify Hospitalization and Emergency Department Treatment for Outpatient-Originating Sudden Cardiac Death and Ventricular Arrhythmia in Medicaid and Medicare Data [501]**

*Sean Hennessy, Charles E Leonard, Cristin M Palumbo, Rajat Deo, Craig Newcomb, Stephen E Kimmel, Warren B Bilker. (United States)*

**29 Antidepressants and the Risk of Emergency Department or Inpatient Admission for Sudden Cardiac Death and Ventricular Arrhythmia [502]**

*Sean Hennessy, Charles E Leonard, Craig Newcomb, Stephen E Kimmel, Warren B Bilker. (United States)*

**30 Atomoxetine and Cerebrovascular Outcomes in Adults [503]**

*Crystal N Holick, Bruce R Turnbull, Meghan E Jones, Saadia Chaudhry, Mark E Bangs, John D Seeger. (United States)*

**31 Risk of Valvular Heart Disease in Patients Treated with Dopamine Agonists in Japan: A Study Using Spontaneous Reports [504]**

*Kiyoshi Kubota, Hikaru Watanabe, Tsugumichi Sato. (Japan)*

**32 Comorbid Conditions among Patients with Acute Coronary Syndrome [505]**

*Jamie Laudati, Helen Huang, Shirin Ahmed. (United States)*

**33 The Relationship between the Length of Oral Anticoagulation and Recurrence of Venous Thromboembolism in Taiwan – A Nationwide Population-Base Study [506]**

*Cheng-Han Lee, Yea-Huei Kao Yang, Li-Jen Lin, Ching-Lan Cheng. (Taiwan)*

**34 Atrial Fibrillation in US Veteran Fracture Patients Treated with Bisphosphonates [507]**

*Jay R McDonald, Cory Pittman, Angelique L Zeringue, Seth A Eisen, Fran Cunningham, Kent Wehmeier, Liron Caplan. (United States)*

**35 The Secondary Prevention of Hypertensive Patients with Cerebrovascular Diseases [508]**

*Zulfia T Radjapova, Aynagul S Djumagulova, Andrew G Polupanov. (Kyrgyzstan)*

**36 Risks of Mortality and Stroke Associated with Suboptimally Anticoagulated Atrial Fibrillation Patients [509]**

*Efrosini Setakis, Bill Zhang, Tjeerd P van Staa. (United Kingdom)*

**37 Statins and Total (not LDL) Cholesterol Concentration and Outcome of Myocardial Infarction: Results from a Meta-Analysis and Observational Study [510]**

*Xia Sheng, Li Wei, Michael J Murphy, Thomas M MacDonald. (United Kingdom)*

**38 Recent Use of Bisphosphonates Is Associated with Atrial Fibrillation [512]**

*Charlotte van Noord, Miriam CJM Sturkenboom, Sabine MJM Straus, Jacqueline CM Witteman, Bruno HC Stricker. (Netherlands)*

**39 Use of Oral Bisphosphonates among Women and the Risk of Deep Venous Thromboembolism – A Population-Based Case-Control Study [513]**

*Anna L Lamberg, Erzsebet Horvath-Puho, Steffen Christensen, Cathy Critchlow, Jon Frysek, Henrik T Sørensen. (Denmark)*

**40 Validation of Serious Ventricular Arrhythmias in an Administrative Database [514]**

*Cristina Varas-Lorenzo, Catherine Johannes, Lisa McQuay, Kirk Midkiff, Mary Rose Stang, Daniel Fife. (Spain)*

## Disease Epidemiology/ Burden of Illness

**41 Incidence of Vaginitis and Balanitis among Type 2 Diabetes Patients. Experience from the General Practice Research Database (GPRD) [515]**

*Ishan Hirji, Zhenchao Guo, Susan Andersson, Niklas Hammar, Andres Gomez Caminero. (United States)*

**42 Is Withholding Osteoporosis Medication after Fracture Sometimes Rational? A Comparison of the Risk for Recurrent Fracture vs. Death [516]**

*Jeffrey R Curtis, Tarun Arora, David J Becker, Lisa C Gary, Meredith L Kilgore, Robert S Matthews, Michael A Morrissey, Kenneth G Saag, Monika Safford, Allison Taylor, Amy Warriner, Elizabeth Delzell. (United States)*

**43 Deprivation and Prevalence of Risk Factors and Chronic Diseases – Is There a Trend? [517]**

*Betina T Blak, Yingfen Hsia, Michelle Hards. (United Kingdom)*

**44 Estimation of the Incidence and Prevalence of Hodgkin's Disease in the EU Pediatric Population for Pediatric Investigational Plans [518]**

*Carles Blanch, Katarzyna Sablinska. (Spain)*

# Poster Session C: Wednesday, Aug. 19

- 45 Neuronopathic Gaucher Disease: Demographics, Clinical Features in 131 Patients Enrolled in the ICGG Neurological Outcomes Subregistry [519]**  
*Anna Tylki-Szymanska, Ashok Vellodi, Amal El-Beshlawy, J Alexander Cole, Edwin Kolodny. (United States)*
- 46 Avascular Necrosis in Type 1 Gaucher Disease: Impact of Imiglucerase Therapy, Its Timing and Associated Factors [520]**  
*Pramod K Mistry, Patrick Deegan, Ashok Vellodi, J Alexander Cole, Michael Yeh, Neal J Weinreb. (United States)*
- 47 A Report from the International Collaborative Gaucher Group (ICGG) Gaucher Registry [521]**  
*Stephan vom Dahl, J Alexander Cole, Neal J Weinreb. (United States)*
- 48 Incidence, Survival and Initial Treatment in Adults Diagnosed with Glioblastoma 1981-2005 in the US [522]**  
*Wei Dong, Laura Chu, Asha Das, Meghna K Samant, Michael Taylor. (United States)*
- 49 A Region-Wide Database To Study the Therapeutic Management of Stroke Patients Using Hospital Inpatient Admission Data, Death Certificates and Radiology Reports [523]**  
*Robert Flynn, Thomas MacDonald, Gordon Murray, Alexander Doney. (United Kingdom)*
- 50 Validity of the Health Improvement Network (THIN) for Epidemiologic Studies of Hepatitis C Virus Infection [524]**  
*Kevin Haynes, Kimberly A Forde, AR Locallio, James D Lewis, Vincent R LoRe. (United States)*
- 51 Epidemiological & Resource Utilization Trends of HIV/AIDS Patients in Unique Care Model in WNY [525]**  
*Amy Hayward, Christopher Purdy, Raf Magar, Brian Hargrave, Christopher Voltz. (United States)*
- 52 The Risk of Depression in Patients with Psoriasis [526]**  
*Shanu K Kurd, Andrea B Troxel, Joel M Gelfand. (United States)*
- 53 Prevalence of Diabetes among Female Breast Cancer Patients: A Systematic Review [527]**  
*Sonia S Maruti, Nadia Foskett, Noah Jamie Robinson. (United States)*
- 54 Economic Burden of Managing Adverse Drug Reactions in Children in Lagos, Nigeria [528]**  
*Kazeem A Oshikoya, Idowu O Senbanjo, Olisamedua F Njokanma, Ayodele I Soipe. (United Kingdom)*



Genentech is a leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. We commit ourselves to high standards of integrity in contributing to the best interests of patients, the medical profession, our employees and our communities, and to seeking significant returns to our stockholders, based on the continual pursuit of scientific and operational excellence. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science.



The Genentech Epidemiology group provides evidence-based epidemiology strategy, expertise and data to optimize Genentech's therapeutic molecule selection, development, and commercialization. Our activities range from estimating disease incidence and prevalence, describing clinical course of disease and real world treatment practices and providing epidemiological context for adverse events, to collaborating in the design, analysis, and reporting of observational studies and patient registries.

---

CONTACT INFORMATION - Genentech, Inc. - 1 DNA Way, South San Francisco, CA 94080-4990  
Phone: (650) 225-1000 - [www.gene.com](http://www.gene.com)

# Poster Session C: Wednesday, Aug. 19

- 55 Psychiatric Comorbidities in New Users of Antiepileptic Medications [529]**  
*Elisabetta Patorno, Amanda Patrick, Rhonda Bohn, Peter Wahl, Sebastian Schneeweiss. (United States)*
- 56 Epidemiology of Cataract in Europe [530]**  
*Elena Prokofyeva, Robert Wilke, Eberhart Zrenner. (Germany)*
- 57 Head and Neck Cancer Patients at Increased Risk of Comorbidity Compared to Cancer-Free Controls [531]**  
*Myrthe PP van Herk-Sukel, Sarah H Landis, Pieter van den Haak, Maryska LG Janssen-Heijnen, Iman A El-Hariry, Fernie JA Penning-van Beest, Ron MC Herings. (Netherlands)*
- 58 Epidemiology of Hyponatremia in the US Hospitalized Patients [532]**  
*Lili Wang, Wanju Dai. (United States)*
- 59 Defining Mild Cognitive Impairment: Disparity of Incidence and Prevalence Estimates with Variable Operationalized Definitions [533]**  
*Alex Ward, Shannon L Michels, Jesse Cedarbaum, H Michael Arrighi. (United States)*
- 60 Abstract Withdrawn by Author [534]**
- 61 Adherence to the Pentavalent Rotavirus Vaccine Dosing Schedule in the US: 2006-2007 [535]**  
*Jeanne Loughlin, Florence Wang, El Khoury Antoine, Michael Doherty, T Christopher Mast, John D Seeger. (United States)*
- 62 Unused Drugs in Iceland — Value of and Reasons for Disposal [536]**  
*Anna Birna Almarsdóttir, Árni Gunnar Ásgeirsson. (Iceland)*
- 63 Analysis of Angiotensin-Converting-Enzyme Inhibitors in the US Medicaid Program from 1991 to 2007 [537]**  
*Boyang Bian, Jeff J Guo, Christina ML Kelton, Yonghua Jing, Xing Li. (United States)*
- 64 Drug Information from the Pharmaceutical Industry in Primary Health Care Settings and Prescribing of Drugs [538]**  
*Daniel Carlzon, Lena Gustafsson, Anna L Eriksson, Karin Rignér, Susanna M Wallerstedt. (Sweden)*
- 65 New Antifungal Medication Impact on Traditional Agent Utilization and Charges in a Single Healthcare System [539]**  
*Teresa M Cavanaugh, Jeff J Guo, Jill E Martin-Boone, Kevin Enzweiler, Michelle Wiest. (United States)*
- 66 Anti-Osteoporosis Drug Use in Norway during 2004-2007 [540]**  
*Helene M Devold, Man Duong, Aage Tverdal, Kari Furu, Haakon E Meyer, Jan A Falch, Anne Johanne Sogaard. (Norway)*
- 67 Patients' Knowledge about Their Chronic Medication [541]**  
*Monique M Elseviers, Bart Van Rompaey. (Belgium)*
- 68 Drug Treatment of Urologic Symptoms: Estimating the Magnitude of Unmet Need in the Community [542]**  
*Susan A Hall, Carol L Link, Jim C Hu, Paul W Eggers, John B McKinlay. (United States)*
- 69 Abstract Withdrawn by Author [543]**
- 70 Factors Associated with Increase of Benzodiazepine Dose in a Cohort of New-Onset Benzodiazepine Use Community-Dwelling Elderly [544]**  
*Brice Kitio, Patrice Dosquet. (France)*
- 71 Long Term Use of Benzodiazepine in French Elderly: Longitudinal Patterns of Use in New Benzodiazepine Users [545]**  
*Brice Kitio, Patrice Dosquet. (France)*
- 72 The Effect of Adolescent Smoking on Opioid Use – A Prospective Population Based Cohort Study [546]**  
*Tomas Log, Svetlana Skurtveit, Ingeborg Hartz, Aage Tverdal, Marte Handal, Kari Furu. (Norway)*
- 73 Use of Antidepressant Drugs in Extremadura (Spain) 2003- 2005 [547]**  
*Nuria González-Bermejo, Diana González-Bermejo, Javier García del Pozo, Ramona Mateos-Campos. (Spain)*
- 74 Drug Persistency with Cholinesterase Inhibitors for Elderly Patients with Alzheimer's Disease in Korea [548]**  
*So-Hyeon Ahn, Ye-Jee Kim, Sun-Young Jung, Nam-Kyong Choi, Ju-Young Shin, Byung-Joo Park. (Republic of Korea)*
- 75 Abstract Withdrawn by Author [549]**
- 76 Drug Utilization Patterns in a Community Oncology Electronic Medical Record (EMR) Database in Response to Clinical Trial Evidence and Drug Availability [550]**  
*Reejis Stephen, Joyce George, Kevin Knopf, Natalie Jones, Matthew Reynolds. (United States)*
- 77 Spatial Variation in Off-Label Quetiapine Use among Alcohol Dependent Patients in the Veteran's Health Administration [551]**  
*Shirley Wang, Vincent Mor, David Dore, Robert Swift. (United States)*
- 78 Substantial Differences in Utilization and Expenditures of PPI across Europe [552]**  
*Brian Godman, Vera Vlahovic Palcevski, Arash Ghaffarian Samavarchi, Ulf Bergman, Björn Wettermark. (Sweden)*
- 79 Research on Asian Psychotropic Prescription Patterns for Antipsychotics III (REAP-AP3)—Taiwan Results [553]**  
*Shu-yu Yang, Shih-ku Lin, Lih-chi Chen, Chen-pang Wang, Tzu-ting Chen, Ming-chao Chen, Chi-fa Hung, Chieh-hsin Chang, Chun-chieh Fan, Tung-ping Su, Mian-yoon Chong. (Taiwan)*

## Drug Utilization Studies

# Poster Session C: Wednesday, Aug. 19

## Economics

- 80 **Inpatient Costs Associated with 6 Months of Care Post Acute Rejection Events in Renal Transplant Patients: A Single Center Retrospective Analysis [554]**  
*Teresa M Cavanaugh, Jill E Martin-Boone, Pamela Heaton, Mark Eckman, Paul Succop, Paul Volek, Gautham Mogilishetty. (United States)*
- 81 **Estimation of the Cost of a Half-Day of Hospitalization among Patients with Community Acquired Pneumonia [555]**  
*Michael Dickson, Chris M Kozma, Daniel B Ng, Monika K Raut, Samir H Mody, Alan Fisher, Jeff Schein. (United States)*

## Error Prevention/ Patient Safety

- 82 **Nurses and Medication Errors: Factors Contributing to Medication Errors [556]**  
*Monica GE Bergqvist, Eva Andersén Karlsson, Sara Eklöf, Johanna Ulfvarson. (Sweden)*
- 83 **Using Electronic Medical Records To Study the Safety of Psychiatric Medications Used in Pediatric Patients [557]**  
*Cynthia de Luise, John S March, Kenneth R Gersing, Guy Cohen, Carolyn Sikes. (United States)*
- 84 **Preventable Fatal Adverse Drug Reactions and Drug Intoxications in a Swedish Population [558]**  
*Katja ME Hakkarainen, Anna K Jönsson, Olav Spigset, Henrik Druid, Anne Hiselius, Staffan Hägg. (Sweden)*
- 85 **Self-Reported Knowledge of Prescription Cardiovascular Medications among Older Adults in the US [559]**  
*Katherine E Kelley, Judith P Kelly, David W Kaufman, Lynn Rosenberg, Allen A Mitchell. (United States)*
- 86 **Pharmacists' Intervention in Oncology Ward: A Study from Nepal [560]**  
*Saval Khanal, Arjun Poudel, Krishna Sharan, Subish Palaian. (Nepal)*

- 87 **Assessment of Cardiovascular (CV) Comorbidity in Patients with Overactive Bladder (OAB) [561]**  
*Jaewhan Kim, Carl Asche, Kristijan Kahler, Amit Kulkarni, Karl-Eric Andersson. (United States)*
- 88 **How Drug-Drug Interactions Related to Serotonin Reuptake Inhibitors Affect Drug Dispensing: A Population-Based Study [562]**  
*Buster Mannheimer, Björn Wettermark, Michael Lundberg, Hans Pettersson, Christer von Bahr, Erik Eliasson. (Switzerland)*
- 89 **Drug-Drug Interactions among Elderly Patients with Diabetes [563]**  
*Arpit Misra, Leigh G Hansen, Stella Chang. (United States)*
- 90 **Comparing Methods To Identify Patients at Risk of Medication Related Harm [564]**  
*Jasperien van Doormaal, Mirjam Rommers, Jos Kosterink, Irene Teepe-Twiss, Flora Haaïjer-Ruskamp, Peter Mol. (Netherlands)*
- 91 **The ASPOC Project in Orthopedics Surgery: Preliminary Results from 3 European Countries [565]**  
*Paraskevi Papaioannidou, Vera Vlahovic-Palcevski, Giuseppina M Benoni, Branko Sestan, Fares Saieh, Laura Cuzzolin, Panagiotis Akritopoulos, George Kapetanos, Giampaolo Velo. (Greece)*
- 92 **The ASPOC Project in Obstetrics and Gynecology: Preliminary Results from 5 European Countries [566]**  
*P Papaioannidou, A Sabo, V Vlahovic-Palcevski, R Benko, G Velo, D Vavilis, B Tarlatzis. (Greece)*
- 93 **The ASPOC Project in Neurosurgery: Preliminary Results from 6 European Countries [567]**  
*P Papaioannidou, K Nanassis, A Sabo, V Vlahovic-Palcevski, MP Stojiljkovic, L Pejakov, O Horvat, GM Benoni, L Cuzzolin, Z Tomic, G Velo. (Greece)*

- 94 **Acute Drug Poisoning Attributed to Doctor Shopping among Korea Elderly Patients [568]**  
*Ju-Young Shin, Nam-Kyong Choi, Sun-Young Jung, Joongyub Lee, Jong-Mi Seong, Ye-Jee Kim, Byung-Joo Park. (Republic of Korea)*
- 95 **Evaluation of Medication Safety in Medical Inpatients with Three Different Prescription Support Solutions [569]**  
*Daniela Fritz, Alessandro Ceschi, Ivanka Curkovic, Martin Huber, Marco Egbring, Gerd A Kullak-Ublick, Stefan Russmann. (Switzerland)*
- 96 **Common Types of Medication Errors of Outpatient Service in Pediatric Psychiatry Care [570]**  
*Samai Sirithongthavorn, Assawin Narkpongphun, Nootjaree Kamduang, Pinyo Isarapongs, Penkam Kanjanarat. (Thailand)*
- 97 **Nicotine Dependence Predicts Problematic Use of Prescribed Opioids. Prospective Population Based Cohort Study [571]**  
*Svetlana Skurtveit, Kari Furu, Randi Selmer, Marte Handal, Aage Tverdal. (Norway)*
- 98 **Abstract Withdrawn by Author [572]**
- 99 **Comparison of Potential Determinants of Medication Errors with and without Patient Harm [573]**  
*Rianne J Zaal, Jasperien E van Doormaal, Bertil W Lenderink, Peter GM Mol, Jos GW Kosterink, Flora M Haaïjer-Ruskamp, Patricia MLA van den Bemt. (Netherlands)*
- 100 **Data Mining in Monitoring Medical Device Safety: Are We There Yet? [574]**  
*Baoguang Wang, Yan Bai, Wanju Dai. (United States)*

## Pharmacovigilance

- 101 **Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM): Design and Rationale [575]**  
*Quazi Ataher, Srinivas R Valluri, Herman Valdez, Joseph Massaro. (United States)*

# Poster Session C: Wednesday, Aug. 19

- 102 A Study of Adverse Drug Reactions in an Intensive Care Unit (ICU) of a Major Hospital in India [576]**  
*Vishudha M Kaushal, Pipasha N Biswas. (United Kingdom)*
- 103 Comparison of Patient Information Leaflet (PIL) of CNS Drugs Marketed by Indian Companies with the Original SmPC [577]**  
*Uday Pratap Singh, Pipasha N Biswas. (United Kingdom)*
- 104 Interim Results of a Modified Prescription Event Monitoring Study on Atomoxetine; Reports of Suicide Related Behaviour [578]**  
*M Davies, L Wilton, D Layton, C Fogg, SAW Shakir. (United Kingdom)*
- 105 Differences in Demographics and Cardiovascular Risk Factors in European and US Users of Oral Contraceptives [579]**  
*Juergen C Dinger, Kristina Voigt, Anita Assmann. (Germany)*
- 106 Introduction of Hospital Nurses in the Reporting of Adverse Drug Reactions in Sweden – Evaluation of the Reports [580]**  
*Elisabet Ekman, Martin Bäckström. (Sweden)*
- 107 Monoclonal Antibody Use and Risk of QT Prolongation: A Disproportionality Analysis of the FDA AERS Database [581]**  
*E Dawn Flick, Victor V Gogolak, Collette F Saccomanno, Andrew Erdman, Pavel Napalkov. (United States)*
- 108 Renal Impairment among Adult ITP Patients: Use of GPRD for Proactive Safety Surveillance [582]**  
*Victor Gastanaga, Chuck Wentworth, Anthony Yeo, Gail Hughes, Steven Cha, Sean Zhao. (United States)*
- 109 Signal Detection using a Global Database of Reports of Suspected Adverse Drug Reactions [583]**  
*Richard Hill, Maria Tengstrand, Jeanette Johansson, Helena Sköld, Monica Plöen. (Sweden)*
- 110 Effects of a One Page ADR Information Letter on the Reporting Rate and the Information Value of ADR Reports [584]**  
*Marie-Louise Johansson, Gertrud Brunlöf, Staffan Hägg, Susanna M Wallerstedt. (Sweden)*
- 111 Analysis of Adverse Drug Reaction Collected by the Electronic Reporting System in a Single Hospital [585]**  
*Hye-Ryun Kang, Ji-Min Cheon, Yong-Il Hwang. (Korea)*
- 112 Descriptive Analysis of Progressive Multifocal Leukoencephalopathy (PML) within the FDA Adverse Event Reporting System [586]**  
*Bao-Anh Nguyen-Khoa, Earl L Goehring Jr, Kimberly Alexander, Pavel K Napalkov, Robin L Seitzman, Judith K Jones. (United States)*
- 113 Abstract Withdrawn by Author [587]**
- 114 Use of Selected “Control Events” in Signal Detection Methodology [588]**  
*Nobuhiro Ooba, Kiyoshi Kubota. (Japan)*
- 115 Execution Benchmark Results of Large-Scale Safety Analyses Utilizing Disparate Observational Databases [589]**  
*Stephanie Reisinger, Donald O’Hara, Gregory Powell. (United States)*
- 116 Do Pregnancy Prevention Programs Work in Dutch Female Isotretinoin Users of Reproductive Age? [590]**  
*Martina Teichert, Loes E Visser, Mark Dufour, Bruno HCh Stricker. (Netherlands)*
- 117 Abstract Withdrawn by Author [591]**
- 118 Trends in Long-Acting Beta Agonist Prescription Patterns among Patients with Asthma [592]**  
*Kandace L Amend, Shuhua Su, Kourtney J Davis, John Seeger. (United States)*
- 119 Antibiotic Effectiveness To Prevent New Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Current Medical Practice [593]**  
*P Blin, S Lignot, S Lamarque, R Lasalle, D Guillemot, C Mayaud, M Molimard, N Moore. (France)*
- 120 Long-Acting beta2-Agonists in Adult Asthma and the Pattern of Risk of Death and Severe Asthma Outcomes: A Study with the UK General Practice Research Database (GPRD) [594]**  
*Bill Zhang, Frank de Vries, Efrosini Setakis, Tjeerd-Pieter van Staa. (United Kingdom)*
- 121 The Direct Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Review of the Literature [595]**  
*Edmond L Toy, Kevin F Gallagher, Elizabeth L Stanley, Mei Sheng Duh. (United States)*
- 122 Treatment Patterns and Persistence in Asthma Therapy—A Population Based Study [596]**  
*Joerg Hasford, Julia Uricher, Martin Tauscher, Peter Bramlage, Johann Christian Virchow. (Germany)*
- 123 Patterns of Asthma Medication Use in the First 8 Years of Life [597]**  
*Ellen S Koster, Alet Wyga, Jan AM Raaymakers, Henriette A Smit, Anke-Hilse Maitland-vd Zee. (Netherlands)*
- 124 Asthma and Prospective Risk of Anaphylaxis in a Large Integrated Health Care Delivery System [598]**  
*Carlos Iribarren, Irina V Tolstykh, Mary K Miller, Mark D Eisner. (United States)*
- 125 SERETIDE and Risk of Incident Non-Vertebral Fractures among COPD Patients in the UK [599]**  
*David P Miller, Kourtney J Davis. (United States)*
- 126 Twelve-Month Persistence of COPD Therapy after Initiation in Patients Aged 50 and Over: Results from an Observational Survey [600]**  
*Laurent Laforest, Cecile Ritleng, Gaele Desamericq, Eric Van Ganse. (France)*

## Pulmonary/Respiratory

# Poster Session C: Wednesday, Aug. 19

## Use of Indicators

### Quality of Life, Patient's Perceptions) Improvements in Quality of Life

#### 127 Functional Status in Patients with Psoriatic Arthritis Receiving Anti-TNF Therapies: Analysis of the BSR Biologics Register (BSRBR) [601]

Amr A Saad, Darren M Ashcroft, Kath D Watson, Deborah P Symmons, Kimme L Hyrich. (United Kingdom)

#### 128 Description of Drug Use According To Interview and Reimbursement Data in Repeated Cross-Sectional Cohort Studies: Data from the Three-City (3C) Study [602]

Pernelle Noize, Fabienne Bazin, Antoine Pariente, Nicholas Moore, Annie Fourier-Réglat. (France)

#### 129 Life Quality and Quality of Drug Treatment in Elderly Patients [603]

Inger Nordin Olsson, Peter Engfeldt. (Sweden)

#### 130 Assessing the Value to Practitioners of a Pharmacy Benefit Management Program: Lessons from the MineRx Program [604]

MP Powell, Eric P Jack, Jeroan J Allison, Kenneth G Saag, Norman W Weissman. (United States)

#### 131 Reliability and Validity of the Work Limitations Questionnaire in Patients with Psoriatic Arthritis: Results from ACCLAIM [605]

John S Sampalis, Dafna D Gladman, Marie-Josée Martel, Kathy L Gooch, Robert L Wong, Benoit Guerette. (Canada)

#### 132 Assessment of the Quality of Life in Women with Venous Disease [606]

Charles Taieb. (France)

#### 133 Improving the Quality and Efficiency of Drug Prescribing in Primary Care by Means of Financial Incentives [607]

Björn Wettermark, Åke Pehrsson, Maria Juhasz-Haverinen, Aniko Veg, Maria Edler, Gunilla Törnwall-Bergendahl, Henrik Almkvist, Brian Godman, Ulf Bergman. (Sweden)

## End Session C



**One decision**  
gave her the opportunity  
to improve the lives  
of millions.

We impact lives by delivering answers to some of the world's toughest health care questions. And, with over a century of experience behind our name, there is no one better prepared than Eli Lilly and Company to tackle these questions and the challenges of our changing industry.

We have laid the foundation for continued success with a rich pipeline of best-in-class, first-in-class pharmaceutical products and a collaborative culture that supports people in reaching their greatest potential. It is through the diverse perspectives and accomplishments of our people that we are able to touch the lives of patients by providing the medicines that will enable them to lead longer, healthier lives.

Be connected. Be inspired. Be a catalyst.  
Visit [lilly.com/careers](http://lilly.com/careers)

Joined the Lilly Team



# Abstract Index - Final Program

Abstract #	Poster #	Presentation Time	Room	Format
<i>Monday, August 17</i>				
1		10:30am	552AB	Oral
2		10:45am	552AB	Oral
3		11:00am	552AB	Oral
4		11:15am	552AB	Oral
5		11:30am	552AB	Oral
6		11:45am	552AB	Oral
7		10:30am	555AB	Oral
8		10:45am	555AB	Oral
9		11:00am	555AB	Oral
10		11:15am	555AB	Oral
11		11:30am	555AB	Oral
12		11:45am	555AB	Oral
13		10:30am	556AB	Oral
14		10:45am	556AB	Oral
15		11:00am	556AB	Oral
16		11:15am	556AB	Oral
17		11:30am	556AB	Oral
18		11:45am	556AB	Oral
19		10:30am	554AB	Oral
20		10:45am	554AB	Oral
21		11:00am	554AB	Oral
22		11:15am	554AB	Oral
23		11:30am	554AB	Oral
24		11:45am	554AB	Oral
25		10:30am	Ballroom B	Oral
26		10:45am	Ballroom B	Oral
27		11:00am	Ballroom B	Oral
28		11:15am	Ballroom B	Oral
29		11:30am	Ballroom B	Oral
30		11:45am	Ballroom B	Oral
31		1:30pm	Ballroom B	Oral
32		1:45pm	Ballroom B	Oral
33		2:00pm	Ballroom B	Oral
34		2:15pm	Ballroom B	Oral
69		2:30pm	Ballroom B	Oral
36		2:45pm	Ballroom B	Oral
37		1:30pm	554AB	Oral
38		1:45pm	554AB	Oral
39		2:00pm	554AB	Oral
40		2:15pm	554AB	Oral
41		2:30pm	554AB	Oral
42		2:45pm	554AB	Oral
43		1:30pm	555AB	Oral
44		1:45pm	555AB	Oral
45		2:00pm	555AB	Oral
46		2:15pm	555AB	Oral
47		2:30pm	555AB	Oral
48		2:45pm	555AB	Oral
49		1:30pm	552AB	Oral
50		1:45pm	552AB	Oral
51		2:00pm	552AB	Oral
52		2:15pm	552AB	Oral
53		2:30pm	552AB	Oral

Abstract #	Poster #	Presentation Time	Room	Format
<i>Monday, August 17 (Cont.)</i>				
54		2:45pm	552AB	Oral
55		1:30pm	556AB	Oral
56		1:45pm	556AB	Oral
57		2:00pm	556AB	Oral
58		2:15pm	556AB	Oral
59		2:30pm	556AB	Oral
60		2:45pm	556AB	Oral
61		3:30pm	556AB	Sympos.
62		3:30pm	555AB	Sympos.
63		3:30pm	Ballroom B	Sympos.
64		3:30pm	552AB	Sympos.
65		3:30pm	551AB	Sympos.
66		3:30pm	Ballroom A	Sympos.
285		3:30pm	554AB	Sympos.
<b>Poster Session A</b>				
<b>Analysis Methods</b>				
68	1	8:30am-6:00pm		Poster
35	2	<i>Abstract Withdrawn by Author</i>		Poster
69.5	3	8:30am-6:00pm		Poster
70	4	8:30am-6:00pm		Poster
71	5	8:30am-6:00pm		Poster
72	6	8:30am-6:00pm		Poster
73	7	8:30am-6:00pm		Poster
74	8	8:30am-6:00pm		Poster
75	9	8:30am-6:00pm		Poster
76	10	8:30am-6:00pm		Poster
77	11	8:30am-6:00pm		Poster
78	12	8:30am-6:00pm		Poster
79	13	<i>Abstract Withdrawn by Author</i>		Poster
<b>Cancer</b>				
80	14	8:30am-6:00pm		Poster
81	15	8:30am-6:00pm		Poster
82	16	8:30am-6:00pm		Poster
83	17	8:30am-6:00pm		Poster
84	18	8:30am-6:00pm		Poster
85	19	<i>Abstract Withdrawn by Author</i>		Poster
86	20	8:30am-6:00pm		Poster
87	21	8:30am-6:00pm		Poster
88	22	8:30am-6:00pm		Poster
89	23	8:30am-6:00pm		Poster
90	24	8:30am-6:00pm		Poster
<b>CNS/Neurological</b>				
91	25	8:30am-6:00pm		Poster
92	26	8:30am-6:00pm		Poster
93	27	8:30am-6:00pm		Poster
94	28	8:30am-6:00pm		Poster
95	29	8:30am-6:00pm		Poster
96	30	8:30am-6:00pm		Poster
97	31	8:30am-6:00pm		Poster
98	32	8:30am-6:00pm		Poster
99	33	8:30am-6:00pm		Poster

# Abstract Index - Final Program

Abstract #	Poster #	Presentation Time	Room	Format
<i>Monday, August 17 (Cont.)</i>				
100	34	8:30am-6:00pm		Poster
101	35	8:30am-6:00pm		Poster
102	36	8:30am-6:00pm		Poster
<b>Coverage without Evidence</b>				
103	37	8:30am-6:00pm		Poster
104	38	8:30am-6:00pm		Poster
<b>Devices</b>				
105	39	8:30am-6:00pm		Poster
<b>Disease Epidemiology/Burden of Illness</b>				
107	40	8:30am-6:00pm		Poster
108	41	8:30am-6:00pm		Poster
109	42	8:30am-6:00pm		Poster
110	43	8:30am-6:00pm		Poster
111	44	8:30am-6:00pm		Poster
112	45	8:30am-6:00pm		Poster
113	46	8:30am-6:00pm		Poster
114	47	8:30am-6:00pm		Poster
115	48	8:30am-6:00pm		Poster
116	49	8:30am-6:00pm		Poster
117	50	8:30am-6:00pm		Poster
118	51	8:30am-6:00pm		Poster
119	52	8:30am-6:00pm		Poster
120	53	8:30am-6:00pm		Poster
121	54	8:30am-6:00pm		Poster
122	55	8:30am-6:00pm		Poster
123	56	8:30am-6:00pm		Poster
124	57	8:30am-6:00pm		Poster
125	58	8:30am-6:00pm		Poster
126	59	8:30am-6:00pm		Poster
<b>Drug Utilization Studies</b>				
127	60	8:30am-6:00pm		Poster
128	61	8:30am-6:00pm		Poster
129	62	8:30am-6:00pm		Poster
130	63	8:30am-6:00pm		Poster
131	64	8:30am-6:00pm		Poster
132	65	8:30am-6:00pm		Poster
133	66	8:30am-6:00pm		Poster
134	67	8:30am-6:00pm		Poster
135	68	8:30am-6:00pm		Poster
136	69	8:30am-6:00pm		Poster
137	70	8:30am-6:00pm		Poster
138	71	8:30am-6:00pm		Poster
139	72	8:30am-6:00pm		Poster
140	73	8:30am-6:00pm		Poster
141	74	8:30am-6:00pm		Poster
142	75	8:30am-6:00pm		Poster
143	76	8:30am-6:00pm		Poster
144	77	8:30am-6:00pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
<i>Monday, August 17 (Cont.)</i>				
<b>Measurement Methods</b>				
145	78	8:30am-6:00pm		Poster
147	79	8:30am-6:00pm		Poster
148	80	8:30am-6:00pm		Poster
149	81	8:30am-6:00pm		Poster
150	82	8:30am-6:00pm		Poster
151	83	8:30am-6:00pm		Poster
152	84	8:30am-6:00pm		Poster
153	85	8:30am-6:00pm		Poster
154	86	8:30am-6:00pm		Poster
155	87	8:30am-6:00pm		Poster
156	88	8:30am-6:00pm		Poster
<b>Medications in Pregnancy/Birth Defects</b>				
157	89	8:30am-6:00pm		Poster
158	90	8:30am-6:00pm		Poster
159	91	8:30am-6:00pm		Poster
160	92	8:30am-6:00pm		Poster
161	93	8:30am-6:00pm		Poster
162	94	8:30am-6:00pm		Poster
163	95	8:30am-6:00pm		Poster
164	96	8:30am-6:00pm		Poster
165	97	8:30am-6:00pm		Poster
166	98	8:30am-6:00pm		Poster
167	99	8:30am-6:00pm		Poster
168	100	8:30am-6:00pm		Poster
169	101	8:30am-6:00pm		Poster
170	102	8:30am-6:00pm		Poster
171	103	8:30am-6:00pm		Poster
172	104	8:30am-6:00pm		Poster
173	105	8:30am-6:00pm		Poster
174	106	8:30am-6:00pm		Poster
175	107	8:30am-6:00pm		Poster
176	108	8:30am-6:00pm		Poster
177	119	8:30am-6:00pm		Poster
178	110	8:30am-6:00pm		Poster
179	111	8:30am-6:00pm		Poster
180	112	8:30am-6:00pm		Poster
<b>Pharmacovigilance</b>				
181	113	<i>Abstract Withdrawn by Author</i>		
182	114	8:30am-6:00pm		Poster
183	115	8:30am-6:00pm		Poster
184	116	8:30am-6:00pm		Poster
185	117	8:30am-6:00pm		Poster
186	118	8:30am-6:00pm		Poster
187	119	8:30am-6:00pm		Poster
188	120	8:30am-6:00pm		Poster
189	121	8:30am-6:00pm		Poster
190	122	8:30am-6:00pm		Poster
191	123	8:30am-6:00pm		Poster
192	124	8:30am-6:00pm		Poster
193	125	8:30am-6:00pm		Poster

# Abstract Index - Final Program

Abstract #	Poster #	Presentation Time	Room	Format
<i>Monday, August 17 (Cont.)</i>				
194	126	8:30am-6:00pm		Poster
195	127	8:30am-6:00pm		Poster
196	128	8:30am-6:00pm		Poster
197	129	<i>Abstract Withdrawn by Author</i>		
198	130	8:30am-6:00pm		Poster
199	131	8:30am-6:00pm		Poster
200	132	8:30am-6:00pm		Poster
201	133	8:30am-6:00pm		Poster

Psychotropics				
202	134	8:30am-6:00pm		Poster
203	135	8:30am-6:00pm		Poster
204	136	8:30am-6:00pm		Poster
205	137	8:30am-6:00pm		Poster
206	138	8:30am-6:00pm		Poster
207	139	8:30am-6:00pm		Poster
208	140	8:30am-6:00pm		Poster
209	141	8:30am-6:00pm		Poster
210	142	8:30am-6:00pm		Poster
211	143	8:30am-6:00pm		Poster
212	144	8:30am-6:00pm		Poster
213	145	8:30am-6:00pm		Poster
214	146	8:30am-6:00pm		Poster
215	147	8:30am-6:00pm		Poster
216	148	8:30am-6:00pm		Poster
217	149	8:30am-6:00pm		Poster
218	150	8:30am-6:00pm		Poster
219	151	8:30am-6:00pm		Poster
220	152	8:30am-6:00pm		Poster
221	153	8:30am-6:00pm		Poster
222	154	<i>Abstract Withdrawn by Author</i>		
223	155	8:30am-6:00pm		Poster
224	156	8:30am-6:00pm		Poster
225	157	8:30am-6:00pm		Poster
226	158	8:30am-6:00pm		Poster

<i>Tuesday, August 18</i>				
608		7:00am	557	Sympos
227		11:00am	552B	Oral
228		11:15am	552B	Oral
229		11:30am	552B	Oral
230		11:45am	552B	Oral
231		12:00pm	552B	Oral
232		12:15pm	552B	Oral
233		11:00am	Ballroom D	Oral
234		11:15am	Ballroom D	Oral
235		11:30am	Ballroom D	Oral
236		11:45am	Ballroom D	Oral
237		12:00pm	Ballroom D	Oral
238		12:15pm	Ballroom D	Oral
239		11:00am	Ballroom B	Oral

Abstract #	Poster #	Presentation Time	Room	Format
<i>Tuesday, August 18 (Cont.)</i>				
240		11:15am	Ballroom B	Oral
241		11:30am	Ballroom B	Oral
242		11:45am	Ballroom B	Oral
243		12:00pm	Ballroom B	Oral
244		12:15pm	Ballroom B	Oral
245		11:00am	552A	Oral
246		11:15am	552A	Oral
247		11:30am	552A	Oral
248		11:45am	552A	Oral
249		12:00pm	552A	Oral
250		12:15pm	552A	Oral
251		11:00am	557	Oral
252		11:15am	557	Oral
253		11:30am	557	Oral
254		11:45am	557	Oral
255		12:00pm	557	Oral
256		12:15pm	557	Oral
257		2:00pm	551A	Oral
258		2:15pm	551A	Oral
259		2:30pm	551A	Oral
261		2:45pm	551A	Oral
262		3:00pm	551A	Oral
263		2:00pm	Ballroom D	Oral
264		2:15pm	Ballroom D	Oral
265		2:30pm	Ballroom D	Oral
266		2:45pm	Ballroom D	Oral
267		3:00pm	Ballroom D	Oral
268		3:15pm	Ballroom D	Oral
609		2:00pm	Ballroom B	Oral
610		2:15pm	Ballroom B	Oral
611		2:30pm	Ballroom B	Oral
612		2:45pm	Ballroom B	Oral
613		3:00pm	Ballroom B	Oral
614		3:15pm	Ballroom B	Oral
269		2:00pm	551B	Oral
270		2:15pm	551B	Oral
271		2:30pm	551B	Oral
272		2:45pm	551B	Oral
273		3:00pm	551B	Oral
274		3:15pm	551B	Oral
275		2:00pm	557	Oral
276		2:15pm	557	Oral
277		2:30pm	557	Oral
278		2:45pm	557	Oral
279		3:00pm	557	Oral
280		3:15pm	557	Oral
469		4:00pm	557	Sympos.
67		4:00pm	552 B	Sympos.
282		4:00pm	552A	Sympos.
283		4:00pm	Ballroom B	Sympos.
284		4:00pm	Ballroom D	Sympos.
286		4:00pm	Ballroom A	Sympos.
615		<i>Abstract Withdrawn by Author</i>		

# Abstract Index - Final Program

Abstract #	Poster #	Presentation Time	Room	Format
<i>Tuesday, August 18 (Cont.)</i>				
<b>Poster Session B</b>				
<b>Cardiovascular Drugs</b>				
287	1	8:30am-6:00pm		Poster
288	2	8:30am-6:00pm		Poster
289	3	8:30am-6:00pm		Poster
290	4	8:30am-6:00pm		Poster
291	5	8:30am-6:00pm		Poster
292	6	8:30am-6:00pm		Poster
293	7	8:30am-6:00pm		Poster
294	8	8:30am-6:00pm		Poster
295	9	8:30am-6:00pm		Poster
296	10	8:30am-6:00pm		Poster
297	11	8:30am-6:00pm		Poster
298	12	8:30am-6:00pm		Poster
299	13	8:30am-6:00pm		Poster
300	14	8:30am-6:00pm		Poster
301	15	8:30am-6:00pm		Poster
302	16	8:30am-6:00pm		Poster
303	17	8:30am-6:00pm		Poster
304	18	8:30am-6:00pm		Poster
305	19	8:30am-6:00pm		Poster
306	20	8:30am-6:00pm		Poster
307	21	8:30am-6:00pm		Poster
308	22	8:30am-6:00pm		Poster
309	23	8:30am-6:00pm		Poster
310	24	8:30am-6:00pm		Poster
311	25	8:30am-6:00pm		Poster
312	26	8:30am-6:00pm		Poster
313	27	<i>Abstract Withdrawn by Author</i>		
314	28	8:30am-6:00pm		Poster
315	29	8:30am-6:00pm		Poster
316	30	8:30am-6:00pm		Poster
317	31	8:30am-6:00pm		Poster
318	32	<i>Abstract Withdrawn by Author</i>		
<b>Drug Utilization Studies</b>				
319	43	8:30am-6:00pm		Poster
320	44	8:30am-6:00pm		Poster
321	45	8:30am-6:00pm		Poster
322	46	8:30am-6:00pm		Poster
323	47	8:30am-6:00pm		Poster
324	48	8:30am-6:00pm		Poster
325	49	8:30am-6:00pm		Poster
326	50	8:30am-6:00pm		Poster
327	51	8:30am-6:00pm		Poster
328	52	8:30am-6:00pm		Poster
329	53	8:30am-6:00pm		Poster
330	54	8:30am-6:00pm		Poster
331	55	8:30am-6:00pm		Poster
332	56	8:30am-6:00pm		Poster
333	57	8:30am-6:00pm		Poster
334	58	8:30am-6:00pm		Poster
335	59	8:30am-6:00pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
<i>Tuesday, August 18 (Cont.)</i>				
336	60	8:30am-6:00pm		Poster
<b>Economics</b>				
337	61	8:30am-6:00pm		Poster
338	62	8:30am-6:00pm		Poster
339	63	8:30am-6:00pm		Poster
340	64	8:30am-6:00pm		Poster
<b>Effectiveness Research</b>				
341	65	8:30am-6:00pm		Poster
342	66	8:30am-6:00pm		Poster
343	67	8:30am-6:00pm		Poster
344	68	8:30am-6:00pm		Poster
345	69	8:30am-6:00pm		Poster
346	70	8:30am-6:00pm		Poster
<b>Emerging Epidemics</b>				
347	71	8:30am-6:00pm		Poster
<b>Endocrine/Diabetes</b>				
348	72	8:30am-6:00pm		Poster
349	73	8:30am-6:00pm		Poster
350	74	8:30am-6:00pm		Poster
351	75	8:30am-6:00pm		Poster
352	76	8:30am-6:00pm		Poster
353	77	8:30am-6:00pm		Poster
<b>Gastrointestinal</b>				
354	78	8:30am-6:00pm		Poster
355	79	8:30am-6:00pm		Poster
356	80	<i>Abstract Withdrawn by Author</i>		
357	81	8:30am-6:00pm		Poster
358	82	8:30am-6:00pm		Poster
359	83	8:30am-6:00pm		Poster
<b>Hematological</b>				
360	84	8:30am-6:00pm		Poster
361	85	8:30am-6:00pm		Poster
362	86	8:30am-6:00pm		Poster
363	87	8:30am-6:00pm		Poster
364	88	8:30am-6:00pm		Poster
<b>Hormones/Reproductive Agents</b>				
366	89	8:30am-6:00pm		Poster
367	90	8:30am-6:00pm		Poster
368	91	8:30am-6:00pm		Poster
<b>Molecular Epidemiology/Pharmacogenetics</b>				
369	92	8:30am-6:00pm		Poster
370	93	8:30am-6:00pm		Poster
371	94	8:30am-6:00pm		Poster
372	95	8:30am-6:00pm		Poster
373	96	8:30am-6:00pm		Poster
374	97	8:30am-6:00pm		Poster
375	98	8:30am-6:00pm		Poster

# Abstract Index - Final Program

Abstract #	Poster #	Presentation Time	Room	Format
<b>Tuesday, August 18 (Cont.)</b>				
<b>Pharmacovigilance</b>				
376	99	8:30am-6:00pm		Poster
377	100	8:30am-6:00pm		Poster
378	101	8:30am-6:00pm		Poster
379	102	8:30am-6:00pm		Poster
380	103	8:30am-6:00pm		Poster
381	104	8:30am-6:00pm		Poster
382	105	8:30am-6:00pm		Poster
383	106	8:30am-6:00pm		Poster
384	107	8:30am-6:00pm		Poster
385	108	8:30am-6:00pm		Poster
386	109	8:30am-6:00pm		Poster
387	110	8:30am-6:00pm		Poster
388	111	8:30am-6:00pm		Poster
389	112	8:30am-6:00pm		Poster
390	113	8:30am-6:00pm		Poster
391	114	<i>Abstract Withdrawn by Author</i>		
392	115	8:30am-6:00pm		Poster
393	116	8:30am-6:00pm		Poster
<b>Regulatory Issues/Drug Policy</b>				
394	117	8:30am-6:00pm		Poster
395	118	<i>Abstract Withdrawn by Author</i>		
396	119	8:30am-6:00pm		Poster
397	120	8:30am-6:00pm		Poster
398	121	8:30am-6:00pm		Poster
399	122	8:30am-6:00pm		Poster
400	123	8:30am-6:00pm		Poster
401	124	8:30am-6:00pm		Poster
402	125	8:30am-6:00pm		Poster
<b>Risk Management/Communication</b>				
403	126	8:30am-6:00pm		Poster
404	127	8:30am-6:00pm		Poster
405	128	8:30am-6:00pm		Poster
406	129	8:30am-6:00pm		Poster
407	130	8:30am-6:00pm		Poster
408	131	8:30am-6:00pm		Poster
409	132	8:30am-6:00pm		Poster
410	133	8:30am-6:00pm		Poster
411	134	8:30am-6:00pm		Poster
412	135	8:30am-6:00pm		Poster
413	136	8:30am-6:00pm		Poster
414	137	8:30am-6:00pm		Poster
415	138	8:30am-6:00pm		Poster
416	139	8:30am-6:00pm		Poster
417	140	8:30am-6:00pm		Poster
418	141	8:30am-6:00pm		Poster
419	142	8:30am-6:00pm		Poster
420	143	8:30am-6:00pm		Poster
421	144	8:30am-6:00pm		Poster
<b>Use of Linked Databases</b>				
422	145	8:30am-6:00pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
<b>Tuesday, August 18 (Cont.)</b>				
423	146	8:30am-6:00pm		Poster
424	147	8:30am-6:00pm		Poster
425	148	8:30am-6:00pm		Poster
426	149	8:30am-6:00pm		Poster
428	150	8:30am-6:00pm		Poster
429	151	8:30am-6:00pm		Poster
430	152	8:30am-6:00pm		Poster
431	153	8:30am-6:00pm		Poster
432	154	8:30am-6:00pm		Poster
433	155	8:30am-6:00pm		Poster
434	156	8:30am-6:00pm		Poster
435	157	8:30am-6:00pm		Poster
436	158	8:30am-6:00pm		Poster
437	159	8:30am-6:00pm		Poster
<b>Wednesday, August 19</b>				
438		8:30am	Ballroom B	Oral
439		8:45am	Ballroom B	Oral
440		9:00am	Ballroom B	Oral
441		9:15am	Ballroom B	Oral
442		9:30am	Ballroom B	Oral
443		9:45am	Ballroom B	Oral
444		8:30am	551A	Oral
445		8:45am	551A	Oral
446		9:00am	551A	Oral
447		9:15am	551A	Oral
448		9:30am	551A	Oral
449		9:45am	551A	Oral
450		8:30am	551B	Oral
451		8:45am	551B	Oral
452		9:00am	551B	Oral
453		9:15am	551B	Oral
454		9:30am	551B	Oral
455		9:45am	551B	Oral
456		8:30am	552A	Oral
457		8:45am	552A	Oral
458		9:00am	552A	Oral
459		9:15am	552A	Oral
460		9:30am	552A	Oral
461		9:45am	552A	Oral
462		8:30am	552B	Oral
463		8:45am	552B	Oral
464		9:00am	552B	Oral
465		9:15am	552B	Oral
466		9:30am	552B	Oral
467		9:45am	552B	Oral
281		10:30am	551B	Sympos.
468		10:30am	551A	Sympos.
470		10:30am	Ballroom D	Sympos.
471		10:30am	Ballroom B	Sympos.
472		10:30am	557	Sympos.
473		10:30am	552A	Sympos.
616		10:30am	552B	Sympos.

# Abstract Index - Final Program

Abstract #	Poster #	Presentation Time	Room	Format
<i>Wednesday, August 19 (Cont.)</i>				
<b>Poster Session C</b>				
<b>Analgesics/Anti-Inflammatory Agents</b>				
474	1	8:30am-2:00pm		Poster
475	2	8:30am-2:00pm		Poster
476	3	8:30am-2:00pm		Poster
477	4	8:30am-2:00pm		Poster
478	5	8:30am-2:00pm		Poster
<b>Analysis Methods</b>				
479	6	8:30am-2:00pm		Poster
480	7	8:30am-2:00pm		Poster
481	8	8:30am-2:00pm		Poster
482	9	8:30am-2:00pm		Poster
483	10	8:30am-2:00pm		Poster
484	11	8:30am-2:00pm		Poster
485	12	8:30am-2:00pm		Poster
486	13	8:30am-2:00pm		Poster
487	14	8:30am-2:00pm		Poster
<b>Anti-Infectives</b>				
488	15	8:30am-2:00pm		Poster
489	16	8:30am-2:00pm		Poster
490	17	8:30am-2:00pm		Poster
491	18	8:30am-2:00pm		Poster
492	19	8:30am-2:00pm		Poster
493	20	8:30am-2:00pm		Poster
494	21	8:30am-2:00pm		Poster
495	22	8:30am-2:00pm		Poster
496	23	8:30am-2:00pm		Poster
<b>Cardiovascular Disease</b>				
497	24	8:30am-2:00pm		Poster
498	25	8:30am-2:00pm		Poster
499	26	8:30am-2:00pm		Poster
500	27	<i>Abstract Withdrawn by Author</i>		
501	28	8:30am-2:00pm		Poster
502	29	8:30am-2:00pm		Poster
503	30	8:30am-2:00pm		Poster
504	31	8:30am-2:00pm		Poster
505	32	8:30am-2:00pm		Poster
506	33	8:30am-2:00pm		Poster
507	34	8:30am-2:00pm		Poster
508	35	8:30am-2:00pm		Poster
509	36	8:30am-2:00pm		Poster
510	37	8:30am-2:00pm		Poster
512	38	8:30am-2:00pm		Poster
513	39	8:30am-2:00pm		Poster
514	40	8:30am-2:00pm		Poster
<b>Disease Epidemiology/Burden of Illness</b>				
515	41	8:30am-2:00pm		Poster
516	42	8:30am-2:00pm		Poster
517	43	8:30am-2:00pm		Poster
518	44	8:30am-2:00pm		Poster

Abstract #	Poster #	Presentation Time	Room	Format
<i>Wednesday, August 19 (Cont.)</i>				
519	45	8:30am-2:00pm		Poster
520	46	8:30am-2:00pm		Poster
521	47	8:30am-2:00pm		Poster
522	48	8:30am-2:00pm		Poster
523	49	8:30am-2:00pm		Poster
524	50	8:30am-2:00pm		Poster
525	51	8:30am-2:00pm		Poster
526	52	8:30am-2:00pm		Poster
527	53	8:30am-2:00pm		Poster
528	54	8:30am-2:00pm		Poster
529	55	8:30am-2:00pm		Poster
530	56	8:30am-2:00pm		Poster
531	57	8:30am-2:00pm		Poster
532	58	8:30am-2:00pm		Poster
533	59	8:30am-2:00pm		Poster
534	60	<i>Abstract Withdrawn by Author</i>		
535	61	8:30am-2:00pm		Poster
<b>Drug Utilization Studies</b>				
536	62	8:30am-2:00pm		Poster
537	63	8:30am-2:00pm		Poster
538	64	8:30am-2:00pm		Poster
539	65	8:30am-2:00pm		Poster
540	66	8:30am-2:00pm		Poster
541	67	8:30am-2:00pm		Poster
542	68	8:30am-2:00pm		Poster
543	69	<i>Abstract Withdrawn by Author</i>		
544	70	8:30am-2:00pm		Poster
545	71	8:30am-2:00pm		Poster
546	72	8:30am-2:00pm		Poster
547	73	8:30am-2:00pm		Poster
548	74	8:30am-2:00pm		Poster
549	75	<i>Abstract Withdrawn by Author</i>		
550	76	8:30am-2:00pm		Poster
551	77	8:30am-2:00pm		Poster
552	78	8:30am-2:00pm		Poster
553	79	8:30am-2:00pm		Poster
<b>Economics</b>				
554	80	8:30am-2:00pm		Poster
555	81	8:30am-2:00pm		Poster
<b>Error Prevention/Patient Safety</b>				
556	82	8:30am-2:00pm		Poster
557	83	8:30am-2:00pm		Poster
558	84	8:30am-2:00pm		Poster
559	85	8:30am-2:00pm		Poster
560	86	8:30am-2:00pm		Poster
561	87	8:30am-2:00pm		Poster
562	88	8:30am-2:00pm		Poster
563	89	8:30am-2:00pm		Poster
564	90	8:30am-2:00pm		Poster
565	91	8:30am-2:00pm		Poster
566	92	8:30am-2:00pm		Poster

